docetaxel anhydrous has been researched along with Androgen-Independent Prostatic Cancer in 830 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 540 (65.06) | 24.3611 |
| 2020's | 290 (34.94) | 2.80 |
| Authors | Studies |
|---|---|
| Andreassen, BK; Fosså, SD; Storås, AH; Ursin, G | 1 |
| Carpenter, V; Faber, AC; Gewirtz, DA; Harada, H; Min Lee, S; Murray, G; Reed, J; Saleh, T; Souers, A | 1 |
| Blas, L; Eto, M; Inokuchi, J; Kashiwagi, E; Kobayashi, S; Matsumoto, T; Shiga, KI; Shiota, M; Takeuchi, A; Yokomizo, A | 1 |
| Bello, T; Diaz-Gomez, LA; Dondossola, E; Gujral, TS; Melchiorri, A; Mikos, AG; Nelson, PS; Paindelli, C | 1 |
| Jiang, ZG; Liao, SG | 1 |
| Cao, H; Chen, L; Feng, Y; Gao, R; Sun, P; Wang, D | 1 |
| Yuasa, T | 2 |
| Besson, D; Borchiellini, D; Bost, F; Cheli, S; Deville, JL; El Kouri, C; Ferrero, JM; Guillot, A; Hilgers, W; Hoch, B; Milano, G; Paoli, JB; Priou, F; Pujalte Martin, M; Schiappa, R; Tanti, JF; Thamphya, B | 1 |
| Ahmed, ME; Andrews, JR; Bold, MS; Bryce, AH; Dundar, A; Jimbo, M; Karnes, RJ; Kendi, AT; Kwon, ED; Lowe, VJ | 1 |
| Allen, T; Armstrong, AJ; Chen, X; Foo, WC; Freedman, JA; George, DJ; Gregory, S; Gupta, S; Hsu, DS; Huang, J; Inman, BA; Kittles, RA; Li, Y; McCall, SJ; Owzar, K; Patierno, BM; Patierno, SR; Qin, X; Somarelli, JA; Ware, KE; Wise, JP; Wise, S; Xu, L; Zhang, D | 1 |
| Fruehauf, JP; Lilly, M; Uchio, E; Zhuang, E; Zi, X | 1 |
| Hwang, C; Kim, SH; Pilling, A | 1 |
| Pramod, SV; Safriadi, F; Tresnanda, RI | 1 |
| Emir, B; Freedland, SJ; Hong, A; Mu, Q; Ratiu, A; Sah, J; Sandin, R; Serfass, L; Tagawa, ST | 1 |
| Amin, NP; Armstrong, AJ; Bastos, DA; Castellano, D; Fizazi, K; González Mella, P; Horvath, L; Li, J; Minatta, JN; Pachynski, RK; Petrylak, DP; Retz, M; Rezazadeh Kalebasty, A; Saad, F; Sánchez López, HM; Shaffer, D; Unsal-Kacmaz, K; Vázquez Limón, JC | 1 |
| Blanchet, P; Brureau, L; Gourtaud, G; Roux, V; Sadreux, Y; Senechal, C; Vestris, PG | 1 |
| Deveci Ozkan, A; Guney Eskiler, G; Kaleli, S; Sahin, E | 1 |
| Byeon, S; Jeon, HG; Jeon, SS; Kim, H; Lee, HM; Lee, SI; Park, SH; Seo, SI | 1 |
| Bhadree, S; Gabela, NC; Mathibe, LJ | 1 |
| Bracht, T; Csizmarik, A; Fazekas, T; Hadaschik, B; Keresztes, D; Kramer, G; Küronya, Z; Lászik, A; Lázár, J; Módos, O; Nagy, N; Nyirády, P; Puhr, M; Sevcenco, S; Shariat, S; Sitek, B; Szarvas, T; Szűcs, M; Takács, L; Tornyi, I; Witzke, K | 1 |
| Donix, L; Dubrovska, A; Erb, HHH; Erdmann, K; Fuessel, S; Peitzsch, C; Pfeifer, M; Thomas, C | 1 |
| Capart, P; Combest, AJ; de Wit, R; Freedland, SJ; Marinov, G; Morgans, AK; Oudard, S; Ozatilgan, A; Peterson, R | 1 |
| Arora, S; Batra, A; Das, CJ; Haresh, KP; Kaushal, S; Nayak, B; Sahoo, RK; Shamim, SA; Singh, P; Verma, S | 1 |
| Anton, A; Azad, A; Chazan, G; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Bahl, A; Bartunkova, J; Beer, TM; Cheung, E; Csöszi, T; Feyerabend, S; Filipovic, Z; Fricke, H; Gerritsen, W; Goncalves, F; Hajek, J; Hussain, A; Hussain, S; Kadlecova, P; Khoo, V; Korolkiewicz, RP; Kukielka-Budny, B; Oudard, S; Prokhorov, A; Samal, V; Scheiner, T; Sousa, N; Spisek, R; Stenzl, A; Vogelzang, NJ; Wiechno, P | 1 |
| Chen, H; Chen, X; Li, Y; Pang, J; Tian, J; Wang, D; Xu, D; Yang, X | 1 |
| Dalhaug, A; Haukland, E; Nieder, C; Stanisavljevic, L | 1 |
| Aggarwal, R; Carneiro, BA; de Kouchkovsky, I; Fong, L; Friedlander, T; Lewis, C; Paris, PL; Phone, A; Rao, A; Ryan, CJ; Small, EJ; Szmulewitz, RZ; Zhang, L | 1 |
| Alekseev, B; Crawford, ED; Cruz, F; Fizazi, K; Fu, C; Hussain, M; Joensuu, H; Kopyltsov, E; Kuss, I; Li, R; Maughan, BL; Méndez-Vidal, MJ; Montesa-Pino, Á; Park, CH; Parnis, F; Saad, F; Smith, MR; Sternberg, CN; Suzuki, H; Tammela, TLJ; Thiele, S; Tombal, B; Uemura, M; Utriainen, T; Ye, D | 1 |
| Gyawali, B; Van Wambeke, S; Vera-Badillo, FE | 1 |
| Basappa, NS; Cagiannos, I; Chan, KFY; Fernandes, R; Ferrario, C; Gotto, GT; Hamilton, RJ; Hew, H; Hotte, SJ; Malone, S; Morgan, SC; Niazi, T; Noonan, KL; Park-Wyllie, L; Roy, S; Saad, F; Shayegan, B; Wallis, CJD | 1 |
| Chiba, S; Egawa, S; Habuchi, T; Hata, K; Hatakeyama, S; Horikawa, Y; Ishida, T; Kashima, S; Kimura, T; Koizumi, A; Kumazawa, T; Maita, S; Narita, S; Nomura, K; Ohyama, C; Okane, K; Sato, H; Shimoda, J; Suzuki, T; Takayama, K; Yamamoto, R; Yanagisawa, T | 1 |
| Enokida, H; Hashine, K; Ichikawa, T; Kamiyama, M; Matsuyama, H; Mizokami, A; Nakajima, K; Nishimoto, K; Shiina, H; Sugiyama, Y; Takahashi, S | 1 |
| Du, P; Jia, S; King, BL; Kohli, M; Roacho, J; Tan, W; Thao, S; Wang, A; Yu, J; Zheng, T | 1 |
| Barker, C; Choudhury, A; Elliott, T; Elumalai, T; Hoskin, P; Hudson, A; Lyons, J; Malik, J; Mistry, H; Patel, K; Song, YP; Tran, A | 1 |
| Azad, AA; Briscoe, K; Butler, LM; Crumbaker, M; Davis, ID; Du, P; Fettke, H; Horvath, LG; Hoy, AJ; Huynh, K; Jia, S; Joshua, AM; Kohli, M; Kwan, EM; Lin, HM; Mahon, K; Mak, B; Marx, G; Meikle, PJ; Meikle, TG; Mellett, NA; Stockler, MR; Tan, W; Tran, B; Waugh, DJ; Yu, J; Zhang, A | 1 |
| Fong, L; Gutierrez, AA; Haas, NB; Lam, ET; Mega, A; Parsi, M; Stein, MN; Tutrone, R; Vangala, S | 1 |
| Salari, K; Thoman, ME | 1 |
| Appleman, LJ; Berry, WR; Bögemann, M; Conter, HJ; de Bono, JS; Emmenegger, U; Gravis, G; Gurney, H; Joshua, AM; Kolinsky, MP; Laguerre, B; Li, XT; Linch, M; Massard, C; Mourey, L; Piulats, JM; Poehlein, CH; Retz, M; Romano, E; Schloss, C; Sridhar, S; Yu, EY | 1 |
| Aieta, M; Airoldi, M; Ardizzoia, A; Beccaglia, P; Bonetti, A; Chiuri, VE; Conforti, S; D'Aniello, C; De Tursi, M; Di Lorenzo, G; Francolini, G; Fratino, L; Galli, L; Maestri, A; Muto, A; Petrioli, R; Pisconti, S; Quadrini, S; Rossetti, S; Satta, F; Sbrana, A; Scavelli, C; Sirotova, Z | 1 |
| Chen, M; Hu, Q; Li, Z; Lu, K; Sun, J | 1 |
| Kise, H | 1 |
| Hattahara, K; Nishizawa, K; Onishi, H; Yoshida, T | 1 |
| Bilen, MA; Brown, JR; Carthon, B; Caulfield, S; Hadadi, A; Kucuk, O; Lafollette, J; Liu, Y; Moore, M; Nazha, B; Russler, G; Smith, KE; Wan, L; Yantorni, L | 1 |
| Beijnen, JH; Bergman, AM; Rosing, H; van der Heijden, LT; van Nuland, M; Vermunt, MAC | 1 |
| Altavilla, A; Casadei, C; Conteduca, V; Cursano, MC; De Giorgi, U; Gargiulo, S; Gurioli, G; Lolli, C; Santini, D; Scarpi, E; Tonini, G; Vincenzi, B | 1 |
| Riaz, IB; Sweeney, CJ | 1 |
| Coleman, IM; Corey, E; DeSarkar, N; Haffner, MC; Li, D; Morrissey, C; Nelson, PS; Roudier, MP; Sayar, E; Xin, L | 1 |
| Calais, G; Cancel, M; Florence, AM; Fromont, G; Laurent, E; Linassier, C; Narciso, B; Pobel, C | 1 |
| Atsuta, M; Egawa, S; Enei, Y; Habuchi, T; Hata, K; Hatakeyama, S; Iwamoto, Y; Iwatani, K; Kimura, T; Matsukawa, A; Miki, J; Mori, K; Nakazono, M; Narita, S; Nishikawa, H; Ohyama, C; Otsuka, T; Sakanaka, K; Sano, T; Shariat, SF; Tsuzuki, S; Yanagisawa, T | 1 |
| Alimohamed, N; Batuyong, E; Gagnon, R; Lee-Ying, R; Watson, AS | 1 |
| Aprikian, AG; Dragomir, A; Gatete, J; Guertin, JR; Yanev, I | 1 |
| Fujimoto, N; Fukuda, A; Harada, K; Hiroshige, T; Igawa, T; Minato, A; Mizushima, Y; Nagata, Y; Obara, W; Tomisaki, I | 1 |
| Enokida, H; Harada, K; Hashine, K; Horikoshi, H; Ichikawa, T; Ito, A; Kamijima, T; Kamiyama, M; Matsuyama, H; Miyao, T; Mizokami, A; Nakajima, K; Nishimoto, K; Shiina, H; Sugiyama, Y; Takahashi, S; Yaegashi, H | 1 |
| Gourdin, T | 3 |
| Alcaraz, A; Alekseev, B; Armstrong, AJ; Azad, A; Ganguli, A; Gomez-Veiga, F; Haas, GP; Holzbeierlein, J; Iguchi, T; Ivanescu, C; Petrylak, D; Ramaswamy, K; Rosbrook, B; Shore, ND; Stenzl, A; Szmulewitz, RZ; Villers, A | 1 |
| Birtle, AJ; Crabb, SJ; Downs, N; Dunkley, D; Ellis, M; Griffiths, G; Jones, RJ; Khoo, V; Light, M; Northey, J; Radford, M; Whitehead, A; Wilding, S | 1 |
| Bracht, T; Csizmarik, A; Hadaschik, B; Jurányi, Z; Keresztes, D; Kramer, G; Lázár, J; Maj-Hes, A; Nagy, N; Nyirády, P; Puhr, M; Sevcenco, S; Sitek, B; Szarvas, T; Takács, L; Tornyi, I; Witzke, K | 1 |
| Egawa, S; Habuchi, T; Hata, K; Hatakeyama, S; Hoshi, S; Ishi, N; Ishidoya, S; Ito, A; Kawamura, S; Kimura, T; Mitsuzuka, K; Miura, Y; Narita, S; Ohyama, C; Tanaka, T; Tsuchiya, N; Yanagisawa, T | 1 |
| Chiba, S; Egawa, S; Habuchi, T; Hata, K; Hatakeyama, S; Horikawa, Y; Ishida, T; Kashima, S; Kimura, T; Koizumi, A; Kumazawa, T; Maita, S; Narita, S; Ohyama, C; Okane, K; Sato, H; Shimoda, J; Suzuki, T; Takayama, K; Yamamoto, R; Yanagisawa, T | 1 |
| Hongo, H; Kamisawa, K; Kosaka, T; Matsumoto, K; Nakamura, K; Nishihara, H; Oya, M; Takeda, T; Yasumizu, Y | 1 |
| Atsuta, M; Egawa, S; Enei, Y; Habuchi, T; Hata, K; Hatakeyama, S; Kimura, T; Kondo, Y; Mori, K; Narita, S; Obayashi, K; Oguchi, T; Ohyama, C; Sadakane, I; Shariat, SF; Yanagisawa, T; Yoshihara, K | 1 |
| Ay, S; Dülgar, Ö; Efiloğlu, Ö; Gümüş, M; Mutlu Günaydın, U; Tataroğlu Özyükseler, D; Yıldırım, A | 1 |
| Bratt, O; Carlsson, S; Fransson, P; Karlsson, CT; Kindblom, J; Stranne, J | 1 |
| Drea, E; Garcia, D; Guan, AKD; Hutson, T; Morgans, AK; Vogelzang, NJ; Zhou, A | 1 |
| Oh, TH; Park, SC | 1 |
| Crawford, ED | 1 |
| Goly, N; Grüne, B; Haney, CM; Hartung, F; Herrmann, J; Jarczyk, J; Kowalewski, KF; Kriegmair, MC; Milczynski, V; Neuberger, M; Nitschke, K; Nuhn, P; Skladny, J; Waldbillig, F; Weiß, C; Wessels, F; Westhoff, N; Worst, TS | 1 |
| Ciccarese, C; Fizazi, K; Gillessen, S; Iacovelli, R; Sternberg, CN; Tortora, G | 1 |
| Egawa, S; Karakiewicz, PI; Kawada, T; Kimura, T; König, F; Laukhtina, E; Mostafaei, H; Motlagh, RS; Nyirady, P; Pallauf, M; Pradere, B; Quhal, F; Rajwa, P; Shariat, SF; Yanagisawa, T | 1 |
| Bazil, ML; Bignon, E; Blin, P; Capone, C; de Pouvourville, G; Droz-Perroteau, C; Gross-Goupil, M; Haaser, T; Jové, J; Lamarque, S; Messaoudi, F; Moore, N; Rébillard, X; Rouyer, M; Soulié, M; Thurin, NH | 1 |
| Ayers, K; Chen, R; Deitz, M; Fink, M; Guin, S; Jun, T; Klein, M; Liaw, BK; Mullaney, T; Newman, S; O'Connell, T; Oh, WK; Patel, B; Prentice, T; Schadt, EE; Zhou, X | 1 |
| Alan, O; Arikan, R; Basoglu, T; Cetin, IA; Dane, F; Demircan, NC; Ercelep, O; Filizoglu, N; Isik, S; Ones, T; Ozguven, S; Ozturk, MA; Sariyar, N; Telli, TA; Yumuk, PF | 1 |
| Ilbasmis-Tamer, S; Karagoz, ID; Simitcioglu, B; Tamer, U | 1 |
| Arranz, JA; Augustin, M; Carles, J; de Bono, JS; Fong, PCC; Gravis, G; Gurney, H; Heinzelbecker, J; Kolinsky, MP; Laguerre, B; Li, XT; Massard, C; Nordquist, LT; Oudard, S; Piulats, JM; Poehlein, CH; Qiu, P; Schloss, C; Tafreshi, A; Todenhöfer, T; Yu, EY | 1 |
| Alekseev, B; Burgents, J; Chiuri, VE; Clarke, NW; Degboe, A; Fléchon, A; Gresty, C; Jassem, J; Jones, R; Kang, J; Kocak, I; Redfern, C; Saad, F; Sala, N; Thiery-Vuillemin, A; Wiechno, P | 1 |
| Azuma, H; Burton, F; Carducci, MA; Chakraborty, G; Chen, YH; Davicioni, E; Frank, D; Hirani, R; Kantoff, PW; Lee, GM; Liu, G; Mazzu, YZ; Nandakumar, S; Rajanala, SH; Stopsack, KH; Sweeney, CJ; Wang, XV; Yoshikawa, Y | 1 |
| Agarwal, N; Antonarakis, ES; Fisher, V; Graf, RP; Li, G; Mathew Thomas, V; Nussenzveig, RH; Oxnard, GR; Ross, JS; Sayegh, N; Schrock, AB; Swami, U; Tripathi, N; Tukachinsky, H | 1 |
| Ahmed, ME; Alamiri, J; Andrews, JR; Bold, MS; Britton, CJ; Dundar, A; Higa, JL; Karnes, RJ; Kendi, AT; Kwon, E; Lowe, VJ; Pagliaro, LC | 1 |
| Chen, ML; Chuu, CP; Ho, CH; Huang, HL; Lai, CJ; Lin, YH; Liu, CH | 1 |
| Kamoto, T; Kimura, T; Mukai, S; Nagano, M; Okabe, KO; Onizuka, C; Otuka, I; Shirakawa, T; Takamori, H; Terada, N; Ueno, T; Yamashita, Y | 1 |
| Chen, CS; Chen, SY; Cheng, CL; Chiu, KY; Hsu, CY; Hung, SC; Li, JR; Lu, K; Wang, SS; Yang, CK | 1 |
| Denis, C; Sautois, B | 1 |
| Daaka, Y; Ishov, AM; Morozov, VM; Purayil, H; Sarwar, S | 1 |
| Borgmann, H; Borkowetz, A; Dotzauer, R; Hoffmann, MA; Höfner, T; Klümper, N; Lieb, V; Linxweiler, J; Neuberger, M; von Hardenberg, J; Wenzel, M; Worst, TS | 1 |
| Chen, W; Deol, A; Dickow, B; Dobson, K; Fontana, JA; Heath, EI; Lum, LG; Patel, M; Polend, A; Schalk, D; Schienschang, A; Thakur, A; Vaishampayan, UN; Whitaker, S | 1 |
| Shiota, M | 1 |
| Åström, L; Attard, G; Boysen, G; Bracarda, S; Chowdhury, S; Esen, A; Feyerabend, S; Gourgioti, G; López-Brea Piqueras, M; Martins, K; Matveev, VB; Merseburger, AS; Senkus, E | 1 |
| Al-Ezzi, E; Canil, C; Emmenegger, U; Hansen, AR; Mahler, M; Ong, M; Shrem, NS; Winquist, E; Zhang, L | 1 |
| Ashizawa, T; Hirano, H; Horie, S; Lu, Y; Nagata, M; Nagaya, N; Nakamura, S | 1 |
| Alekseev, B; Bulavkina, E; Dalina, A; Fedorova, M; Katunina, I; Kobelyatskaya, A; Krasnov, G; Kudryavtseva, A; Nyushko, K; Pavlov, V; Pudova, E; Snezhkina, A; Tkachev, S; Volodin, V | 1 |
| Chihara, I; Fujimoto, T; Hashimoto, K; Kamoto, T; Kawanishi, H; Kubota, M; Magaribuchi, T; Nakashima, M; Narita, S; Okabe, K; Sakurai, T; Sawada, A; Shimizu, Y; Terada, N; Tohi, Y; Uegaki, M; Yamada, Y; Yatsuda, J | 1 |
| Bosse, D; Kushnir, I; Lavallée, LT; Leigh, J; Mahdavi, R; Ong, M; Qureshi, D; Sucha, E; Tanuseputro, P; Webber, C | 1 |
| Barret, E; Beauval, JB; Brureau, L; Créhange, G; Dariane, C; Fiard, G; Fromont, G; Gauthé, M; Mathieu, R; Ploussard, G; Renard-Penna, R; Roubaud, G; Rouprêt, M; Rozet, F; Ruffion, A; Sargos, P | 1 |
| Alawi, M; Alsdorf, W; Böckelmann, L; Bokemeyer, C; Dyshlovoy, SA; Gild, P; Graefen, M; Hauschild, J; Kaune, M; Krisp, C; Langebrake, C; Mansour, W; Oh-Hohenhorst, SJ; Perner, S; Rohlfing, T; Saygi, C; Schlüter, H; Tilki, D; von Amsberg, G; Zielinski, A; Zilles, M | 1 |
| Chen, M; Chen, W; Diao, W; Ding, M; Gan, W; Guo, H; Ji, C; Qin, H; Yang, Y; Yin, H | 1 |
| He, C; Li, B; Li, C; Li, J; Qi, Z; Wang, S; Wei, W; Xiao, S; Yan, S; Yang, K; Zhang, Y | 1 |
| Ács, N; Csizmarik, A; Fazekas, T; Grünwald, V; Hadaschik, B; Hegyi, P; Kói, T; Kopa, Z; Lang, Z; Nyirády, P; Szarvas, T; Széles, ÁD; Teutsch, B; Váradi, A; Vékony, B | 1 |
| Kalabova, H; Melichar, B; Ondruskova, A; Purova, D; Rusarova, N; Studentova, H; Vitaskova, D | 1 |
| Galsky, MD; Gong, Y; Jun, T; Liaw, BC; Oh, WK; Seng, S; Tsao, CK | 1 |
| Habuchi, T; Hamaya, T; Hashimoto, Y; Hata, K; Hatakeyama, S; Kimura, T; Narita, S; Ohyama, C; Okamoto, T; Ozaki, K; Tanaka, T; Togashi, K; Yamamoto, H; Yanagisawa, T; Yoneyama, T | 1 |
| Anton, A; Azad, AA; Brown, S; Franchini, F; Gibbs, P; Goh, J; Gunjur, A; IJzerman, M; Kwan, EM; Mahar, RK; Parente, P; Parnis, F; Pereira-Salgado, A; Shapiro, J; Spain, L; Steer, C; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Akamatsu, S; Blas, L; Eto, M; Fujimoto, N; Habuchi, T; Kamoto, T; Kimura, H; Momozawa, Y; Narita, S; Sekine, Y; Shiota, M; Terada, N | 1 |
| Hwang, C; Li, P; Maahs, L; Pilling, A; Stangl, A; Wilner, C | 1 |
| Bian, XJ; Dai, B; Gu, WJ; Li, JH; Wan, FN; Ye, DW; Zhang, XM | 1 |
| Blin, P; Bosco-Levy, P; Droz-Perroteau, C; Jové, J; Lamarque, S; Lassalle, R; Rouyer, M; Schneeweiss, S; Segalas, C; Thurin, NH | 1 |
| Enei, Y; Fukuokaya, W; Habuchi, T; Hara, S; Hata, K; Hatakeyama, S; Kimura, T; Matsukawa, A; Miki, J; Miyajima, K; Mori, K; Nakazono, M; Narita, S; Ohyama, C; Otsuka, T; Sano, T; Shariat, SF; Yanagisawa, T; Yata, Y | 1 |
| Alibhai, SMH; Breunis, H; Emmenegger, U; Gregg, R; Hansen, AR; Kim, VS; Timilshina, N; Tomlinson, G; Yang, H | 1 |
| Hakamata, Y; Imai, S; Kanda, Y; Sugiura, K; Yoneda, T | 1 |
| Bundorf, MK; George, DJ; Gordee, A; Kaye, DR; Lee, HJ; Scales, CD; Ubel, PA | 1 |
| Furlow, B | 1 |
| Kim, JY; Lee, HJ; Lee, JL; Park, I; Park, K; Shin, SH | 1 |
| Chen, CH; Chen, IA; Chen, YH; Chen, YT; Cheng, YT; Chiang, PC; Chiang, PH; Kang, CH; Liu, YY; Luo, HL; Su, YL; Wang, HJ | 1 |
| Agarwal, N; Blauer-Peterson, CJ; Diessner, BJ; El-Chaar, NN; Hong, A; Nimke, D; Ramaswamy, K; Sandin, R; Swami, U | 1 |
| Burns, J; Caram, MEV; Hollenbeck, BK; Kumbier, K; Shahinian, V; Skolarus, TA; Sparks, JB; Stensland, KD; Tsao, PA; Washington, SL | 1 |
| Marchetti, A; Massari, F; Mollica, V; Rizzo, A; Rosellini, M; Tassinari, E | 1 |
| Bögemann, M; Crawford, ED; Cruz, F; Fizazi, K; Hussain, M; Joensuu, H; Kalebasty, AR; Kapur, S; Kopyltsov, E; Kuss, I; Saad, F; Shore, N; Smith, MR; Srinivasan, S; Sternberg, CN; Suzuki, H; Tombal, B; Verholen, F; Ye, D | 1 |
| Abida, W; Bambury, RM; Bryce, AH; Chowdhury, S; Daugaard, G; Despain, D; Emmenegger, U; Fizazi, K; Gingerich, JR; Heidenreich, A; Heyes, CA; Krieger, L; Lindberg, H; Loehr, A; McDermott, R; Morris, D; Nolè, F; Ostler, P; Pintus, E; Piulats, JM; Reaume, MN; Redfern, C; Ryan, CJ; Sáez, MI; Sautois, B; Sridhar, SS; Staffurth, J; Watkins, SP | 1 |
| Cang, S; Guo, Y; Li, M; Liu, L; Xu, D; Zhang, H; Zhang, J | 1 |
| Halabi, S; McSweeney, S; Morgans, AK; Oyenuga, A; Oyenuga, M; Prizment, A; Ryan, CJ | 1 |
| Habuchi, T | 1 |
| Deris, A; Sohrabi-Haghighat, M | 1 |
| Azem, O; Camden, NB; Cueto-Marquez, AE; D'souza, LA; King, K; Kishan, AU; Malone, S; Morgan, SC; Roy, S; Saad, F; Spratt, DE; Sun, Y; Wallis, CJD; Zhou, YM | 1 |
| Abe, H; Amiya, Y; Hayashi, S; Kaneko, Y; Kimura, N; Nakatsu, H; Shima, T; Suzuki, N; Takei, A; Tetsuka, T; Uchida, T | 1 |
| Cai, D; Chen, J; Chen, N; Chen, Y; Dai, J; Hu, X; Liang, J; Liu, H; Liu, Z; Ni, Y; Nie, L; Pan, X; Shen, P; Sun, G; Wang, M; Wang, Z; Xu, N; Yin, W; Yin, X; Zeng, H; Zeng, Y; Zhang, X; Zhang, Y; Zhao, F; Zhao, J; Zheng, L; Zhu, S; Zhu, X | 1 |
| Abramowitz, E; O'Sullivan, JM; Sierra-Scacalossi, L | 1 |
| Appleman, LJ; Autio, KA; Babiker, H; Billotte, S; Bogg, O; Cavazos, N; Chan, K; Cho, H; Higano, CS; Hollingsworth, R; Kaneda, M; Kern, KA; Li, R; Madan, RA; Nordquist, L; Petrylak, DP; Prasad, SM; Schweizer, MT; Tang, SY; Vogelzang, NJ; Wang, IM; Zhang, T; Zheng, J; Zhu, XH | 1 |
| Gourdin, T; Velayati, A | 1 |
| Arondekar, B; Barata, PC; Ivanova, J; Last, M; Leith, A; Montgomery, R; Niyazov, A; Ribbands, A | 1 |
| Araujo, JC; Armstrong, AJ; Carducci, MA; Chi, KN; de Bono, JS; Fizazi, K; Halabi, S; Higano, CS; Kelly, WK; Logothetis, C; Luo, B; Morris, MJ; Petrylak, DP; Rathkopf, DE; Roy, A; Ryan, CJ; Saad, F; Small, EJ; Sternberg, CN; Yang, Q | 1 |
| Kishan, AU; Le, ATT; Malone, J; Malone, S; Morgan, SC; Roy, S; Saad, F; Spratt, DE; Sun, Y; Wallis, CJD | 1 |
| Aragon-Ching, JB; Atiq, M; Chandran, E; Karzai, F; Madan, RA | 1 |
| Kanji, S; Peltekian, S; Sajwani, S; Wang, X | 1 |
| Abdel-Aty, H; Alzouebi, M; Amos, CL; Attard, G; Birtle, A; Brawley, C; Brown, LC; Brown, MD; Cathomas, R; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; Das, P; Dearnaley, DP; Diaz-Montana, C; Gale, J; Gilbert, D; Gillessen, S; Gilson, C; Grant, W; Gray, E; Hoyle, A; Jain, Y; James, ND; Jones, C; Jones, RJ; Langley, RE; Malik, Z; Mason, MD; Matheson, D; Millman, R; Montazeri, AH; Murphy, C; Murphy, L; O'Sullivan, JM; Parikh, O; Parkar, N; Parker, CC; Parmar, MKB; Pedley, I; Pezaro, C; Pugh, C; Robinson, A; Rush, H; Russell, JM; Sachdeva, A; Saxby, H; Srihari, N; Sydes, MR; Tanguay, J; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A | 1 |
| Cai, X; Cui, S; Duan, X; Tang, T; Wu, T | 1 |
| Ghamande, SS; Klaassen, Z; Wallis, CJD | 1 |
| Hiratsuka, K; Iwamoto, H; Izumi, K; Kadomoto, S; Mizokami, A; Naito, R; Nakata, H; Natsagdorj, A; Shigehara, K; Yaegashi, H | 1 |
| Arai, S; Fujizuka, Y; Hori, K; Koike, H; Matsui, H; Miyazawa, Y; Nomura, M; Sekine, Y; Suzuki, K; Tsuji, Y | 1 |
| Haldrup, J; Schmidt, L; Sørensen, KD; Weiss, S | 1 |
| Abida, W; Attard, G | 1 |
| Abdel Aziz, MH; Cagle-White, B; Castaneda, M; Lee, J; Oh, J; Rodriguez, L; Suh, H | 1 |
| Abdollah, F; Butaney, M; Cole, AP; Corsi, N; Davis, MJ; Majdalany, SE; Modonutti, D; Novara, G; Rogers, CG; Sood, A; Trinh, QD | 1 |
| Kazama, H; Matsubara, N; Matsuyama, H; Seto, T; Sunaga, Y; Suzuki, K | 1 |
| Bando, Y; Fujisawa, M; Furukawa, J; Hara, T; Harada, K; Nakano, Y; Okamura, Y; Terakawa, T | 1 |
| Bianchi, A; Fukuokaya, W; Kawada, T; Kimura, T; Kramer, G; Laukhtina, E; Majdoub, M; Mori, K; Petrov, P; Pradere, B; Quhal, F; Rajwa, P; Shariat, SF; von Deimling, M; Yanagisawa, T | 1 |
| Njar, VCO; Purushottamachar, P; Thankan, RS; Thomas, E; Weber, DJ | 1 |
| Bianchi, A; Kawada, T; Kimura, T; Laukhtina, E; Majdoub, M; Mori, K; Mostafaei, H; Pallauf, M; Pradere, B; Quhal, F; Rajwa, P; Sari Motlagh, R; Shariat, SF; Shim, SR; von Deimling, M; Yanagisawa, T | 1 |
| Beckstead, R; Cutshall, ZA; Dougherty, M; Haaland, B; Kohli, M; Kohli, R; Nelson, RE; Yoo, M | 1 |
| Agarwal, N; Fortuna, GG; Gebrael, G; Sayegh, N; Swami, U | 1 |
| Eterović, D; Jozić, T; Omrčen, T; Vrdoljak, E | 1 |
| Baba, Y; Fujiwara, S; Kamisawa, K; Kosaka, T; Matsumoto, K; Nishimoto, Y; Oya, M; Takeda, T; Watanabe, K | 1 |
| Anton, A; Azad, AA; Brown, S; Fernando, M; Gibbs, P; Goh, J; Liow, E; Parente, P; Parnis, F; Shapiro, J; Steer, C; Torres, J; Tran, B; Uccellini, A; Warren, M; Weickhardt, A; Wong, S | 1 |
| Das, CK; Goyal, S; Mavuduru, RS; Mittal, BR; Satapathy, S; Shukla, J; Singh, SK; Sood, A | 1 |
| Andreassen, BK; Fosså, SD; Storås, AH; Tsuruda, K | 1 |
| Horak, J; Omlin, A; Petrausch, U | 1 |
| Thomas, C | 1 |
| Fujimoto, K; Hori, S; Miyake, M; Miyamoto, T; Nakai, Y; Onishi, K; Shimizu, T; Takamatsu, N; Tanaka, N; Tomizawa, M | 1 |
| FitzGerald, LM; Koskinen, LM; Mäntylä, LE; Sipeky, C; Szabo, I; Varnai, R | 1 |
| Basch, EM; de Bono, JS; Fizazi, K; Pond, GR; Scher, HI; Smith, MR; Sonpavde, GP | 1 |
| Chen, YF; Man, YN | 1 |
| Anand, M; Armstrong, AJ; Barak, I; George, DJ; Halabi, S; Harrison, MR; Healy, P; Klein, M; Martinez, E; Nixon, AB; Szmulewitz, R; Wilder, R; Winters, C | 1 |
| Chen, B; Din, J; Fu, W; Hong, Z; Li, Q; You, X; Yuan, G; Zhao, B | 1 |
| Attard, G; Claessens, F; Eerlings, R; Handle, F; Helsen, C; Joniau, S; Kharraz, SE; Mills, IG; Moris, L; Prekovic, S; Smeets, E; Urbanucci, A; Van den Broeck, T | 1 |
| Boström, PJ; Ettala, O; Kaikkonen, E; Kellokumpu-Lehtinen, PL; Lehtinen, I; Nikulainen, I; Schleutker, J; Taimen, P | 1 |
| Komai, Y; Kondo, Y; Numao, N; Ogawa, M; Yamamoto, S; Yasuoka, S; Yonese, J; Yuasa, T | 1 |
| Abdel-Rahman, O | 2 |
| Ittmann, M; Kahraman, N; Ozpolat, B; Shao, L; Wang, J; Yan, G | 1 |
| Kramer, G; Shariat, SF; Stangl-Kremser, J | 1 |
| Barrack, ER; Gupta, N; Hwang, C; Maahs, L; Reddy, PV; Sanchez, BE; Van Harn, M | 1 |
| Carbonetti, G; Clement, T; Converso, C; Kaczocha, M; Ojima, I; Trotman, LC; Wang, C | 1 |
| Gao, F; Gao, X; Gou, X; He, D; Li, L; Pei, X; Sun, Y; Wu, K; Xu, J | 1 |
| Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F | 1 |
| Hu, TT; Li, LN; Lin, JZ; Wang, WW; Wu, HF; Xu, Z; Yu, HB; Zhang, CY; Zhu, GY; Zhu, JG | 1 |
| Fujita, T; Hanada, K; Inoue, D; Koutake, Y; Nakagawa, Y; Tsurusaki, Y | 1 |
| Bai, J; Chang, C; He, X; Hu, L; Li, G; Luo, J; Sun, Y; Ye, M; Zhang, D; Zhang, Y | 1 |
| Azuma, H; Fujiwara, Y; Hirano, H; Ibuki, N; Ichihashi, A; Inamoto, T; Komura, K; Matsunaga, T; Minami, K; Nishimoto, Y; Nomi, H; Saito, K; Takahara, K; Takai, T; Tanaka, T; Tanda, N; Taniguchi, K; Tsujino, T; Tsutsumi, T; Uchimoto, T; Uehara, H; Yoshikawa, Y | 1 |
| Bergman, A; Bianchini, D; Bournakis, E; Bria, E; Caffo, O; De Giorgi, U; Galli, L; Gelderblom, H; Oudard, S; Pappagallo, G; Schmid, S; Sella, A; Sperduti, I; Thomsen, FB; Tucci, M; Wissing, M; Yu, EY; Zagonel, V | 1 |
| Kunthur, A | 1 |
| Hasumi, H; Hayashi, N; Kawahara, T; Kishida, T; Makiyama, K; Miyoshi, Y; Nakaigawa, N; Tatenuma, T; Uemura, H; Yao, M | 1 |
| Arai, Y; Habuchi, T; Hatakeyama, S; Hoshi, S; Ishida, M; Ishidoya, S; Ito, A; Kawaguchi, T; Kawamura, S; Mitsuzuka, K; Narita, S; Ohyama, C; Okita, K; Sakurai, T; Sato, H; Shimoda, J; Takahashi, M; Tsuchiya, N | 1 |
| Akakura, K; Ando, K; Fujimoto, A; Ichikawa, T; Imamura, Y; Komiya, A; Maimaiti, M; Saito, S; Sakamoto, S; Sanjyon, P; Sato, N; Takeshita, N | 1 |
| Al-Adhami, M; Armstrong, AJ; Beer, TM; de Bono, J; Lin, P; Parli, T; Scher, HI; Steinberg, J; Sternberg, CN; Sugg, J; Tombal, B | 1 |
| Gotoh, M; Hattori, K; Hattori, R; Ishikawa, T; Kato, M; Kawanishi, H; Naito, Y; Sano, T; Tochigi, K; Tsuzuki, T; Yamamoto, A; Yuba, T | 1 |
| Fang, Z; Guo, F; Shi, X; Sun, Y; Wang, F; Yang, B; Zhang, C; Zhang, W; Zhu, Y | 1 |
| Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; Haanen, JB; Hamberg, P; Lam, MGEH; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W | 1 |
| Colapietro, A; Del Fattore, A; Delle Monache, S; Festuccia, C; Fogler, W; Gravina, GL; Iorio, R; Magnani, J; Mancini, A; Pompili, S; Ventura, L; Vetuschi, A | 1 |
| Eto, M; Harano, M; Hasegawa, S; Kuroiwa, K; Nakamura, M; Sakamoto, N; Seki, N; Shiota, M; Tomoda, T; Yokomizo, A; Yunoki, T | 3 |
| Bouleftour, W; Bousarsar, A; Chanal, E; Chanelière, AF; Daguenet, E; Flechon, A; Guillot, A; Magné, N; Méry, B; Vallard, A; Vassal, C; Vincent, L | 1 |
| Hayashi, Y; Ishibashi, Y; Onuki, T; Suzuki, K; Yamaguchi, K | 1 |
| Assenholt, J; Hansen, TF; Madsen, JS; Osther, PJS; Zedan, AH | 1 |
| Ahmed, ME; Andrews, JR; Bryce, AH; Karnes, RJ; Kwon, E | 1 |
| Culig, Z; Eder, IE; Ferrone, L; Furlan, T; Gruber, M; Handle, F; Puhr, M; Sampson, N; Santer, FR; Schäfer, G | 1 |
| Briganti, A; D'Andrea, D; Enikeev, DV; Glybochko, PV; Karakiewicz, P; Korn, SM; Kramer, G; Mari, A; Pones, M; Shariat, SF; Stangl-Kremser, J; Suarez-Ibarrola, R | 1 |
| Baretton, GB; Diehl, T; Erb, HHH; Haferkamp, A; Hemmerlein-Thomas, M; Jüngel, E; Neisius, A; Sommer, U; Sparwasser, P; Thomas, C; Tsaur, I | 1 |
| Casadei, C; Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D; Stellato, M; Tonini, G | 1 |
| Gao, WQ; Li, L; Liu, L; Liu, Y; Tong, Y; Wang, F | 1 |
| Arai, G; Egawa, S; Eto, M; Itoh, K; Kakuma, T; Matsumoto, K; Naito, S; Nakagawa, M; Nasu, Y; Noguchi, M; Ohyama, C; Sasada, T; Shichijo, S; Suekane, S; Uemura, H; Yamada, A | 1 |
| Almassi, N; Carducci, MA; Chen, YH; DiPaola, RS; Dreicer, R; Garcia, JA; Hearn, JWD; Hobbs, B; Jarrard, DF; Li, H; Reddy, CA; Reichard, CA; Sharifi, N; Sweeney, CJ | 1 |
| George, DJ; Higano, CS; Jiao, X; Kalinovský, J; Miller, K; Saad, F; Sartor, O; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
| Aiello, P; Balsari, A; Giussani, M; Regondi, V; Ripamonti, F; Rossini, A; Tagliabue, E; Triulzi, T | 1 |
| Jeong, KC; Kwon, WA; Lee, SJ; Seo, HK | 1 |
| Hatano, K; Kakimoto, KI; Kuribayashi, S; Nakai, Y; Nakayama, M; Nishimura, K; Tsuji, H; Yumiba, S | 1 |
| Dalhaug, A; Haukland, E; Nieder, C | 1 |
| Cao, W; Cui, D; Hou, N; Li, W; Liu, B; Liu, Y; Tan, H; Wang, Z; Xu, B; Zheng, D | 1 |
| Chen, Z; Hu, D; Jiang, L; Luo, S; Shao, L; Tang, W | 1 |
| Dutta, S; Halabi, S; Kelly, WK; Middleberg, R; Morris, MJ; Russell, C; Ryan, CJ; Taplin, ME | 1 |
| Merseburger, AS; von Amsberg, G | 1 |
| Ohlmann, CH; Thomas, C | 1 |
| Buttigliero, C; Di Maio, M; Di Stefano, RF; Guglielmini, P; Lacidogna, G; Numico, G; Pisano, C; Scagliotti, GV; Sonetto, C; Tucci, M; Turco, F; Vignani, F | 1 |
| Araujo, JC; Chi, KN; De Bono, JS; Dutta, S; Eisenberger, MA; Fizazi, K; Halabi, S; Higano, CS; Kelly, WK; Logothetis, C; Morris, MJ; Petrylak, DP; Quinn, DI; Rosenthal, M; Small, EJ; Tangen, CM; Tannock, IF; Thompson, IM | 1 |
| Bourlon, MT; Crawford, ED; Gonzalez-Ochoa, E; Verduzco-Aguirre, H | 1 |
| Galsky, MD; Martini, A; Montorsi, F; Oh, WK; Pfail, J | 1 |
| Csizmarik, A; Fazekas, T; Grünwald, V; Hadaschik, B; Hüttl, A; Jurányi, Z; Kocsis, Z; Kramer, G; Maj-Hes, A; Nyirády, P; Püllen, L; Sevcenco, S; Shariat, SF; Szarvas, T | 1 |
| Csizmarik, A; Keresztes, D; Küronya, Z; Nagy, N; Nyirády, P; Riesz, P; Szarvas, T; Váradi, M | 1 |
| Arai, Y; Habuchi, T; Hamano, I; Hatakeyama, S; Hoshi, S; Ishida, M; Ishidoya, S; Ito, A; Kawaguchi, T; Kawamura, S; Mitsuzuka, K; Narita, S; Ohyama, C; Okamoto, T; Sakurai, T; Sato, H; Shimoda, J; Takahashi, M; Tsuchiya, N | 1 |
| Fang, Y; Lin, S; Luo, Y; Situ, J; Yang, F | 1 |
| Gao, S; Li, J; Liu, B; Tang, M; Wang, Z; Zhang, L; Zhang, W | 1 |
| Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D | 1 |
| Buonerba, C; Crocetto, F; De Placido, S; Di Lorenzo, G; Dolce, P; Facchini, S; Ferro, M; Imbimbo, C; Longo, N; Lucarelli, G; Marinelli, A; Mirone, V; Montella, L; Scafuri, L; Sonpavde, G; Terracciano, D; Vaia, A; Verde, A | 1 |
| Fan, WL; Li, JZ; Pu, CL | 1 |
| Egawa, S; Fukuokaya, W; Kimura, S; Kimura, T; Koike, Y; Miki, K; Sasaki, H; Tashiro, K; Tsuzuki, S; Urabe, F | 1 |
| Eterović, D; Omrčen, T; Vrdoljak, E | 1 |
| Aalinkeel, R; Bulmahn, JC; Cwiklinski, K; Kutscher, HL; Prasad, PN; Schwartz, SA | 1 |
| Miller, K | 2 |
| Bektic, J; Borgmann, H; Dotzauer, R; Foti, S; Gandaglia, G; Heidegger, I; Hunting, JCB; Kretschmer, A; Ploussard, G; Tilki, D; Tsaur, I; van den Bergh, RCN | 1 |
| Ahmed, ME; Alamiri, J; Alom, M; Andrews, JR; Haloi, R; Higa, J; Jeffrey Karnes, R; Joshi, V; Kwon, E; Motterle, G; Shah, PH | 1 |
| Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA | 1 |
| Agarwal, N; Beer, TM; Bergman, AM; Bossi, A; Chen, A; Ciuleanu, TE; Danielli, R; den Eertwegh, AJMV; Drake, CG; Fizazi, K; Franke, FA; Gerritsen, WR; Hansen, S; Houede, N; Korbenfeld, E; Krainer, M; Kwon, ED; Logothetis, C; Mahammedi, H; McHenry, MB; Ng, S; Santos, R; Scher, HI; Sengeløv, L; Sundar, S | 1 |
| Batra, SK; Das, A; Datta, K; Halder, S; Islam, R; Kshirsagar, P; Kukreja, RC; Mallya, K; Muniyan, S; Parte, S; Rachagani, S; Rauth, S; Seshacharyulu, P; Siddiqui, JA; Teply, BA; Vengoji, R; Xi, L | 1 |
| Chen, KC; Chen, YL; Chiu, HW; Hung, RC; Kuei, CH; Lee, HH; Lee, WJ; Lin, CH; Lin, HY; Lin, MH; Lin, YF; Lu, LS; Zheng, JQ | 1 |
| Basal, FB; Bilgetekin, I; Cinkir, HY; Demirci, U; Esin, E; Oksuzoglu, B | 1 |
| Bannowsky, A; Becker, K; Bokemeyer, C; Eichenauer, R; Lehmann, J; Merseburger, AS; Mickisch, G; Steuber, T; von Amsberg, G; von Kügelgen, T; Wülfing, C | 1 |
| Al Harthy, M; Arlen, PM; Bilusic, M; Chun, G; Cordes, L; Couvillon, A; Dahut, WL; Dawson, NA; Figg, WD; Gulley, JL; Hankin, A; Karzai, FH; Kim, JW; Lee, MJ; Lee, S; Madan, RA; Marte, JL; Owens, H; Peer, CJ; Petrylak, DP; Rosner, I; Steinberg, SM; Theoret, MR; Tomita, Y; Trepel, JB; Williams, M; Yuno, A | 1 |
| Anton, A; Azad, A; Gibbs, P; Goh, J; Joshua, AM; Kwan, E; Muthusamy, A; Parente, P; Parnis, F; Pook, D; Schmidt, A; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Byeon, S; Hur, JY; Jeon, HG; Jeon, SS; Kim, H; Kim, J; Kwon, M; Lee, HM; Park, SH | 1 |
| Aghai, A; Chen, M; de Morrée, ES; de Ridder, CMA; de Wit, R; Erkens-Schulze, S; Gibson, A; Lolkema, MP; Mathijssen, RHJ; Moll, JM; Mout, L; Sparreboom, A; Stuurman, D; van Weerden, WM | 1 |
| Csizmarik, A; Fazekas, T; Grünwald, V; Hadaschik, B; Hüttl, A; Kramer, G; Maj-Hes, A; Nyirády, P; Sevcenco, S; Shariat, SF; Szarvas, T; Tschirdewahn, S; Váradi, M | 1 |
| Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kano, H; Makino, T; Mizokami, A; Naito, R; Shigehara, K; Shimada, T; Yaegashi, H | 1 |
| Hu, YC; Jiang, JH; Ma, L; Ma, Q; Wang, KY; Zhang, LL | 1 |
| Aytes, A; Bakht, M; Beltran, H; Buisan, O; Bystrup, S; Castro, E; Conteduca, V; Font, A; Indacochea, A; Jimenez, N; Marin-Aguilera, M; Martinez-Balibrea, E; Mellado, B; Olmos, D; Palomero, L; Pardo, JC; Piulats, JM; Ruiz de Porras, V; Solé-Blanch, C; Suarez, JF; Wang, XC | 1 |
| Arai, G; Egawa, S; Fujimoto, H; Fujimoto, K; Fujisawa, M; Fukasawa, S; Hashine, K; Hinotsu, S; Itoh, K; Kohjimoto, Y; Matsumoto, H; Naito, S; Nakatsu, H; Noguchi, M; Takenaka, A; Uemura, H | 1 |
| de Wit, R; Freedland, S; Tombal, B | 1 |
| Pienta, KJ; Reyes, DK; Rowe, SP; Sheikhbahaei, S | 1 |
| Hervonen, P; Huttunen, T; Jekunen, A; Kataja, V; Kautio, AL; Kellokumpu-Lehtinen, PL; Klintrup, K; Leskinen, M; Luukkaa, M; Marttila, T; Pulkkanen, K; Utriainen, T | 1 |
| Brown, J; Cunningham, J; Gatenby, R; Peeters, R; Staňková, K; Thuijsman, F; Viossat, Y | 1 |
| Buonerba, C; Busetto, GM; Caraglia, M; Crocetto, F; de Cobelli, O; De Placido, S; Di Lorenzo, G; Dolce, P; Facchini, BA; Ferro, M; Klain, M; La Civita, E; Lucarelli, G; Onofrio, L; Porreca, A; Scafuri, L; Sonpavde, G; Terracciano, D; Verde, A; Zappavigna, S | 1 |
| Bahl, A; Birtle, AJ; Crabb, SJ; Downs, N; Dunkley, D; Elliott, T; Griffiths, G; Jagdev, S; Jones, RJ; Khoo, V; Kumar, S; Light, M; Martin, K; Marwood, E; Northey, J; Robinson, A; Rooney, C; Salinas-Souza, C; Shaw, E; Stephens, C; Sundar, S; Westbury, C; Whitehead, A; Wilding, S | 1 |
| Fontana, F; Limonta, P; Marzagalli, M; Montagnani Marelli, M; Moretti, RM; Raimondi, M | 1 |
| Eichenauer, R; Goebell, PJ; Lange, C; Machtens, S; Schostak, M; Schwentner, C; Tauber, R; Todenhöfer, T; Wülfing, C | 1 |
| Eto, M; Inokuchi, J; Kashiwagi, E; Kobayashi, S; Machidori, A; Matsumoto, T; Monji, K; Shiga, KI; Shiota, M; Takahashi, R; Takeuchi, A; Yamashita, T; Yokomizo, A | 1 |
| Li, Q; Xie, D; Zhang, PF | 1 |
| Anai, S; Fujimoto, K; Ichikawa, K; Miyake, M; Nakai, Y; Tanaka, N | 1 |
| Fan, Y; Hu, S; Jin, J; Li, S; Liu, Z; Lv, T; Sheng, J; Song, Y; Yu, W; Zhang, C | 1 |
| Galsky, MD; Martini, A; Montorsi, F; Oh, WK; Parikh, AB; Sfakianos, JP; Tsao, CK | 1 |
| Fan, J; He, D; Li, L; Liu, T; Pei, X; Shi, X; Wu, K; Yang, T; Zhang, D | 1 |
| Abouassaly, R; Bryk, DJ; Ericson, K; Fascelli, M; Haywood, SC; Khanna, A; Murthy, PB; O'Connor, LP; Yerram, NK | 1 |
| Eto, M; Inokuchi, J; Kashiwagi, E; Kobayashi, S; Koura, M; Matsumoto, T; Monji, K; Shiga, KI; Shiota, M; Takeuchi, A; Ueda, S; Yokomizo, A | 1 |
| Arranz, JA; Castro, E; Climent, MA; Gallardo, E; González Del Alba, A; Gonzalez-Billalabeitia, E; Lorente, D; Maroto, JP; Méndez-Vidal, MJ; Vazquez, S | 1 |
| Ebinç, S; Isikdogan, A; Kaplan, MA; Karaağaç, M; Kaya, AO; Koca, S; Kut, E; Menekşe, S; Oruç, Z; Özyurt, N; Sakin, A; Sever, ÖN; Tatlı, AM; Turhal, NS; Yasin, İ; Zeynelgil, E | 1 |
| Abuín, C; Aguín-Losada, S; Anido, U; Brea Iglesias, J; Cebey, V; Costa, C; García González, J; González-Conde, M; León-Mateos, L; López-López, R; Martínez-Fernández, M; Muinelo-Romay, L; Pereira-Veiga, T; Piñeiro-Cid, R | 1 |
| Baeksted, C; Johansen, C; Pappot, H; Stormoen, DR; Taarnhøj, GA | 1 |
| Chen, J; Hu, C; Jiang, Y; Liu, T; Liu, W; Wu, S; Xia, H; Xu, Y; Yang, Y; Zhao, L | 1 |
| Abrial, C; Atger, M; Chollet, P; Durando, X; Eymard, JC; Ginzac Couvé, A; Kwiatkowski, F; Mahammedi, H; Monange, B; Passildas-Jahanmohan, J; Pouget, M; Richard, D; Savareux, L; Thivat, E; Van Praagh, I | 1 |
| Aggarwal, RR; Alva, AS; Borno, HT; Chi, KN; Chou, J; Desai, A; Dhawan, MS; Feng, FY; Koshkin, VS; Kwon, DH; Reimers, MA; Small, EJ; Wright, F; Wyatt, AW; Yip, SM; Zhang, L | 1 |
| Beijnen, JH; Bergman, AM; Devriese, LA; Eskens, FALM; Janssen, JM; Keessen, M; Kessels, R; Mehra, N; Robbrecht, DGJ; Thijssen, B; van Eijk, M; Vermunt, MAC | 1 |
| Barwick, B; Boise, L; Chen, HR; Chen, J; Dong, JT; Fu, C; Kowalski, J; Kucuk, O; Li, M; Li, X; Li, Y; Osunkoya, AO; Qian, WP; Vertino, PM; Wu, D; Wu, Q; Xia, S; Xie, L; Yang, L; Zhang, B; Zhao, Y; Zhou, W | 1 |
| Aben, KKH; Bergman, AM; Coenen, JLLM; de Wit, R; Gerritsen, WR; Kuppen, MCP; Mehra, N; Somford, DM; Uyl-de Groot, CA; van den Bergh, ACM; van den Eertwegh, AJM; van Moorselaar, RJA; van Oort, IM; Westgeest, HM | 1 |
| Bauman, J; Burns, J; Caram, MEV; Chapman, CH; Hollenbeck, BK; Kumbier, K; Shahinian, VB; Skolarus, TA; Sparks, JB; Tsao, PA | 1 |
| Alongi, F; Alongi, P; Baldari, S; Borsatti, E; Bortolus, R; Caffo, O; Cortesi, E; Costa, RP; De Giorgi, U; De Vincentis, G; Donner, D; Facchini, G; Fanti, S; Frantellizzi, V; Galli, L; Lo Re, G; Masini, C; Monari, F; Morabito, A; Pignata, S; Pinto, C; Salgarello, M; Sbrana, A; Spada, M; Tucci, M; Zichi, C | 1 |
| Izard, JP; Robinson, AG; Vera-Badillo, FE | 1 |
| Alibhai, SMH; Breunis, H; Emmenegger, U; Fleshner, N; Gregg, R; Hansen, AR; Hotte, S; Joshua, AM; Timilshina, N; Tomlinson, G; Warde, P | 1 |
| Dai, J; Li, J; Li, Y; Liu, N; Song, Y; Tang, X; Wu, Y; Xian, P; Xiong, L; Zhou, H | 1 |
| Cardoso, APG; Cortés, DEL; Costa, LAGA; da Trindade, KM; Dettino, ALA; Dos Santos, LV; Gillessen, S; Herchenhorn, D; Jardim, DLF; Kann, AG; Kater, FR; Maia, MC; Maluf, FC; Morbeck, IAP; Pereira, FMT; Reolon, JFN; Rinck, JA; Sade, JP; Sasse, AS; Silva, AG; Siqueira, MB; Soares, A; Zarbá, JJ | 1 |
| Aguiar, S; Ayadi, M; Bastos, DA; Boghikian, PS; de Almeida Saito, HP; de Araújo Cavallero, SR; de Carvalho, RS; de Fogace, RN; de Oliveira, FNG; de Pádua, FV; Kater, FR; Kopp, RM; Maluf, FC; Marques Monteiro, FS; Orlandi, FJ; Pereira, FMT; Rodrigues da Rosa, DA; Schutz, FA; Serrano Uson, PL; Sommer, SG; Souza, VC; Wiermann, EG | 1 |
| Chan, K; Chan, TW; Johnson, D; Lee, KC; Ng, B; Ng, J; Poon, DMC; Siu, S | 1 |
| Fan, J; Guo, G; He, D; Li, L; Pei, X; Shi, X; Wang, X; Wang, Y; Yang, T | 1 |
| Bury, D; de Bono, J; Eisenberger, M; Fizazi, K; Oudard, S; Ozatilgan, A; Poole, EM; Sartor, O; Thiery-Vuillemin, A | 1 |
| Chen, W; Cheng, H; Chi, C; Dong, B; Dong, H; Dong, L; Fan, L; Li, L; Li, Y; Pan, J; Sha, J; Wu, K; Xue, W; Yang, B; Yao, X; Zhang, F; Zhu, Y | 1 |
| Kramer, G; Maj-Hes, A; Sevcenco, S; Szarvas, T | 1 |
| Guan, W; Hu, J; Li, F; Zhang, Y; Zhang, Z; Zhao, Z | 1 |
| Aragón, IM; Attard, G; Brighi, N; Casadei, C; Castro, E; Conteduca, V; De Giorgi, U; Gonzalez-Billalabeitia, E; Gurioli, G; Jayaram, A; Lolli, C; Lozano, R; Marin-Aguilera, M; Mellado, B; Olmos, D; Romero-Laorden, N; Scarpi, E; Schepisi, G; Wetterskog, D; Wingate, A | 1 |
| Colassin, A; Denis, C; Hermesse, J; Sautois, B; Waltregny, D | 1 |
| Akre, O; Aly, M; Andersson, TML; Dearden, L; Eklund, M; Eloranta, S; Leval, A; Liwing, J; Mehra, M; Nair, S; Nordström, T; Pettersson, A; Schain, F; Vigneswaran, HT; Warnqvist, A | 1 |
| Burgents, J; Chandana, SR; Facchini, G; Fizazi, K; Flaig, TW; Gafanov, R; Kramer, G; Li, B; Petrylak, DP; Piulats, JM; Ratta, R | 1 |
| Fujiwara, M; Fujiwara, R; Komai, Y; Numao, N; Oguchi, T; Yamamoto, S; Yasuoka, S; Yonese, J; Yuasa, T | 1 |
| Abdulkhayevich, AA; Kim, SC; Kim, SH; Kim, YM; Lee, SH; Lee, WH; Moon, KH; Park, JW; Park, S | 1 |
| Akdeniz, N; Bayoğlu, İV; Bilgetekin, İ; Bilir, C; Çınkır, HY; Demirci, A; Demirci, U; Gül, D; Gülbağcı, B; Hacıbekiroğlu, İ; Koca, S; Öksüzoğlu, B; Varım, C | 1 |
| Glaeske, G; Horenkamp-Sonntag, D; Kreis, K; Schneider, U; Weissbach, L; Zeidler, J | 1 |
| Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C | 1 |
| Christy, J; Kandah, E; Kesari, K; Singh, T | 1 |
| Bögemann, M; Grimm, MO; Rexer, H | 1 |
| Armstrong, CM; D'Abronzo, LS; Evans, CP; Gao, AC; Lombard, AP; Lou, W; Ning, S | 1 |
| Anton, A; Azad, A; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Pezaro, C; Semira, MC; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Aglietta, M; Altosole, T; Astone, G; Boccardo, F; Carles, J; Criscuolo, D; Del Conte, G; Fenoglio, D; Ferrera, F; Filaci, G; Gianese, F; Guglielmini, P; Kalli, F; Lamperti, G; Morales-Barrera, R; Nolè, F; Parodi, A; Scagliotti, G; Signori, A; Tomasello, L; Zanardi, E | 1 |
| Aglietta, M; Aieta, M; Bozza, G; Buti, S; Caffo, O; Carrozza, F; Ciccarese, C; D'Angelo, A; De Giorgi, U; Ermacora, P; Facchini, G; Fratino, L; Galli, L; Gasparro, D; Giordano, M; Iacovelli, R; Kinspergher, S; Lippe, P; Lo Re, G; Maines, F; Maruzzo, M; Messina, C; Morelli, F; Mucciarini, C; Nicodemo, M; Nolè, F; Ortega, C; Palesandro, E; Pappagallo, G; Porta, C; Razzini, G; Rossetti, S; Sabbatini, R; Sartori, D; Scapoli, D; Schepisi, G; Valcamonico, F; Veccia, A; Verri, E; Vittimberga, I; Zagonel, V | 1 |
| Amoroso, D; Baier, S; Bellissimo, AR; Berruti, A; Bianchi, S; Buttigliero, C; Chiappino, I; Ciccone, G; Comandone, A; Dal Canton, O; Dalla Volta, A; Fea, E; Gennari, A; Masini, C; Montagnani, F; Mosca, A; Ortega, C; Prati, V; Sacco, C; Sirotova, Z; Tucci, M; Valcamonico, F; Vanella, P; Zamparini, M | 1 |
| Bektic, J; Brandt, MP; Debedde, E; Dotzauer, R; Ermacora, P; Foti, S; Gadot, M; Gandaglia, G; Heidegger, I; Höfner, T; Hunting, JCB; Kafka, M; Kretschmer, A; Ploussard, G; Rodler, S; Rosenzweig, B; Surcel, C; Thibault, C; Thomas, A; Tilki, D; Tsaur, I; van den Bergh, RCN; von Amsberg, G; Zattoni, F | 1 |
| Li, X; Petinrin, OO; Wong, KC | 1 |
| Eto, M; Inokuchi, J; Kashiwagi, E; Kobayashi, H; Kobayashi, S; Matsumoto, T; Monji, K; Sato, N; Shiga, KI; Shiota, M; Takeuchi, A; Yokomizo, A | 1 |
| Bai, GC; He, ZS; Jin, J; Song, Y; Yu, W | 1 |
| Chen, J; Chen, N; Chen, X; Dai, J; He, B; Liang, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Tao, R; Wang, Z; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhu, S; Zhu, X | 1 |
| Cicero, G; DE Luca, R; Dieli, F; Dorangricchia, P | 1 |
| Armstrong, A; Balk, M; Brown, B; Bui, C; Chambers, J; Deangelis, J; Fitch, K; Flanders, S; Sawhney, TG | 1 |
| Aneja, R; Choi, DH; Donthamsetty, S; Gupta, MV; Kaur, R; Mittal, K; Reid, MD; Rida, PCG; Yang, C | 1 |
| Corman, S; Drea, E; Flannery, K; Gao, X; Hudspeth, L; Miao, R; Xue, M | 1 |
| Sidaway, P | 1 |
| Berdah, JF; Culine, S; Massard, C; Pasquier, D; Penel, N; Turpin, A | 1 |
| Arranz, JA; Climent, MÁ; Gironés, R; Torregrosa, MD; Vázquez, S | 1 |
| Beeker, A; Bloemendal, HJ; de Klerk, JMH; Hoekstra, OS; Jonker, MA; Los, M; O'Sullivan, JM; Oprea-Lager, DE; van den Berg, HP; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW | 1 |
| Breaker, K; Flaig, TW; Gao, D; Kessler, ER; Lam, ET; Wacker, M; Wold, M | 1 |
| Baldari, S; Boni, G; Bortolus, R; Caffo, O; Conti, G; De Vincentis, G; Monari, F; Procopio, G; Santini, D; Seregni, E; Valdagni, R | 1 |
| Armstrong, CM; Evans, CP; Gao, AC; Liu, C; Lombard, AP; Lou, W | 1 |
| Bao, L; Cao, Q; Chen, K; Huang, X; Li, X; Liu, L; Lou, N; Qiu, B; Ruan, H; Wang, K; Xiao, W; Xu, G; Yang, H; Yuan, C; Zhang, X | 1 |
| Chen, M; Du, Z; Goodin, S; He, Y; Huang, H; Li, D; Wang, H; Wu, X; Yu, L; Zhang, K; Zheng, X | 1 |
| Eiber, M; Graham, J; Gschwend, JE; James, N; Maurer, T | 1 |
| Izumi, K; Kadono, Y; Kitagawa, Y; Konaka, H; Mizokami, A | 1 |
| Agarwal, N; Carducci, MA; Garzotto, MG; Goldkorn, A; Higano, CS; Hussain, MHA; Lara, PN; Mack, PC; Monk, JP; Plets, M; Pond, GR; Quinn, DI; Sonpavde, G; Tangen, CM; Thompson, IM; Twardowski, PW; Van Veldhuizen, PJ; Vogelzang, NJ | 1 |
| Gallagher, M; Reinhart, M; Sartor, O; Summers, N; Vanderpuye-Orgle, J | 1 |
| Hinz, S | 1 |
| Albany, C; Antonarakis, ES; Bai, Y; Ballman, K; Eisenberger, MA; Galletti, G; Giannakakou, P; Gjyrezi, A; Gruber, CN; Kirby, BJ; Lannin, TB; Nanus, DM; North, S; Portella, L; Pratt, ED; Saad, F; Sonpavde, G; Stewart, J; Suri, S; Szatrowski, T; Tagawa, ST; Tasaki, S; Tsao, CK; Vanhuyse, M; Worroll, D; Zaher, A; Zhou, W | 1 |
| Crumbaker, M; Gurney, H | 1 |
| Albers, P; Goebell, PJ; Grimm, MO; Klier, J; König, F; Machtens, S; Ohlmann, CH; Schostak, M; Schrader, AJ | 1 |
| Aki, R; Ito, T; Matsushita, Y; Miyake, H; Motoyama, D; Otsuka, A; Sugiyama, T; Tamura, K | 2 |
| Bianchini, D; de Bono, J; Gilman, A; Hall, E; IJzerman, M; Kolinsky, M; Lorente, D; Mateo, J; Mehra, N; Miranda, M; Omlin, A; Payne, H; Perez, R; Pezaro, C; Porta, N; Ravi, P; Rescigno, P; Terstappen, L; Tunariu, N | 1 |
| Beerlage, HP; Bloemendal, HJ; Boerma, MO; Bos, MMEM; Coenen, JLLM; Cordia, I; de Vos, AI; de Wit, R; Geenen, MM; Gerritsen, WR; Hendriks, MP; Peters, FPJ; Polee, MB; Spermon, R; Tick, LW; Uyl-de Groot, CA; van de Wouw, AJ; van den Berg, P; van den Bergh, ACM; van den Bosch, J; van den Eertwegh, AJM; van Moorselaar, RJA; Westgeest, HM | 1 |
| Antonarakis, ES; Harshman, LC; Kantoff, PW; Lee, GM; Maughan, BL; McKay, R; Mucci, LA; Nakabayashi, M; Pomerantz, M; Sweeney, CJ; Taplin, ME; Tripathi, A; Wang, X; Werner, L | 1 |
| Cheng, WY; Dhawan, R; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Sung, J; Vekeman, F | 1 |
| Armstrong, AJ; Zhang, T | 1 |
| Beer, TM | 1 |
| Bando, Y; Fujisawa, M; Furukawa, J; Harada, KI; Hinata, N; Nakano, Y; Terakawa, T | 1 |
| Scott, LJ | 1 |
| Fukasawa, S; Kamiya, N; Kawahara, T; Kawakami, S; Matsubara, N; Otsuka, M; Satoh, T; Suzuki, H; Tabata, KI; Uemura, H; Yamada, Y; Yano, A | 1 |
| Blasi, L; Cicero, G; De Luca, R; Dieli, F; Pavone, C; Pepe, A; Simonato, A | 1 |
| Bolenz, C; Frangenheim, T; Fuxius, S; Heinrich, E; Müller, M; Schwartz, M; VON Hardenberg, J; Weiss, C; Werner, T | 1 |
| Cicero, G; De Luca, R; Dieli, F | 1 |
| Bteich, J; Ernsting, MJ; Hoang, B; Kiyota, T; Li, SD; Tang, WS; Undzys, E | 1 |
| Chikazawa, I; Inoue, S; Miyazawa, K; Morita, N; Motoo, Y; Nakai, D; Nakazawa, Y; Tanaka, T | 1 |
| Enokida, H; Inoue, S; Ishibashi, K; Izumi, K; Kamiyama, M; Kawai, N; Mizokami, A; Namiki, M; Shima, T; Takahara, S; Tanaka, N; Yoshio, Y | 1 |
| Alekseev, B; Beer, TM; Blumenstein, B; Chi, KN; Fizazi, K; Fléchon, A; Gravis, G; Hotte, SJ; Jacobs, CA; Joly, F; Malik, Z; Matveev, V; Saad, F; Stewart, PS | 1 |
| Baton, F; Bellmunt, J; Chowdhury, S; Climent, MA; Daugaard, G; Dumez, H; Fizazi, K; Flechon, A; Germann, N; Guida, A; Ladoire, S; Liutkauskiene, S; Matouskova, M; Moe, M; Penel, N; Sengeløv, L; Stachurski, L; Sternberg, CN; Thiery-Vuillemin, A; Ulys, A | 1 |
| Kucuk, O; Li, X; Mamouni, K; Wu, D; Yang, Y | 1 |
| Albers, P; Bögemann, M; Goebell, P; Gschwend, JE; Heidenreich, A; Klier, J; König, F; Machtens, S; Pantel, K; Thomas, C | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Boher, JM; Bousquet, G; Culine, S; Dauba, J; Delva, R; Deplanque, G; Eymard, JC; Ferrero, JM; Fizazi, K; Foulon, S; Gravis, G; Habibian, M; Hasbini, A; Joly, F; Kouri, CE; Krakowski, I; Laguerre, B; Latorzeff, I; Lavaud, P; Legoupil, C; Linassier, C; Machiels, JP; Mourey, L; Oudard, S; Platini, C; Pouessel, D; Priou, F; Ravaud, A; Rolland, F; Soulié, M; Suc, E; Tergemina-Clain, G; Théodore, C; Tubiana-Mathieu, N; Zanetta, S | 1 |
| Lundholm, M; Nilsson, RJA; Schröder, M; Thellenberg-Karlsson, C; Tjon-Kon-Fat, LA; Widmark, A; Wikström, P; Wurdinger, T | 1 |
| Arima, K; Ishii, K; Kajiwara, S; Kanda, H; Kato, M; Matsuoka, I; Miki, M; Sasaki, T; Shiraishi, T; Sugimura, Y | 1 |
| Choi, EK; Hwang, JJ; Jeong, SY; Jung, YJ; Kim, CS; Kim, DE; Kim, HG; Kim, Y; Park, SE | 1 |
| Guo, H; Hu, Y; Lian, H; Wu, J | 1 |
| Aggarwal, R | 1 |
| Burgio, SL; Caroli, P; Casadio, V; Conteduca, V; De Giorgi, U; Gurioli, G; Lolli, C; Matteucci, F; Menna, C; Paganelli, G; Salvi, S; Scarpi, E; Schepisi, G; Testoni, S | 1 |
| Ito, T; Matsushita, Y; Miyake, H; Motoyama, D; Otsuka, A; Sugiyama, T; Tamura, K | 2 |
| Klotz, LH; Mayer, MJ; Venkateswaran, V | 2 |
| Bansal, S; Emmenegger, U; Kulkarni, GS; Nam, RK; Saskin, R; Satkunasivam, R; Wallis, CJD | 1 |
| Chen, JS; Gao, HT; Gu, JF; Li, JD; Li, W; Liu, KL; Qu, CB; Wang, XL; Wen, JK; Yang, Z; Zhang, ML; Zhang, Y; Zhang, YP; Zheng, B | 1 |
| Cicero, G; Costa, RP; De Luca, R; Murabito, A; Tripoli, V | 1 |
| Cui, R; Fang, JM; Guo, XL; Hu, F; Liu, ZQ; Xu, Q; Yu, Y; Zhao, Y | 1 |
| Boér, K; Dank, M; Dankovics, Z; Küronya, Z; Lahm, E; Maráz, A; Petrányi, Á; Révész, J; Ruzsa, Á; Szûcs, M; Valikovics, A; Vas, M | 1 |
| Cai, W; Chi, C; Dong, B; Fan, L; Pan, J; Qian, H; Shangguan, X; Shao, X; Wang, R; Wang, Y; Xu, F; Xue, W; Zhang, Y; Zhou, L; Zhu, Y | 1 |
| Heidenreich, A; Nilsson, S; Parker, C; Shore, N | 1 |
| Butler, LM; Castillo, L; Centenera, MM; Daly, RJ; Grogan, J; Haynes, AM; Horvath, LG; Kench, JG; Lee, BY; Lin, HM; Shreeve, SM; Spielman, C; Stricker, PD; Yeung, NK | 1 |
| Ahmed, S; Alimohamed, NS; Ardolino, L; Evan, CP; Francini, E; Heng, DYC; Joshua, AM; Kantoff, PW; Kaymakcalan, M; Li, H; Shaw, GK; Sweeney, CJ; Taplin, ME; Yip, S | 1 |
| Choi, YJ; Kim, BS; Kim, HG; Kim, HS; Kim, KH; Lee, HJ; Lee, HY; Lee, JL; Lee, KH; Park, KH; Park, SH; Shin, DY; Song, HS | 1 |
| Ghatalia, P; Pond, GR; Sonpavde, G; Templeton, AJ | 1 |
| Baser, O; Huang, A; Miao, R; Sonpavde, G; Wang, L | 1 |
| Funahashi, Y; Gotoh, M; Hattori, R; Ishida, R; Kamihira, O; Kato, M; Kimura, T; Matsui, H; Matsukawa, Y; Sassa, N; Tsuzuki, T; Yamamoto, A | 1 |
| Ozgur, BC | 1 |
| Hong, JH | 1 |
| Gou, X; He, WY; Hossain, A; Wang, Q; Zeng, YZ | 1 |
| Egawa, S; Ito, K; Kimura, T; Miki, K; Onuma, H; Shimomura, T; Tabata, R; Tomita, M | 1 |
| Elkon, JM; Lin, J; Millado, KF; Millett, RL | 1 |
| Baciarello, G; Fizazi, K; Hamilou, Z | 1 |
| Boerner, J; Dobson, K; Fontana, J; Heath, E; Heilbrun, L; Li, J; Smith, D; Stark, K; Thakur, MK; Vaishampayan, U | 1 |
| Angelergues, A; Balea, BC; Bellmunt, J; Birtle, AJ; Borrega, P; Carbonero, IG; Castellano, DE; Delanoy, N; Efstathiou, E; Esteban, E; Flechon, A; Gonzalez, I; Guillot, A; Gyftaki, R; Lainez, N; Le Moulec, S; Munarriz, J; Oudard, S; Ozguroglu, M; Rubio, G; Wysocki, PJ | 1 |
| Aymonier, M; Boissier, R; Deville, JL; Ebbo, M; Pourroy, B; Rochigneux, P; Salas, S; Schleinitz, N | 1 |
| de Reijke, TM; Poorthuis, MHF; van Moorselaar, RJA; Vernooij, RWM | 1 |
| Cui, P; Huang, S; Li, H; Li, S; Lin, Y; Liu, Q; Sun, Z; Wu, F; Zhang, L; Zhao, Q | 1 |
| Alexander, DD; Deuson, R; Fryzek, JP; Reichert, H; Summers, N; Townes, L; Vanderpuye-Orgle, J | 1 |
| Taneja, SS | 1 |
| Chen, Z; Du, Z; Hao, Y; Li, L; Li, T; Liu, N; Luo, C; Quan, Z; Sun, W; Wang, J; Wang, X; Wu, X; Yuan, M; Zhang, Y | 1 |
| Chan, K; Chan, M; Chan, T; Lam, D; Law, K; Lee, EKC; Poon, DMC | 1 |
| Ali, A; Brown, M; Clarke, N; Elliott, T; Hart, CA; Hiew, K; Lau, M; Maddineni, S; Ramani, V; Sangar, V | 1 |
| Albiges, L; Bernard, B; Francini, E; Gray, KP; Harshman, LC; Kantoff, PW; Shaw, GK; Sweeney, CJ; Taplin, ME; Valença, L; Xie, W | 1 |
| Campins, L; Font, A; Lianes, P; Marin, S; Miarons, M; Querol, R | 1 |
| Lei, BH; Lu, ZJ; Wang, Y; Zhang, Y; Zhu, QY; Zou, Q | 1 |
| Filleur, S; Jarvis, C; Martinez-Marin, D; Nelius, T; Sennoune, SR | 1 |
| Boyer, Z; Castillo, L; Chan, CL; Daly, RJ; Deng, N; Dodson, E; Elsworth, B; Horvath, LG; Lee, BY; Lin, HM; Nikolic, I; Simpson, KJ; Spielman, C; Swarbrick, A; Yang, J; Yeung, NK | 1 |
| Gillessen, S; Isensee, G; Müller, J; Omlin, A; Péporté, A; Schmid, S | 1 |
| Csizmarik, A; Hadaschik, B; Hoffmann, MJ; Keresztes, D; Kramer, G; Maj-Hes, A; Módos, O; Niedworok, C; Nyirády, P; Puhr, M; Ristl, R; Sevcenco, S; Shariat, SF; Szarvas, T | 1 |
| Graefen, M; Knipper, S; Mandel, P; Steuber, T; Strölin, P; V Amsberg, G | 1 |
| Buttigliero, C; Di Maio, M; Di Stefano, RF; Guglielmini, P; Lacidogna, G; Leone, G; Numico, G; Pignataro, D; Scagliotti, GV; Tucci, M; Vignani, F; Zichi, C | 1 |
| Barata, P; Emamekhoo, H; Garcia, JA; Gilligan, T; Koshkin, V; Kyriakopoulos, C; Mendiratta, P; Ornstein, M; Rini, BI; Tyler, A | 1 |
| Huang, C; Song, P; Wang, Y | 1 |
| Ali, R; Chambers, C; Ghosh, S; North, S; Sawyer, M; Shivji, A | 1 |
| Csizmarik, A; Darr, C; Hadaschik, B; Krafft, U; Kramer, G; Küronya, Z; Maj-Hes, A; Nyirady, P; Reis, H; Sevcenco, S; Shariat, SF; Szarvas, T; Tschirdewahn, S | 1 |
| Chen, J; Chen, Y; Fang, Y; Liang, G; Lin, S; Qiu, W; Zheng, H | 1 |
| Bejrananda, T; Karnjanawanichkul, W; Pripatnanont, C; Tanthanuch, M | 1 |
| Alva, A; Anderson, J; Autio, KA; Dittamore, R; Dreicer, R; Garcia, JA; Graf, RP; Hart, LL; Milowsky, MI; Morris, MJ; Posadas, EM; Ryan, CJ; Scher, HI; Schreiber, NA; Summa, JM; Youssoufian, H | 1 |
| Fizazi, K; Hamilou, Z; Saad, F | 1 |
| Ma, Y; Newton, PK; West, J | 1 |
| Bradley, CA | 1 |
| Caplan, S; Chen, YL; Chen, YS; Farmer, T; Keller, ET; Lin, MF; Miller, DR; Tzeng, CC | 1 |
| Barnes, G; Bury, D; Carles, J; El Karak, F; Ghosn, M; Hitier, S; Katolicka, J; Koroleva, I; Korunkova, H; Makdessi, J; Özatilgan, A; Pichler, A; Tomova, A | 1 |
| Baldauf, S; Bartsch, G; Borgmann, H; Brandt, MP; Dotzauer, R; Frees, S; Haferkamp, A; Jäger, W; Neisius, A; Schneider, M; Thomas, C; Tsaur, I | 1 |
| Cicardi, ME; Cristofani, R; Fontana, F; Limonta, P; Marzagalli, M; Montagnani Marelli, M; Moretti, RM; Poletti, A | 1 |
| Cheng, WY; Drea, E; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Szatrowski, TP; Vekeman, F | 1 |
| Basso, U; Caffo, O; Campadelli, E; Conteduca, V; De Giorgi, U; Facchini, G; Fratino, L; Gasparro, D; Kinspergher, S; Maines, F; Massari, F; Messina, C; Mosillo, C; Procopio, G; Rossetti, S; Sabbatini, R; Sava, T; Scagliarini, S; Sirotova, S; Veccia, A; Verzoni, E | 1 |
| Akaza, H; Butt, M; Castillo, L; Ecstein-Fraisse, EB; Facchini, G; Fava, S; Hitier, S; Karavasilis, V; Leung, KC; Pripatnanont, C; Procopio, G; Silva, A; Wheatley, D; Ӧzatılgan, A; Ӧzgüroḡlu, M | 1 |
| Bolognini, C; Gassian, N; Klajer, E; Loriot, Y; Meynard, G; Thiery-Vuillemin, A | 1 |
| Hongo, H; Kikuchi, E; Kosaka, T; Mizuno, R; Oya, M; Watanabe, K | 1 |
| Chen, J; Gao, AC; Liao, B; Liu, J; Liu, Z; Shen, P; Shu, K; Sun, G; Yang, Y; Zeng, H; Zhang, X; Zhao, J; Zhao, P | 1 |
| Ballester, I; González-Billalabeitia, E; Rosino, A; Tudela, J | 1 |
| Bosland, MC; Eskra, JN; Schlicht, MJ | 1 |
| Chi, KN; Eigl, BJ; Finch, D; Khalaf, D; Kollmannsberger, CK; Lavoie, JM; Noonan, K; Vergidis, J; Zou, K; Zulfiqar, M | 1 |
| Bollag, G; Guan, W; Hu, J; Tan, P; Tang, Z; West, BL; Wu, L; Xu, H; Yang, L | 1 |
| Binder, L; Eidizadeh, A; Friedewald, S; von Ahsen, N | 1 |
| Eto, M; Imada, K; Inokuchi, J; Kashiwagi, E; Murakami, T; Shiota, M; Takeuchi, A; Tatsugami, K | 1 |
| Ding, X; Gao, S; Gao, Y; Gong, C; Hu, C; Jiang, W; Qiang, L; Ren, F; Wang, Z | 1 |
| Chan, K; Chan, MFT; Chan, T; Cheng, NM; Lai, KM; Lam, D; Law, S; Lee, EKC; Leung, CH; Ng, CF; Poon, DMC; Teoh, JYC | 1 |
| Cain, D; Chi, KN; Clark, SJ; de Bono, JS; Higano, CS; Horvath, LG; Jacobs, C; Lin, HM; Mahon, KL; Qu, W; Spielman, C; Stockler, MR | 1 |
| Davis, ID; Hamid, AA; Morris, MJ | 1 |
| Araujo, JC; Chi, KN; De Bono, JS; Dutta, S; Eisenberger, MA; Fizazi, K; George, DJ; Halabi, S; Higano, CS; Kelly, WK; Logothetis, C; Morris, MJ; Petrylak, DP; Quinn, DI; Rosenthal, M; Small, EJ; Tangen, CM; Tannock, IF; Thompson, IM | 1 |
| Bass, R; Cantu, FP; Kelley, SO; Klotz, L; Mohamadi, RM; Roberto, D; Venkateswaran, V; Wang, DZ | 1 |
| Haukland, E; Mannsåker, B; Nieder, C; Norum, J; Pawinski, A; Yobuta, R | 1 |
| Hongo, H; Kikuchi, E; Kosaka, T; Matsumoto, K; Mizuno, R; Morita, S; Oya, M; Shigeta, K; Shinojima, T; Yanai, Y | 1 |
| Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M | 1 |
| Chi, C; Dong, B; Fan, L; Gong, Y; Ma, X; Pan, J; Wang, R; Xue, W; Yang, Y; Zheng, H; Zhu, Y | 1 |
| Akpinar, C; Baltaci, S; Beduk, Y; Gokce, MI; Gulpinar, O; Hamidi, N; Suer, E; Turkolmez, K | 1 |
| Hoque, MO; Izumchenko, E; Rosenbaum, E; Shavit Grievink, L | 1 |
| Abdallah, K; Bare, C; Costello, JC; Elo, LL; Fuchs, C; Gofer, E; Greiner, R; Guinney, J; Kanigel Winner, K; Koestler, DC; Kumar, L; Neto, EC; Norman, T; Piccolo, SR; Ryan, CJ; Sartor, O; Scher, HI; Seyednasrollah, F; Shen, L; Soule, HR; Stolovitzky, G; Sweeney, CJ; Vega, R; Wang, T; Wolfinger, RD; Yu, T; Zhou, FL | 1 |
| Bíró, K; Géczi, L; Gyergyay, F; Jorgo, K; Kovács, Á; Küronya, Z; Laczó, I; Maráz, A; Nagyiványi, K; Pepó, J; Pósfai, B; Sükösd, F; Szarvas, T; Varga, L; Varga, Z | 1 |
| Bettaieb, A; Bouaouiche, S; Dondaine, L; Isambert, N; Jeannin, JF; Laurens, V; Magadoux, L; Plenchette, S; Reveneau, S | 1 |
| Chung, BH; Ha, JS; Hah, YS; Han, KS; Hong, SJ; Koo, KC; Lee, JS; Lee, KS; Rha, KH | 1 |
| Beijnen, JH; Bergman, AM; Crombag, MBS; de Vries Schultink, AHM; Huitema, ADR; Otten, HM; Schellens, JHM; van Doremalen, JGC | 1 |
| Damodaran, S; Jarrard, DF; Lang, JM | 1 |
| Attard, G; Casadio, V; Castro, E; Conteduca, V; De Giorgi, U; Farolfi, A; Gonzalez-Billalabeitia, E; González-Del-Alba, A; Gurioli, G; Hernando, S; Jayaram, A; Lolli, C; Marin-Aguilera, M; Maugeri, A; Medina, A; Mellado, B; Morales-Barrera, R; Olmos, D; Puente, J; Rodriguez-Vida, A; Romero-Laorden, N; Salvi, S; Scarpi, E; Schepisi, G; Vidal, MJM; Villa-Guzmán, JC; Wetterskog, D; Wingate, A | 1 |
| Hasegawa, Y; Kawahara, T; Kumano, Y; Matsubara, N; Miyoshi, Y; Uemura, H; Yasui, M | 1 |
| Beijnen, JH; Bergman, AM; Crombag, MBS; de Vries Schultink, AHM; Huitema, ADR; Otten, HM; Schellens, JHM; van Werkhoven, E | 1 |
| Anguera, G; Carles, J; Del Alba, AG; Domènech, M; Etxaniz, O; Fernández, PL; Font, A; Jiménez, N; López, S; Marín-Aguilera, M; Maroto, P; Mellado, B; Milà-Guasch, M; Prat, A; Reig, Ò; Ribal, MJ; Rodríguez-Vida, A; Sala-González, N; Suárez, C; Victoria, I | 1 |
| Amin, MB; Balogh, AG; Feng, FY; Garzotto, MG; Gomella, LG; Hannan, R; Horwitz, EM; Hu, C; Michalski, JM; Pervez, N; Peters, CA; Purdy, J; Raben, A; Reaume, MN; Rodrigues, GB; Rosenthal, SA; Sandler, HM; Sartor, O; Shipley, WU; Souhami, L; Williams, SG | 1 |
| Guo, J; He, D; Huang, Y; Jin, J; Li, H; Ma, L; Shan, Y; Sun, Z; Wei, Q; Xiao, J; Ye, D; Zhang, Z | 1 |
| Alsinnawi, M; Balk, S; Bianchi-Frias, D; Burns, J; Cho, E; Montgomery, RB; Mostaghel, EA; Nelson, PS; Porter, C; Slee, AE; Sowalsky, A; Taplin, ME; True, L; Ye, H; Zhang, A; Zhang, X | 1 |
| Bai, S; Dong, Y; Hu, C; Lyu, J; Xia, H; Yu, X; Zhan, Y; Zhang, BY; Zhao, L | 1 |
| Barata, PC; Sartor, AO | 1 |
| Chen, E; Evans, A; Hansen, AR; Joshua, AM; Knox, J; Prawira, A; Sridhar, SS; Tan, S; Tannock, IF; Templeton, A; Vera-Badillo, F; Wang, L; Wouters, BG | 1 |
| Babata, AL; Bello, JO; Olanipekun, OO | 1 |
| Anderson, AR; Brown, JS; Dinh, MN; Gatenby, RA; West, JB; Zhang, J | 1 |
| Aprikian, AG; Bladou, F; Cury, F; Dragomir, A; Hu, J; Kassouf, W; Lahcene, H; Perreault, S; Vanhuyse, M | 1 |
| He, Q; Hu, S; Jin, J; Jin, S; Sheng, J; Song, Y; Xiang, P; Yang, Y; Yu, W | 1 |
| Bögemann, M; Goebell, PJ; Hammerer, P; Machtens, S; Pfister, D; Schostak, M; Schwentner, C; Steuber, T; von Amsberg, G; Wülfing, C | 1 |
| Cho, J; Choi, HY; Jeon, HG; Jeon, SS; Jeong, BC; Kang, M; Kim, Y; Lee, HM; Lee, SJ; Park, SH; Seo, SI; Sung, HH; Yoon, SE | 1 |
| Dutta, S; Halabi, S; Kelly, WK; Morris, MJ; Russell, C; Ryan, CJ; Small, EJ; Taplin, ME | 1 |
| Akakura, K; Fujimoto, K; Gotoh, M; Hirao, Y; Ina, K; Nagata, H; Nishimura, K; Ogawa, O; Okajima, E; Tanaka, N; Teramukai, S | 2 |
| Antonarakis, ES; Carrasquillo, JA; Deandreis, D; Fizazi, K; Higano, CS; Jacene, HA; Loriot, Y; Lu, C; Morris, MJ; Pandit-Taskar, N; Petrenciuc, O; Ryan, CJ; Shevrin, DH; Sweeney, CJ; Vesselle, H | 1 |
| Agus, DB; Diaz, P; Gross, ME; Matasci, N; Patsch, K; Ruderman, D; Soundararajan, A | 1 |
| Cotogno, P; Feibus, A; Ledet, E; Lewis, B; Sartor, O; Schiff, JP; Steinwald, P | 1 |
| Al-Janadi, A; Bolton, S; Flaig, T; Heath, E; Heilbrun, L; Hussain, A; Ivy, SP; Lara, P; Liu, G; Mack, P; Mannuel, H; Monk, JP; Silbiger, D; Smith, D; Stella, P; Usman, M; Vaishampayan, U; Zurita, A | 1 |
| Cao, Z; Xu, L; Zhao, S | 1 |
| Alexandre, J; Baciarello, G; Bahl, A; Barthelemy, P; Basso, U; Beuzeboc, P; Birtle, A; Butt, M; Caffo, O; Chowdhury, S; Daugaard, G; De Giorgi, U; Delanoy, N; Deville, JL; Efstathiou, E; Eymard, JC; Fererro, JM; Fizazi, K; Fléchon, A; Gavrikova, T; Goupil, MG; Guillot, A; Hans, S; Hardy-Bessard, AC; Hasbini, A; Helissey, C; Krainer, M; Laguerre, B; Le Moulec, S; Lechevallier, É; Morales, R; Oudard, S; Priou, F; Sella, A; Spaeth, D; Thiery-Vuillemin, A; Thomson, A; Verret, B | 1 |
| Kajikawa, K; Kanao, K; Kato, Y; Kobayashi, I; Morinaga, S; Muramatsu, H; Nakamura, K; Nishikawa, G; Sumitomo, M; Suzuki, S; Watanabe, M; Yoshikawa, K; Zennami, K | 1 |
| Hongo, H; Kosaka, T; Oya, M | 1 |
| Eto, M; Inokuchi, J; Kashiwagi, E; Kobayashi, T; Shiota, M; Takeuchi, A; Tatsugami, K | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Morizane, S; Sejima, T; Takenaka, A; Yamaguchi, N; Yumioka, T | 1 |
| Chang, LW; Chen, CS; Cheng, CL; Chiu, KY; Ho, HC; Hung, SC; Li, JR; Ou, YC; Wang, SS; Yang, CK | 1 |
| Chiang, CL; Choi, HCW; Lam, TC; So, TH | 1 |
| Armstrong, CM; Cai, D; Chen, J; Chen, N; Dai, J; Guo, W; Liu, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Yin, X; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhao, P; Zhu, S; Zhu, X | 1 |
| Abbas, F; Al Dousari, S; Al Hallaq, Y; Al Hamdani, N; Alameh, W; Ashou, R; Assaf, G; Bachir, B; Bitar, N; Bulbul, M; Dagher, C; Dbouk, H; El Khoury, C; El-Hajj, A; Faddoul, S; Farha, G; Farhat, F; Geara, F; Ghazal, H; Gillessen, S; Haidar, M; Hussain, HK; Ibrahim, K; Jabbour, M; Khauli, R; Mukherji, D; Nasr, R; Nemer, E; Omlin, A; Rabah, D; Said, R; Sakr, G; Sayyid, K; Shamseddine, A; Temraz, S; Wazzan, W; Youssef, B; Zouain, N | 1 |
| Hongo, H; Kosaka, T; Oya, M; Yanai, Y | 1 |
| Kazama, H; Matsubara, N; Matsuyama, H; Seto, T; Suzuki, K; Tsukube, S | 1 |
| Egawa, S; Enei, Y; Furuta, A; Imai, Y; Inaba, Y; Ito, K; Iwamoto, Y; Iwamura, Y; Kimura, T; Matsukawa, A; Miki, J; Miki, K; Mori, K; Onuma, H; Sasaki, H; Tanaka, M | 1 |
| Böhm, K; Borgmann, H; Dotzauer, R; Haferkamp, A; Höfner, T; Jäger, W; Mager, R; Savko, O; Thomas, A; Thomas, C; Tsaur, I | 1 |
| Cuevas Sanz, JM; García García-Porrero, Á; González-Del-Alba, A; Méndez-Vidal, MJ; Muñoz Del Toro, JR; Pinto, A; Puente, J; Rodríguez, Á; Sala-Gonzalez, N; Useros Rodríguez, E; Vázquez, S | 1 |
| Dreicer, R; Garcia, J; Kania, M; Raghavan, D; Rini, B; Shi, P; Somer, B; Srinivas, S; Vogelzang, N | 1 |
| Nakai, Y; Nakayama, M; Nishimura, K; Nonomura, N; Takayama, H; Tsujimura, A; Uemura, M | 1 |
| Miller, K; Saad, F | 1 |
| Cheung, FY; Leung, KC; Ngan, RK | 1 |
| Hotte, SJ; Loblaw, DA; Walker-Dilks, C; Winquist, E | 1 |
| Francini, E; Petrioli, R; Roviello, G | 2 |
| Horimoto, K; Kosaka, T; Nagamatsu, G; Oya, M; Saito, S; Suda, T | 1 |
| Bellmunt, J; Fitzpatrick, JM; Jenkins, C; Merseburger, AS; Parker, C | 1 |
| Aragon-Ching, J; Beatson, M; Chau, CH; Dahut, WL; Figg, WD; Gao, R; Gulley, JL; Madan, RA; Sissung, TM; Spencer, S; Steinberg, SM | 1 |
| Galsky, MD; Goyal, J; Hendricks, R; Pond, GR; Small, A; Sonpavde, G; Tsao, CK | 1 |
| Bahl, A; de Bono, JS; Devin, J; Gravis, G; Hansen, S; Kocak, I; Oudard, S; Ozgüroglu, M; Sartor, AO; Shen, L; Tombal, B | 1 |
| Clarke, S; Galsky, M; Linton, A; Pond, G; Sonpavde, G; Vardy, J | 1 |
| Boegemann, M; Cronauer, MV; Hajili, T; Herrmann, E; Jentzmik, F; Krabbe, LM; Ohlmann, CH; Schnoeller, TJ; Schrader, AJ; Schrader, M; Stoeckle, M | 1 |
| Blaisse, RJ; de Wit, R; Erjavec, Z; Gerritse, FL; Los, M; Meulenbeld, HJ; Roodhart, JM; Smilde, TJ; van der Velden, AM | 1 |
| Evans, CP; Gao, AC; Liu, C; Lou, W; Nadiminty, N; Tummala, R; Zhu, Y | 1 |
| Heidenreich, A; Pfister, D; Piper, C; Porres, D; Thissen, AK | 1 |
| Ahallal, Y; Barret, E; Bennamoun, M; Cathelineau, X; Cerruti, J; Durand, M; Galiano, M; Gaya, JM; Macek, P; Prapotnich, D; Ropert, S; Rozet, F; Sanchez-Salas, R | 1 |
| Blount, D; Chu, F; Ferrari, A; Gabrail, N; Harrop, R; Srinivas, S | 1 |
| Batty, N; Pili, R; Yarlagadda, N | 1 |
| Kikuchi, E; Kosaka, T; Miyajima, A; Miyazaki, Y; Oya, M; Yasumizu, Y | 1 |
| de Morrée, ES; de Wit, R; Eisenberger, MA; Shen, L; Tannock, IF; van Soest, RJ | 1 |
| Gallego, IG; Garcia-Carbonero, R; Giménez, EV; Giuliani, R; Gravanis, I; Hemmings, RJ; Jiménez, JC; Lopez, AS; O'Connor, D; Pignatti, F; Salmonson, T | 1 |
| Arigoni, M; Baldi, A; Boccardo, F; Boccellino, M; Calogero, RA; Cantarella, D; Cardillo, I; Carlini, P; Cognetti, F; Contestabile, M; Crispi, S; Dell'Anna, ML; Felici, A; Ferretti, G; Galluzzo, P; Picardo, M; Piccolo, MT; Quagliuolo, L; Spugnini, EP | 1 |
| Berruti, A; Caffo, O; Chierichetti, F; Galligioni, E; Maines, F; Palermo, A; Veccia, A | 1 |
| Chen, XS; Du, J; Tian, J; Yang, Q; Yao, X | 1 |
| de Braud, F; Grassi, P; Procopio, G; Salvioni, R; Testa, I; Torri, V; Valdagni, R; Verzoni, E | 1 |
| Attard, G; Bianchini, D; Chowdhury, S; de Bono, JS; Ferraldeschi, R; Lorente, D; Omlin, A; Pezaro, C; Rodriguez-Vida, A; Zivi, A | 1 |
| Fizazi, K; Loriot, Y | 1 |
| de Bono, JS; Fizazi, K; Flaig, TW; Goodman, OB; Kheoh, T; Li, J; Molina, A; Mulders, PF; Scher, HI; Suttmann, H | 1 |
| Chi, KN; Fizazi, K; Haqq, CM; Higano, CS; Kheoh, T; Li, J; Marberger, M; Molina, A; Mulders, PF; Saad, F | 1 |
| Amir, E; Attalla, M; De Gouveia, P; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Moore, M; Pond, GR; Sridhar, SS; Tannock, IF; Templeton, AJ; Vera-Badillo, FE; Wang, L | 1 |
| Armstrong, AJ; de Bono, J; Halabi, S; Kaplan, EB; Lin, CY; Oudard, S; Petrylak, D; Sartor, O; Shen, L; Small, EJ; Sternberg, CN | 1 |
| Chiu, HJ; Cottrell, CL; Ghosh, D; Ibrahim, A; Justice, R; Karuri, S; Leighton, J; Liu, Q; Maher, VE; Marathe, D; Mehrotra, N; Ning, YM; Palmby, T; Pazdur, R; Pierce, W; Sridhara, R; Tang, SH; Zirkelbach, JF | 1 |
| Aziz, R; Ghosh, D; Ibrahim, A; Justice, R; Kluetz, PG; Maher, VE; Mehrotra, N; Ning, YM; Palmby, T; Pazdur, R; Pfuma, E; Sridhara, R; Tang, S; Tilley, A; Zhang, L; Zirkelbach, JF | 1 |
| Boni, G; Borsò, E; Cianci, C; Federici, F; Francesca, F; Lorenzoni, A; Mariani, G; Mazzarri, S; Orlandini, C; Pastina, I; Ricci, S; Rubello, D; Selli, C | 1 |
| Chen, WT; Dong, H; Doty, S; Friedlander, TW; Gilbert, EG; Ngo, VT; Paris, PL; Premasekharan, G; Ryan, CJ; Weinberg, V; Zhao, Q | 1 |
| Bitran, JD; Cygan, P; Galvez, AG; Lestingi, TM; Meyer, A; Nabhan, C; Tolzien, K | 1 |
| Bompas, E; Clarisse, B; Cojocarasu, O; Delva, R; Eymard, JC; Guillot, A; Houede, N; Joly, F; Leconte, A; Lheureux, S; Linassier, C; Mourey, L; Oudard, S; Ravaud, A; Ringensen, F; Sevin, E; Tubiana-Mathieu, N; Valenza, B; Vedrine, L | 1 |
| Castillo, L; Daly, RJ; Hochgräfe, F; Horvath, LG; Lee, BY; Lin, HM; Martin Shreeve, S; Raftery, MJ; Wu, J | 1 |
| de Morrée, ES; de Wit, R; Mathijssen, RH; Moll, JM; Teubel, W; van Royen, ME; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
| Araujo, JC; Armstrong, AJ; Begbie, S; Bellmunt, J; Cheng, S; de Bono, JS; Durham, S; Efstathiou, E; Gallardo, E; Goebell, PJ; Heidenreich, A; Hong, JH; Logothetis, CJ; Matveev, VB; McCaffrey, J; Morris, MJ; Oudard, S; Paliwal, P; Richardet, E; Saad, F; Serrano, SV; Sizer, B; Trudel, GC; Wilding, G; Yu, EY | 1 |
| Afonso, J; Antón Aparicio, LM; Campos, B; Fernández, O; Lázaro, M; León, L; Vázquez, S | 1 |
| André, V; Brown, J; Callies, S; Castellano, D; Cervera Grau, JM; Chłosta, PL; Durán, I; Heinrich, B; Hurt, K; Kamradt, J; Lahn, M; Mellado, B; Pikiel, J; Reuter, C; Somer, BG; Stöckle, M; Wedel, S; Wiechno, P | 1 |
| Borre, M; Brasso, K; Iversen, P; Rathenborg, P; Røder, MA; Thomsen, FB | 1 |
| Hoy, SM | 1 |
| Hara, I; Hayashi, T; Kodaira, K; Kohjimoto, Y; Koike, H; Matsuyama, H; Sakurai, T; Shimabukuro, T; Shimizu, N; Suzuki, K; Tomita, Y; Uemura, H; Ueno, M | 1 |
| Abdulkadir, SA; Holder, SL | 1 |
| Ansari, J; Bahl, A; Birtle, A; Butt, M; Chowdhury, S; Eswar, CV; Hughes, S; Malik, Z; Payne, H; Sundar, S | 1 |
| Aydin, S; Danse, E; Machiels, JP; Rizk, R; Tombal, B | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Galsky, MD; Lechuga, M; Leopold, L; Michaelson, MD; Mooney, DJ; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Wang, SL; Wood, BA | 1 |
| Basset, V; Crouzet, S; Flamand, V; Ploussard, G | 1 |
| Badrising, S; Bergman, AM; Coenen, JL; de Jong, IJ; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Tinteren, H | 1 |
| Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Omlin, AG; Parker, C; Pezaro, CJ | 1 |
| Böker, A; Geith, A; Gschwend, JE; Kuczyk, M; Merseburger, AS; Retz, M; Schmid, SC; Seitz, AK; Tauber, R; von Klot, C | 1 |
| Bahl, A | 1 |
| Antonarakis, ES; Bassi, S; Carducci, MA; Eisenberger, MA; Schweizer, MT; Wang, H; Zhou, XC | 1 |
| Alibhai, SM; Amir, E; De Wit, R; Eisenberger, MA; Horgan, AM; Pond, GR; Seruga, B; Tannock, IF | 1 |
| Al Nakouzi, N; Chauchereau, A; Commo, F; Cotteret, S; Dessen, P; Fizazi, K; Gaudin, C; Rajpar, S; Vielh, P | 1 |
| Abalı, H; Gültepe, I; Köse, F; Mertsoylu, H; Muallaoğlu, S; Özyılkan, Ö; Sezer, A; Sümbül, AT | 1 |
| Antonarakis, ES; Carducci, MA; Eisenberger, MA; Goyal, J; Nuhn, P; Vaghasia, AM; Zhou, XC | 1 |
| Aparicio, LM; de Bono, JS; Fong, P; Gillessen, S; Hudes, GR; Pandha, HS; Petrylak, DP; Piulats, JM; Pollak, MN; Saad, F; Sandhu, SK; Scranton, J; Wang, T | 1 |
| Corey, E; Giannakakou, P; Matov, A; Nanus, DM; Plymate, SR; Portella, L; Sun, S; Sung, M; Thadani-Mulero, M; Vessella, RL | 1 |
| Furuse, H; Ishii, Y; Kai, F; Nagata, M; Otsuka, A; Ozono, S; Sugiyama, T; Suzuki, T; Takayama, T; Yajima, T | 1 |
| Ely, B; Gertz, E; Goldkorn, A; Hussain, M; Lara, PN; Mack, PC; Quinn, DI; Tangen, C; Thompson, IM; Twardowski, PW; Van Loan, MD; Vogelzang, NJ | 1 |
| Buzaid, AC; Sartor, O; Schutz, FA | 1 |
| Chen, BD; Li, GH; Yu, SC | 1 |
| Du, Y; Li, S; Oremo, JA; Tang, Y; Zhen, M; Zhu, S | 1 |
| Mangir, N; Türkeri, L | 1 |
| Malhotra, A; Poiesz, BJ; Rosenbaum, P; Welch, D | 1 |
| Abe, H; Betsunoh, H; Fukabori, Y; Kamai, T; Kambara, T; Masuda, A; Mizuno, T; Muraishi, O; Nishihara, D; Yashi, M; Yuki, H | 1 |
| Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Ferraldeschi, R; Grist, E; Lorente, D; Mateo, J; Ravi, P; Sideris, S; Smith, A; Wong, S; Zafeiriou, Z | 1 |
| Mizokami, A; Namiki, M | 1 |
| Fizazi, K; Loriot, Y; Massard, C | 1 |
| Kobayashi, M; Komatsu, K; Kubo, T; Kurokawa, S; Morita, T; Nakano, K; Natsui, S; Nukui, A | 1 |
| Gurney, H; Parente, P; Parnis, F | 1 |
| Fuereder, T; Gerschpacher, M; Horak, P; Kivaranovic, D; Krainer, M; Lamm, W; Strommer, S; Wacheck, V | 1 |
| Petrylak, DP | 1 |
| Aggarwal, R; Formaker, C; Griffin, TW; Harris, A; Molina, A; Ryan, CJ; Small, EJ | 1 |
| Carducci, MA; Chi, KN; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Kavsak, P; Kollmannsberger, CK; Mukherjee, SD; Siu, LL; Smith, DC; Spreafico, A; Sridhar, SS; Sukhai, MA; Takebe, N; Wang, L; Wong, TS | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Clarke, SJ; Lechuga, M; Michaelson, MD; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Templeton, AJ; Vardy, JL; Wang, SL | 1 |
| Albers, P; Eichenauer, R; Geiges, G; Grimm, MO; König, F; Mickisch, G; Miller, K; Pfister, D; Schwentner, C; Suttmann, H; Zastrow, S | 1 |
| de Riese, W; Filleur, S; Hirsch, J; Lopez, J; Martinez-Marin, D; Miller, B; Nelius, T; Rinard, K | 1 |
| Agarwal, N; Beer, TM; Bergman, AM; Bossi, A; Ciuleanu, TE; Drake, CG; Fizazi, K; Franke, FA; Gagnier, P; Gerritsen, WR; Hansen, S; Houede, N; Korbenfeld, E; Krainer, M; Kwon, ED; Liu, D; Logothetis, C; Mahammedi, H; Maio, M; McHenry, MB; Ng, S; Santos, R; Scher, HI; Sengeløv, L; Sundar, S; van den Eertwegh, AJ | 1 |
| Parker, C | 1 |
| Al Nakouzi, N; Albigès, L; Beuzeboc, P; de La Motte Rouge, T; Fizazi, K; Gajda, D; Gleave, M; Gross-Goupil, M; Guillot, A; Le Moulec, S; Loriot, Y; Massard, C; Wang, C | 1 |
| Chevreau, C; De Mont-Serrat, H; Droz, JP; Kaiser, R; Medioni, J; Merger, M; Oudard, S; Stopfer, P | 1 |
| Ernsting, MJ; Hoang, B; Li, SD; Murakami, M; Undzys, E | 1 |
| Han, KS; Hong, SJ | 2 |
| Kwon, WA; Lee, JW; Oh, TH; Park, SC | 1 |
| Chuang, SJ; Chung, SD; Hour, TC; Huang, AM; Huang, CY; Huang, SP; Kang, WY; Lin, YC; Pu, YS; Wu, WJ | 1 |
| Tombal, B | 1 |
| Caffo, O; Creppy, L; Hansen, S; Holmberg, M; Krainer, M; Kramer, G; Loriot, Y; Machiels, JP; Oudard, S; Rolland, F | 1 |
| Adachi, T; Imada, K; Inokuchi, J; Kiyoshima, K; Koga, H; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yamaguchi, A; Yokomizo, A | 1 |
| Isambert, N; Jeannin, JF; Laurens, V; Magadoux, L; Plenchette, S | 1 |
| Bruera, G; Cannita, K; Festuccia, C; Ficorella, C; Gravina, GL; Irelli, A; Palluzzi, E; Ricevuto, E | 1 |
| Byun, SS; Cheon, J; Hong, SK; Jeong, SJ; Lee, SE; Moon, du G; Oh, MM; Park, HS; Yoon, CY | 1 |
| Alesini, D; Basso, U; Caffo, O; Campadelli, E; Conteduca, V; D'Angelo, A; De Giorgi, U; Donini, M; Fraccon, AP; Fratino, L; Galligioni, E; Gasparro, D; Giordano, M; Lo Re, G; Macrini, S; Maines, F; Massari, F; Messina, C; Procopio, G; Ratta, R; Verderame, F; Vicario, G; Zustovich, F | 1 |
| Amir, E; Attard, G; de Bono, JS; Leibowitz-Amit, R; McNamara, MG; Omlin, A; Pezaro, C; Tannock, IF; Templeton, AJ; Vera-Badillo, FE | 1 |
| Inokuchi, J; Kiyoshima, K; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A | 1 |
| Antonarakis, ES; Brodsky, RA; Park, JC; Pratz, CF; Tesfaye, A | 1 |
| Antón Aparicio, LM; Batista, N; Castellano, D; Esteban, E; Germà, JR; Luque, R; Maroto, P; Méndez-Vidal, MJ; Pérez-Valderrama, B; Sánchez-Hernández, A | 1 |
| Allyon, J; Deplanque, G; Dufour-Lamartinie, JF; Elaidi, R; Ferrero, JM; Houillier, P; Lerest, C; Mackenzie, S; Maruani, G; Maurina, T; Medioni, J; Oudard, S; Raymond, E; Renaux, S; Rodier, JM | 1 |
| Bellmunt, J; de Bono, JS; Efstathiou, E; Kheoh, T; Li, J; Loriot, Y; Molina, A; Montgomery, B; Ryan, CJ; Scher, HI; Tran, N | 1 |
| Azad, AA; Chi, KN; Eigl, BJ; Kollmannsberger, C; Murray, RN | 1 |
| de Jong, H; Dijkstra, S; Jannink, SA; Leyten, GH; Mulders, PF; Schalken, JA; van Oort, IM | 1 |
| Antonarakis, ES; Luber, B; Nadal, R; Schweizer, MT; Suzman, DL | 1 |
| Berger, R; Frank, SJ; Gez, E; Hanovich, E; Hayat, H; Keizman, D; Kovel, S; Neiman, V; Peer, A; Rosenbaum, E; Sella, A; Sella, T; Sharide, D | 1 |
| Adelaiye, R; Ellis, L; Ku, S; Lasorsa, E; Pili, R; Ramakrishnan, S | 1 |
| Pal, SK; Sartor, O | 1 |
| Byun, SS; Hong, SJ; Kheoh, T; Kim, CS; Kwak, C; Lee, HM; Ou, YC; Rhim, HY; Wan, Y; Wu, HC; Wu, TT; Yeh, H; Yu, MK | 1 |
| Chang, C; Chen, B; Ding, X; Jing, C; Li, G; Matro, E; Niu, Y; Rehman, F; Wang, M; Xia, L; Yu, S | 1 |
| Boegemann, M; Brasso, K; de Bono, J; Lorente, D; Merseburger, AS; Retz, M; Schmid, SC; Schrader, AJ; Thomsen, FB; von Klot, CA | 1 |
| Antonuzzo, A; Biasco, E; Bocci, G; Danesi, R; Derosa, L; Di Desidero, T; Falcone, A; Farnesi, A; Fioravanti, A; Fontana, A; Francia, G; Galli, L; Marconcini, R; Orlandi, P | 1 |
| Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S | 1 |
| Abd Elmageed, ZY; Abdel-Mageed, AB; Kostochka, ML; Liu, X; Mathur, A; Mondal, D; Zhang, H | 1 |
| Kregel, S; Szmulewitz, RZ; Vander Griend, DJ | 1 |
| Azad, AA; Chi, KN; Eigl, BJ; Heng, DY; Joshua, AM; Kollmannsberger, C; Leibowitz-Amit, R; Lester, R; Murray, RN; Wells, JC | 1 |
| Antonarakis, ES; Carducci, MA; Denmeade, SR; Eisenberger, MA; Nadal, R; Paller, CJ; Rahman, H; Schweizer, MT; Zhang, Z | 1 |
| Gordian, E; Quintero, C; Ramachandran, K; Reis, IM; Singal, R; Zhao, W | 1 |
| Francini, E; Laera, L; Petrioli, R; Rossi, G; Roviello, G | 1 |
| Hasegawa, S; Kikuchi, E; Kosaka, T; Miyajima, A; Mizuno, R; Morita, S; Nagata, H; Nakagawa, K; Oya, M; Shigeta, K; Shinoda, K; Yasumizu, Y; Yazawa, S | 1 |
| Basch, E; Bennett, CL; Carducci, M; Chen, RC; Dusetzina, SB; Frame, JN; Garrels, K; Hotte, S; Kattan, MW; Loblaw, DA; Oliver, TK; Raghavan, D; Rumble, RB; Saad, F; Taplin, ME; Virgo, KS; Walker-Dilks, C; Williams, J; Winquist, E; Wootton, T | 1 |
| Griffin, TW; Nandy, P; Poggesi, I; Ryan, CJ; Saad, F; Smith, MR; Stuyckens, K; Vermeulen, A; Xu, XS; Yu, MK | 1 |
| Chen, W; Jin, H; Pan, Y; Wang, F; Weng, Z; Ye, T; Yu, Z; Zheng, Y | 1 |
| Bergman, AM; Bos, MM; Coenen, JL; de Wit, R; Gelderblom, H; Hamberg, P; Lolkema, MP; Los, M; Ten Tije, AJ; van den Berg, P; van den Eertwegh, AJ; van Oort, IM; Westgeest, HM; Wissing, MD | 1 |
| Anna, M; Baki, M; Beatrice, D; Calogero, S; Davide, F; Detti, B; Di Brina, L; Di Cataldo, V; Eleonora, MP; Franceschini, D; Furfaro, I; Gabriele, S; Icro, M; Ilaria, F; Livi, L; Lorenzo, L; Lucia, DB; Mancuso, A; Meattini, I; Mohammed, B; Pasquetti, EM; Saieva, C; Simontacchi, G; Vanessa, DC | 1 |
| Bokemeyer, C; Steuber, T; Stroelin, P; von Amsberg, G | 1 |
| Alibhai, SM; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Sridhar, SS; Tannock, IF; Templeton, AJ | 1 |
| Dass, RN; Diels, J; Ford, D; Hamberg, P; Price, PW; Spencer, M | 1 |
| Altavilla, A; Bracarda, S; Del Buono, S; Hamzaj, A; Marrocolo, F; Sisani, M | 1 |
| Bui, CN; Cella, D; Fizazi, K; Holmstrom, S; Ivanescu, C; Spalding, J | 1 |
| Hara, H; Itaya, N; Nutahara, K; Okegawa, T; Tambo, M | 1 |
| Carducci, MA; Friedman, PN; Halabi, S; Hertz, DL; Jiang, C; Kelley, MJ; Kelly, WK; Mahoney, JF; McLeod, HL; Morris, MJ; Mulkey, FA; Owzar, K; Patel, JN; Ratain, MJ; Small, EJ | 1 |
| Beltran, H; Cheung, C; Fontugne, J; Galletti, G; Giannakakou, P; Horvath, LG; Kench, JG; Kimovski, D; MacDonald, TY; Matov, A; Miguel Mosquera, J; Nanus, DM; O'Toole, S; Rickman, DS; Rubin, MA; Suk Chae, S; Sung, M; Tagawa, ST | 1 |
| Akaza, H; Imanaka, K; Nakatani, T; Nishiyama, T; Ozono, S; Satoh, T; Tanabe, K; Terai, A; Uemura, H; Yokomizo, A | 1 |
| Den, RB; Kelly, WK | 1 |
| Aksnes, AK; Bottomley, D; Fang, F; Helle, SI; Hoskin, P; Johannessen, DC; Logue, J; Nilsson, S; O'Sullivan, JM; Parker, C; Sartor, O; Vogelzang, NJ; Wahba, M | 1 |
| Beer, TM; Courtney, KD; Elfiky, AA; Kantoff, P; Loda, M; Manola, JB; Oh, WK; Priolo, C; Ross, R; Ryan, CW; Taplin, ME; Van den Abbeele, AD; Yap, JT | 1 |
| Bria, E; Caffo, O; Galligioni, E; Maines, F; Massari, F; Tortora, G | 1 |
| Aieta, M; Alesini, D; Basso, U; Burgio, SL; Buttigliero, C; Caffo, O; Campadelli, E; Carrozza, F; Conteduca, V; Cortesi, E; D'Angelo, A; D'Aniello, C; De Giorgi, U; Donini, M; Facchini, G; Fornarini, G; Fratino, L; Galligioni, E; Gasparro, D; La Torre, L; Lo Re, G; Macrini, S; Maines, F; Massari, F; Messina, C; Morelli, F; Mucciarini, C; Ortega, C; Procopio, G; Ricotta, R; Ruatta, F; Sabbatini, R; Santarossa, S; Santini, D; Sartori, D; Sava, T; Tarasconi, S; Tucci, M; Veccia, A; Verderame, F; Vicario, G; Zagonel, V; Zucali, P; Zustovich, F | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Ghilardi, M; Lonati, V; Petrelli, F | 1 |
| de Morrée, ES; de Ridder, CMA; de Wit, R; Kweldam, CF; Mathijssen, RHJ; van Soest, RJ; van Weerden, WM; Wiemer, EAC | 1 |
| Arnaud, FX; Hélissey, C; Le Moulec, S; Rouanne, M | 1 |
| Fu, S; Guo, XM; Qi, WX; Zhang, Q | 1 |
| Iwasaki, M; Misaki, H; Okajima, K; Takano, T | 1 |
| Amir, E; de Wit, R; Eisenberger, MA; Mercier, F; Rosenthal, M; Sonpavde, G; Tannock, IF; Templeton, AJ; Tombal, B; van Soest, RJ; Vera-Badillo, FE | 1 |
| Barroso-Sousa, R; Chaves, AC; da Fonseca, LG; de Castro, G; Dzik, C; Kann, AG; Souza, KT | 1 |
| Barlow, WE; Etzioni, RB; Hershman, DL; LeBlanc, M; Martin, D; Ramsey, SR; Unger, JM | 1 |
| Agus, DB; Bargfrede, M; Carthon, B; Clark, WR; Gandhi, JG; Heath, E; Kong, N; Lin, J; Liu, G; Moran, S; Oh, WK; Petrylak, DP; Suri, A | 1 |
| Aggarwal, RR; Alumkal, J; Beer, TM; Graff, JN; Herrera, I; Higano, C; Lin, AM; Nordquist, LT; Ryan, CJ; Small, EJ; Taplin, ME; Weinberg, VK | 1 |
| Saad, F | 1 |
| Agarwal, N; Antonarakis, ES; Azad, A; Batten, JA; Cheng, HH; Chi, KN; Galsky, MD; Gulati, R; Heath, EI; Leiter, A; Montgomery, RB; Nadal, R; Pal, SK; Rehman, HT; Twardowski, P; Vaishampayan, UN; Yu, EY | 1 |
| Kongsted, P; Lindberg, H; Mouritsen, LS; Sengeløv, L; Sheikh, K | 1 |
| Caffo, O | 1 |
| Agarwal, N; Agus, D; Bellmunt, J; Borgstein, N; Carcano, F; Cruz, FM; De Bono, J; de Wit, R; Dreicer, R; Efstathiou, E; Fizazi, K; Fountzilas, G; Jones, R; Lee, SY; Oudard, S; Petrylak, DP; Saad, F; Tejura, B; Ulys, A; Webb, IJ | 1 |
| Chen, SP; Huang, YR; Jie, J; Na, YQ; Sun, Y; Sun, YH; Tian, Y; Wei, Q; Xie, LP; Yang, Y; Yao, X; Ye, DW; Ye, ZQ; Zeng, SX; Zhang, W; Zhang, X; Zhou, FJ; Zhou, T | 1 |
| Barbanti, G; Bianco, V; Brozzetti, S; De Rubertis, G; Fiaschi, AI; Francini, E; Laera, L; Miano, ST; Petrioli, R; Roviello, G | 1 |
| Boegemann, M; Herrmann, E; Krabbe, LM; Schrader, AJ | 1 |
| Beckett, LA; Lara, PN; Lo, EN; Pan, CX; Robles, D; Sands, JM; Suga, JM | 1 |
| Batra, SK; Datta, K; Johansson, SL; Lin, MF; Mimeault, M; Muniyan, S; Rachagani, S; Seshacharyulu, P | 1 |
| Berry, W; Chi, KN; Dmuchowski, C; Emmenegger, U; Foley, MA; Haas, NB; Hasabou, N; Hirmand, M; Joshua, AM; Mukherjee, SD; Olsson, CA; Perabo, F; Rathkopf, D; Saad, F; Scholz, M; Shore, ND; Winquist, E | 1 |
| Berman-Booty, LD; Ciment, SJ; de Leeuw, R; Den, RB; Dicker, AP; Gomella, LG; Kelly, WK; Knudsen, KE; Lallas, CD; Schiewer, MJ; Trabulsi, EJ | 1 |
| Beer, TM; Efstathiou, E; Forer, D; Higano, CS; Hirmand, M; Scher, HI; Taplin, ME | 1 |
| Armstrong, AJ; Chin, B; Dhawan, MS; George, DJ; Harrison, MR; Healy, P; Oldan, J; Zhang, T | 1 |
| Andergassen, U; Eiber, M; Gschwend, JE; Hatzichristodoulou, G; Heck, MM; Kehl, V; Krause, BJ; Nawroth, R; Rack, B; Retz, M; Souvatzoglou, M; Thalgott, M | 1 |
| Anderson, SA; Azad, AA; Bazov, J; Bell, RH; Chi, KN; Collins, CC; Gleave, ME; Haegert, A; Le Bihan, S; McConeghy, B; Paris, P; Shukin, R; Small, EJ; Thomas, G; Volik, SV; Wang, Y; Wyatt, AW; Youngren, J | 1 |
| Baumunk, D; Janitzky, A; Liehr, UB; Lux, A; Porsch, M; Reiher, F; Schindele, D; Schostak, M; Seseke, F; Ulrich, M; Wendler, JJ | 1 |
| Dreicer, R | 2 |
| Berry, W; McNamara, M | 1 |
| Bhor, M; Bhowmik, D; Hennessy, D; Nicacio, L; Rembert, D; Schnadig, I; Shen, L; Sonpavde, G; Yap, M | 1 |
| Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Olza, MO; de Wit, R; Doner, K; Fandi, A; Fizazi, K; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, S; Petrylak, DP; Sternberg, CN; Van As, N; Vogelzang, NJ; Wiechno, PJ | 1 |
| Hamada, Y; Hara, K; Horio, M; Kitani, K; Miyamae, K; Miyamura, S; Nakakuma, K; Yamasaki, Y | 1 |
| Hanazawa, K; Haraoka, M; Horie, S; Sakamoto, Y; Takamuki, M; Tanaka, M; Toyonaga, Y | 1 |
| Barile, C; Basso, U; Buti, S; Caffo, O; De Vivo, R; Facchini, G; Fratino, L; Galligioni, E; Gernone, A; Lo Re, G; Lodde, M; Maines, F; Pappagallo, GL; Perin, A; Sacco, C; Sava, T; Veccia, A; Zustovich, F | 1 |
| Ndibe, C; Sonpavde, G; Wang, CG | 1 |
| Fukawa, T; Fukumori, T; Kagawa, J; Kanayama, H; Komori, M; Kusuhara, Y; Mori, H; Takahashi, M; Yamaguchi, K; Yamamoto, Y | 1 |
| Arai, Y; Furuse, H; Ide, H; Kakehi, Y; Kamba, T; Kato, M; Kimura, T; Kitamura, H; Kosaka, T; Kume, H; Miyazaki, J; Mukai, H; Nakai, Y; Nozawa, M; Ohno, K; Okihara, K; Onozawa, Y; Suzuki, K; Takahashi, S; Tomita, Y; Uemura, H; Yokomizo, A | 1 |
| Chaftari, P; Cruz Carreras, MT; Dalal, S; Gonzalez, C; Liu, X; Merriman, K; Tu, SM; Viets-Upchurch, J; Wu, W; Yeung, SC | 1 |
| Azimi, A; Baltatzis, G; Chioureas, D; Fonseca, P; Hultenby, K; Kharaziha, P; Lennartsson, L; Nilsson, S; Panaretakis, T; Rutishauser, D; Ullén, A; Yachnin, J; Zubarev, R | 1 |
| Ito, N; Kanamaru, S; Shimizu, Y | 1 |
| Adachi, H; Fukuta, F; Hirose, T; Itoh, N; Kitamura, H; Kunishima, Y; Masumori, N; Matsukawa, M; Miyake, M; Miyao, N; Shigyo, M; Taguchi, K; Takagi, S; Takahashi, A; Yanase, M | 1 |
| Boyer, MJ; Breit, SN; Brown, DA; Castillo, L; Chatfield, MD; Chiam, K; Daly, RJ; Henshall, SM; Horvath, LG; Lee, BY; Lee-Ng, M; Lin, HM; Mahon, KL; Marx, GM; Molloy, MP; Pavlakis, N; Stockler, MR | 1 |
| Basch, E; Corty, RW; Dusetzina, SB; Green, AK; Meeneghan, M; Milowsky, MI; Reeder-Hayes, KE; Wood, WA | 1 |
| Aieta, M; Alesini, D; Burgio, SL; Caffo, O; Cavaliere, C; D'Angelo, A; De Giorgi, U; Di Lorenzo, G; Federico, P; Fratino, L; Galligioni, E; La Russa, F; Lo Re, G; Lodde, M; Macrini, S; Maines, F; Mansueto, G; Massari, F; Messina, C; Morelli, F; Ortega, C; Pegoraro, MC; Procopio, G; Ratta, R; Ruatta, F; Sava, T; Spizzo, G; Tucci, M; Veccia, A; Vicario, G; Zucali, PA; Zustovich, F | 1 |
| Chen, N; Chen, X; Chen, Z; Gong, J; Gui, H; Li, X; Liao, B; Liu, J; Liu, L; Liu, Z; Peng, Z; Shen, P; Wei, Q; Xu, M; Zeng, H; Zhang, P; Zhang, X; Zhao, T; Zhou, Q | 1 |
| Albiges, L; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Bourdoumis, A; Chrisofos, M; Christopoulos, P; Deliveliotis, C; Kostakopoulos, A; Mourmouris, P; Stasinou, T | 1 |
| Kamiya, N; Kawahara, T; Matsubara, N; Nishiyama, T; Satoh, T; Suzuki, H; Tabata, K; Takizawa, I; Ueda, Y; Uemura, H | 1 |
| Endou, M; Nagamori, S; Takada, S; Tamaki, S | 1 |
| Armstrong, C; Gao, AC; Liu, C; Lou, W; Sandher, A; Zhu, Y | 1 |
| Armstrong, AJ | 1 |
| Cui, Y; Ma, T; Ma, W; Xiao, P; Zhang, H; Zhou, C; Zu, S | 1 |
| Nilsson, S | 1 |
| Deguchi, T; Ehara, H; Fujita, Y; Ito, H; Ito, M; Kameyama, K; Kanimoto, Y; Kato, T; Kawakami, K; Mizutani, K; Nakane, K; Seishima, M | 1 |
| Beuzeboc, P; Massard, C | 1 |
| Akaza, H; Attard, G; Beer, TM; Beltran, H; Chinnaiyan, AM; Daugaard, G; Davis, ID; de Bono, JS; De Santis, M; Drake, CG; Eeles, RA; Efstathiou, E; Fanti, S; Fizazi, K; Gillessen, S; Gleave, ME; Halabi, S; Heidenreich, A; Hussain, M; James, ND; Lecouvet, FE; Logothetis, CJ; Mastris, K; Nelson, PS; Nilsson, S; Oh, WK; Olmos, D; Omlin, A; Padhani, AR; Parker, C; Rubin, MA; Sartor, O; Schalken, JA; Scher, HI; Sella, A; Shore, ND; Small, EJ; Smith, MR; Soule, HR; Sternberg, CN; Suzuki, H; Sweeney, CJ; Tannock, IF; Tombal, B | 1 |
| Chopra, S; Rashid, P | 1 |
| Andergassen, U; Eiber, M; Gschwend, JE; Heck, MM; Kehl, V; Krause, BJ; Kronester, C; Nawroth, R; Rack, B; Retz, M; Souvatzoglou, M; Thalgott, M | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Ponchietti, R; Roviello, G | 1 |
| Attard, G; de Bono, JS; Lorente, D; Mateo, J; Perez-Lopez, R | 1 |
| Babjuk, M; Bartunkova, J; Becht, E; Bilkova, P; Fucikova, J; Gasova, Z; Horvath, R; Hromadkova, H; Jarolim, L; Kayserova, J; Kubackova, K; Lastovicka, J; Podrazil, M; Rozkova, D; Sochorova, K; Spisek, R; Vavrova, K; Vrabcova, P | 1 |
| Armstrong, A; Ferrari, A; Hainsworth, J; Higano, CS; Hozak, RR; Hussain, M; Joshi, A; Kelly, WK; Liu, G; Rathkopf, D; Schwartz, JD; Yang, L | 1 |
| Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Ponchietti, R; Roviello, G | 1 |
| Honda, M; Iwamoto, H; Masago, T; Morizane, S; Sejima, T; Takenaka, A; Yao, A | 1 |
| Kyprianou, N; Martin, SK | 1 |
| Carducci, MA; Chen, YH; DiPaola, RS; Dwyer, AJ; Gulley, JL; Madan, RA; McNeel, DG | 1 |
| Antonarakis, ES; Carducci, MA; Chen, Y; Eisenberger, MA; Lu, C; Luo, J; Nakazawa, M; Paller, CJ | 1 |
| Alvarez, X; Dong, Y; Fu, X; Ledet, E; Li, J; Liu, X; Qi, Y; Sartor, O; Zhang, G; Zhang, H | 1 |
| Antonarakis, ES; Carducci, MA; Chen, Y; Denmeade, SR; Eisenberger, MA; Lu, C; Luber, B; Luo, J; Nadal, R; Nakazawa, M; Paller, CJ; Wang, H | 1 |
| Chen, M; He, ZH; Qi, P; Song, RX; Wang, ZP; Zhang, LX | 1 |
| Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND | 1 |
| Amela, EY; Penel, N; Ryckewaert, T | 1 |
| Daugaard, G; Kongsted, P; Lindberg, H; Sengeløv, L; Svane, IM | 1 |
| Bergman, AM; Bos, MM; Chitu, D; de Morrée, ES; de Wit, R; Goey, SH; Hamberg, P; Mathijssen, RH; Nieuweboer, AJ; van der Meer, N; van Soest, RJ | 1 |
| Ahn, S; Byun, SS; Hong, SK; Jeong, SJ; Jo, JK; Kim, KB; Lee, S; Lee, SE | 1 |
| Fizazi, K; Saad, F | 1 |
| Han, WK; He, ZS; Huang, LH; Jin, J; Song, Y; Yang, KW; Yu, W; Zhou, LQ | 1 |
| Antonarakis, ES; Bassi, S; Maughan, BL; Nadal, R; Schweizer, MT; Suzman, DL; Xhou, XC | 1 |
| Bria, E; Caffo, O; Galligioni, E; Maines, F; Tortora, G; Trentin, C; Veccia, A | 1 |
| Ardizzoni, A; Borghesi, M; Brunocilla, E; Castellucci, P; Ceci, F; Di Tullio, P; Fanti, S; Graziani, T; Renzi, R; Schiavina, R | 1 |
| Armstrong, AJ; Li, J | 1 |
| Bodei, L; Ezziddin, S; Jilg, CA; Lassmann, M; Luster, M; Maecke, HR; Ohlmann, CH; Olbert, PJ; Pfestroff, A | 1 |
| Audenet, F; Basset, V; Branchereau, J; de La Taille, A; Flamand, V; Lebdai, S; Lebret, T; Murez, T; Neuzillet, Y; Ploussard, G | 1 |
| Dickow, B; Fontana, J; Heath, E; Heilbrun, L; Land, S; Li, J; Shevrin, D; Smith, D; Stark, K; Stein, M; Vaishampayan, U | 1 |
| Alesini, D; Basso, U; Caffo, O; Campadelli, E; Conteduca, V; D'Angelo, A; De Giorgi, U; Donini, M; Ermacora, P; Fraccon, AP; Fratino, L; Galligioni, E; Gasparro, D; Giordano, M; Lo Re, G; Maines, F; Massari, F; Messina, C; Procopio, G; Ratta, R; Verderame, F; Vicario, G; Zagonel, V | 1 |
| Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S; Warmerdam, F | 1 |
| Alesini, D; Basso, U; Caffo, O; Campadelli, E; Conteduca, V; D'Angelo, A; De Giorgi, U; Donini, M; Ermacora, P; Fratino, L; Gasparro, D; Giordano, M; Lo Re, G; Lolli, C; Maines, F; Massari, F; Messina, C; Procopio, G; Ratta, R; Veccia, A; Verderame, F; Zagonel, V | 1 |
| Altavilla, A; Bracarda, S; Carlini, P; Caserta, C; Chioni, A; De Angelis, V; Derosa, L; Felici, A; Galli, L; Hamzaj, A; Pastina, I; Rossi, M; Scali, S; Sisani, M | 1 |
| Plow, EF; Sossey-Alaoui, K | 1 |
| Fazli, L; Gleave, M; Hernandez, E; Hsieh, JT; Lin, CJ; Yun, EJ; Zhou, J | 1 |
| Chang, K; Dai, B; Jia, ZW; Kong, YY; Li, GX; Qu, YY; Wang, Y; Ye, DW | 1 |
| Armstrong, AJ; Fandi, A; Petrylak, DP; Pond, GR; Rosenthal, M; Sonpavde, G; Templeton, AJ; Tombal, B | 1 |
| Carprieaux, M; Rappe, B; Schallier, D; Vandenbroucke, F | 1 |
| Bellmunt, J; Davis, ID; de Bono, JS; De Porre, P; Fizazi, K; Griffin, TW; Kheoh, T; Molina, A; Mulders, PF; Oudard, S; Protheroe, A; Rathkopf, DE; Ryan, CJ; Saad, F; Scher, HI; Schrijvers, D; Small, EJ; Smith, MR; Taplin, ME; Yu, MK | 1 |
| Asai, S; Kikugawa, T; Miura, N; Miyauchi, Y; Nishimura, K; Noda, T; Shirato, A; Tanji, N; Yanagihara, Y; Yokoyama, M | 1 |
| Chowdhury, S; Gilson, C; Kirby, R; Manickavasagar, T | 1 |
| Antonarakis, ES; Maughan, BL | 1 |
| Bandali, N; Berry, S; Booth, CM; Chow, A; Emmenegger, U; Kerbel, RS; Ko, YJ; Lee, C; Man, S; Sridhar, SS; Winquist, E; Xu, P | 1 |
| Antonarakis, ES; Dzinic, SH; Freeman, S; Heath, EI; Heilbrun, LK; Li, X; Liu, G; Sheng, S; Smith, D; Stein, M; Thakur, MK; Vaishampayan, U | 1 |
| Beer, TM; Graff, JN | 1 |
| Boyd, T; Cheng, HH; Montgomery, B; Nelson, PS; Pritchard, CC | 1 |
| Abrial, C; Atger, M; Bayet-Robert, M; Chollet, P; Curé, H; Durando, X; Eymard, JC; Gadea, E; Guy, L; Mahammedi, H; Planchat, E; Pouget, M; Savareux, L; Thivat, E; Van-Praagh, I | 1 |
| Aieta, M; Alesini, D; Basso, U; Berruti, A; Bonetti, A; Bortolus, R; Burgio, LS; Caffo, O; D'Angelo, A; De Giorgi, U; Di Lorenzo, G; Donini, M; Facchini, G; Fratino, L; Galligioni, E; Lo Re, G; Lodde, M; Maines, F; Mansueto, G; Massari, F; Mattioli, R; Messina, C; Mucciarini, C; Nicodemo, M; Ortega, C; Perin, A; Procopio, G; Santini, D; Sava, T; Scognamiglio, F; Spizzo, G; Tucci, M; Veccia, A; Vicario, G; Zagonel, V; Zucali, PA | 1 |
| Bolenz, C; Fuxius, S; Heinrich, E; Müller, M; Schwartz, M; von Hardenberg, J; Weiß, C; Werner, T | 1 |
| Uemura, H | 1 |
| de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S | 1 |
| Clausse, M; D'Hondt, L; Demey, W; Everaert, E; Filleul, B; Gil, T; Goeminne, JC; Lumen, N; Machiels, JP; Mebis, J; Pelgrims, G; Rasschaert, M; Rottey, S; Schallier, D; Schatteman, P; Schrijvers, D; Van Aelst, F; Van Erps, J; Van Haverbeke, J; Van Hende, F; Van Praet, C; Verheezen, J; Vermeij, J; Werbrouck, P; Wynendaele, W | 2 |
| Bruce, J; De Porre, P; Gonzalez, MD; Kheoh, T; Lim, EA; Maul, S; Nanus, DM; Peng, W; Petrylak, DP; Posadas, EM; Smit, JW; Tagawa, ST; Tran, N | 1 |
| Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA | 1 |
| Fleming, MT; Gibbons, JA; Khondker, Z; Morris, MJ; Novotny, W; Ouatas, T; Peterson, AC; Rathkopf, DE; Scher, HI | 1 |
| de Bono, JS; Jayaram, A; Sharp, A; Zafeiriou, Z | 1 |
| Chen, Z; De Porre, P; Du, C; Feng, Y; Huang, Y; Jin, J; Li, C; Lin, G; Liu, W; Shan, Y; Sun, Y; Sun, Z; Xie, L; Ye, D; Ye, ZQ; Zou, Q | 1 |
| Hattori, Y; Kawahara, T; Kondo, K; Miyoshi, Y; Moriyama, M; Noguchi, K; Takebayashi, S; Teranishi, J; Uemura, H; Uemura, K; Yao, M; Yokomizo, Y; Yoneyama, S | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Cislo, P; Coleman, RE; Nilsson, S; O'Sullivan, JM; Parker, C; Reuning-Scherer, J; Sartor, O; Shan, M; Vogelzang, NJ; Zhan, L | 1 |
| Carrera, G; Fernández, P; Gaba, L; García-Recio, S; Jiménez, N; Marín-Aguilera, M; Mellado, B; Paré, L; Pereira, MV; Prat, A; Reig, Ò | 1 |
| Attard, G; Bianchini, D; de Bono, JS; Dearnaley, DP; Ferraldeschi, R; Jayaram, A; Kolinsky, MP; Lorente, D; Mateo, J; Mehra, N; Parker, C; Perez-Lopez, R; Reid, A; Rescigno, P; Sideris, S; Smith, AD; Sumanasuriya, S; Tunariu, N; Zafeiriou, Z | 1 |
| Eto, M; Inokuchi, J; Kiyoshima, K; Koga, H; Naito, S; Shiga, KI; Shiota, M; Takeuchi, A; Tatsugami, K; Yamaguchi, A; Yokomizo, A | 1 |
| Allory, Y; Carpentier, G; Céraline, J; Courty, J; De La Taille, A; Destouches, D; Maillé, P; Marchand, C; Sader, M; Semprez, F; Soyeux, P; Terry, S; Vacherot, F | 1 |
| Aghai, A; Burger, H; de Bruijn, P; de Morrée, E; de Ridder, C; de Wit, R; Ghobadi Moghaddam-Helmantel, I; Mathijssen, R; van Soest, R; van Weerden, W; Wiemer, E | 1 |
| Thoma, C | 1 |
| Hara, I; Iba, A; Iguchi, T; Kikkawa, K; Kodama, Y; Kohjimoto, Y; Koike, H; Kusumoto, H; Matsumura, N; Yamashita, S | 1 |
| Coleman, RE; Hoskin, P; Nilsson, S; Parker, C; Petrenciuc, O; Sartor, O; Staudacher, K; Thuresson, M; Vogelzang, NJ | 1 |
| Balk, M; Bui, CN; Flanders, S; Francis, P; O'Day, K; Oestreicher, N; Popelar, B; Posta, L; Tang, H | 1 |
| Ackermann, CJ; Gillessen, S; Hager, S; Joerger, M; Omlin, A | 1 |
| Benincasa, A; Bosso, D; Buonerba, C; De Placido, S; Di Lorenzo, G; Pagliuca, M; Perillo, T | 1 |
| Davies, RS; Lester, JF; Smith, C | 1 |
| Čapoun, O; Hanuš, T; Honová, H; Jančíková, M; Kološtová, K; Michael, P; Mikulová, V; Sobotka, R; Soukup, V; Zima, T | 1 |
| Kongsted, P; Lindberg, H; Sengeløv, L; Svane, IM | 2 |
| Carducci, MA; Dolan, ME; Dorsey, SG; Febbo, PG; Friedman, PN; Furukawa, Y; Halabi, S; Hertz, DL; Jiang, C; Kelley, MJ; Kelly, WK; Krens, SD; Kroetz, DL; Kubo, M; Lassiter, C; Lessans, S; Mahoney, JF; McLeod, HL; Morris, MJ; Mulkey, F; Nakamura, Y; Owzar, K; Patel, J; Ratain, MJ; Renn, CL; Shterev, I; Sibley, AB; Small, EJ; Watson, D; Weisman, L; Wheeler, HE; Wing, C | 1 |
| Bisbjerg, R; Daugaard, G; Kongsted, P; Lindberg, H; Sengeløv, L; Svane, IM | 1 |
| Gyawali, B; Iddawela, M; Koomulli-Parambil, S | 1 |
| Assi, T; Bachour, M; El Rassy, E; Farhat, F; Ghosn, M; Kattan, J | 1 |
| Francini, E; Sweeney, CJ | 1 |
| Azuma, H; Hinohara, K; Hiraki, M; Jeong, SH; Kantoff, PW; Komura, K; Lee, GS; Qu, F; Sweeney, CJ; Wang, X | 1 |
| Amadori, D; Attard, G; Calistri, D; Casadio, V; Conteduca, V; De Giorgi, U; Gurioli, G; Lolli, C; Martignano, F; Salvi, S; Scarpi, E; Schepisi, G; Testoni, S | 1 |
| Adamo, V; Barni, S; Boccardo, F; Bruno, M; Caffo, O; Caserta, C; Chiuri, VE; De Giorgi, U; De Vincenzo, F; De Vivo, R; Derosa, L; Dinota, A; Facchini, G; Fratino, L; Grassi, P; Messina, C; Mosca, A; Porcu, L; Procopio, G; Ricotta, R; Santini, D; Scavelli, C; Surace, G; Susi, M; Tartarone, A; Verzoni, E; Zaniboni, A | 1 |
| Butler, L; Hollande, F; Mølck, C; Paquet-Fifield, S; Sloan, E; Ventura, S; Xie, J | 1 |
| Cheng, HH; Gulati, R; Montgomery, RB; Mostaghel, EA; Nelson, PS; Schweizer, MT; Yu, EY | 1 |
| Gondo, T; Hirasawa, Y; Horiguchi, Y; Nakagami, Y; Nakashima, J; Namiki, K; Ohno, Y; Ohori, M; Sugihara, T; Tachibana, M; Takizawa, I | 1 |
| Agarwal, N; Alex, A; Heilbrun, ME; Parker, SJ; Pond, GR; Sonpavde, G | 1 |
| Matsuyama, H; Nagao, K | 1 |
| Bearrs, J; Gupta, S; Neiss, A; Sharma, S; Soldi, R; Thode, T; Weston, A | 1 |
| Hasegawa, S; Kikuchi, E; Kitano, S; Kosaka, T; Miyajima, A; Miyazaki, Y; Mizuno, R; Oya, M; Shigeta, K; Shinojima, T; Tanoguchi, H; Yasumizu, Y | 1 |
| Cho, KS; Chung, BH; Jang, HS; Koo, KC | 1 |
| de Bono, JS; De Porre, P; Fizazi, K; Flaig, TW; Kheoh, T; Li, J; Mulders, PFA; Rathkopf, DE; Ryan, CJ; Saad, F; Shore, ND; Small, EJ; Smith, MR; Todd, MB | 1 |
| Galsky, MD; Oh, WK; Tsao, CK | 1 |
| Arslan, C | 1 |
| Andronis, L; Barton, D; Beesley, S; Billingham, L; Birtle, A; Brown, J; Chakraborti, P; Collins, S; Goranitis, I; James, N; McLaren, D; O'Sullivan, J; Parker, C; Pirrie, S; Pope, A; Porfiri, E; Russell, M; Staffurth, J; Stanley, A; Wylie, J | 1 |
| Barth, A; Baumann, S; Berthold, D; Cathomas, R; Gillessen, S; Hasler, L; Kühne, R; Mingrone, W; Nussbaum, CU; Papazoglou, D; Richner, J; Rothermundt, C; Rothschild, SI; Schmid, M; Stenner, F; von Burg, P; von Rohr, L; Wannesson, L; Winterhalder, R | 1 |
| Bernhard, J; Cathomas, R; Crabb, SJ; Elliott, T; Gillessen, S; Hayoz, S; Kenner, H; Manetsch, G; Mark, M; Mohaupt, MG; Rauch, D; Roggero, E; Rothermundt, C; Vilei, SB; von Burg, P; Winterhalder, R | 1 |
| Barton, D; Bellmunt, J; Berry, WR; Burke, JM; Crane, E; De Wit, R; Doner, K; Fandi, A; Fizazi, K; Gandhi, A; Hainsworth, JD; Hutson, TE; Jungnelius, U; Liu, K; Petrylak, DP; Sternberg, CN; Vogelzang, NJ; Waldman, MF; Wiechno, PJ | 1 |
| Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S | 1 |
| Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Morrée, ES; de Wit, R; Doner, K; Fandi, A; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, JS; Li, S; Ochoa de Olza, M; Petrylak, DP; Sternberg, CN; van As, N; Vogelzang, NJ; Wiechno, PJ | 1 |
| Cheng, T; Chi, KN; Eigl, BJ; Eliasziw, M; North, S; Parimi, S; Ruether, D; Trudeau, M; Winquist, E | 1 |
| Berretta, M; Cavaliere, C; Cecere, SC; Crispo, A; D'Aniello, C; Daniele, B; De Sangro, C; Della Pepa, C; Di Napoli, M; Facchini, G; Germano, D; Gridelli, C; Iovane, G; Maiorino, L; Pignata, S; Pisconti, S; Rossetti, S; Rossi, E; Turitto, D | 1 |
| Penel, N | 1 |
| Alsdorf, WH; Amann, K; Bähring, R; Bauer, CK; Bokemeyer, C; Dyshlovoy, SA; Ehmke, H; Fedorov, SN; Guzii, AG; Hauschild, J; Honecker, F; Kasheverov, IE; Lange, T; Makarieva, TN; Mandanchi, R; Otte, K; Schröder-Schwarz, J; Schumacher, U; Shubina, LK; Steuber, T; Stonik, VA; Tabakmakher, KM; Venz, S; von Amsberg, G | 1 |
| Bristow, R; Joshua, AM; Milosevic, MF; Smith, AD; Truong, M; Yip, P | 1 |
| Gao, X; Hu, C; Li, K; Lu, L; Lu, M; Mao, Y; Peng, S; Qiu, J; Si-Tu, J; Wang, D | 1 |
| Chen, YT; Cheng, YT; Chiang, PH; Chuang, YC; Hsu, CC; Kang, CH; Lee, WC; Luo, HL; Shen, YC | 1 |
| Ishikawa, A; Matsubara, A; Oue, N; Sakamoto, N; Sekino, Y; Sentani, K; Shigematsu, Y; Teishima, J; Yasui, W | 1 |
| Batra, SK; Chen, HT; Hsieh, KC; Ingersoll, MA; Kao, CL; Lin, MF; Martinez, O; Miller, DR; Simha, MV; Wakefield, CB | 1 |
| Bolton, D; Corfield, J; Crozier, J; Joshua, AM; Lawrentschuk, N | 1 |
| Carducci, MA; Markowski, MC | 1 |
| Balea-Filgueiras, J; Martín-Herranz, I; Ramudo-Cela, L; Vizoso-Hermida, JR | 1 |
| Cookson, MS; Ritch, CR | 1 |
| Alibhai, SM; Aziz, S; Breunis, H; Manokumar, T; Timilshina, N | 1 |
| Aitoku, Y; Basurto, E; Concialdi, K; DiBonaventura, M; Kimura, G; Ledesma, DA; Matsubara, N; McKinnon, I; Mohamed, AF; Narimatsu, A; Uemura, H; Wang, E; Yamaguchi, A | 1 |
| Aziz, T; Chow, MJ; Cutz, JC; Jayasekera, D; Kapoor, A; Major, P; Tang, D; Wei, F; Wong, N; Yan, J; Zheng, M | 1 |
| Choi, HY; Il Seo, S; Jeon, HG; Jeon, SS; Jeong, BC; Kim, JH; Kwon, GY; Lee, HM; Lim, JE; Song, W | 1 |
| Abdallah, K; Airola, A; Aittokallio, T; Bare, JC; Bot, BM; Costello, JC; Friend, S; Guinney, J; Khan, SA; Laajala, TD; Mirtti, T; Neto, EC; Norman, T; Pahikkala, T; Peddinti, G; Ryan, CJ; Sartor, O; Scher, HI; Shen, L; Soule, H; Stolovitzky, G; Sweeney, CJ; Wang, T; Winner, KK; Xie, Y; Yu, T; Zhou, FL | 1 |
| Cicero, G; De Luca, R; Dieli, F; Dispensa, N; Dorangricchia, P; Galvano, A; Lo Re, G; Serretta, V | 1 |
| Griebling, TL | 1 |
| Abdallah, K; Bates, SE; Beetsch, J; Curt, G; Fojo, T; Hugh-Jones, C; Lebowitz, P; Morrell, J; Murphy, M; Rothenberg, M; Sargent, DJ; Scher, HI; Simantov, R; Simon, R; Stein, WD; Wilkerson, J | 1 |
| Argenziano, M; Battaglia, A; Bosco, O; Catalano, MG; Cavalli, R; D'Amelio, P; Fortunati, N; Frairia, R; Gontero, P; Marano, F; Peluso, R; Rinella, L; Sassi, F | 1 |
| Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Guglielmini, P; Iaconis, D; Numico, G; Pisano, C; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Preston, MA | 1 |
| Spratt, D | 1 |
| Birtle, AJ; Crabb, SJ; Downs, N; Ellis, M; Griffiths, G; Jones, RJ; Khoo, V; Ksiazek, L; Maishman, T; Martin, K; Ratcliffe, I; Thompson, S | 1 |
| Abdallah, K; Hamilton, RJ; Joshua, AM; Khoja, L; Pintilie, M; Pitcher, B | 1 |
| Fan, JH; He, DL; Jiang, YM; Lv, W; Pei, XQ; Tian, G; Wu, DP; Wu, KJ | 1 |
| Armstrong, AJ; Bono, J; Dmuchowski, C; Fizazi, K; Forer, D; Hirmand, M; Saad, F; Scher, HI; Shore, ND | 1 |
| Fujisawa, M; Furuse, H; Hara, T; Miyake, H; Ozono, S; Sugiyama, T; Tamura, K | 1 |
| Elo, LL; Hirvonen, O; Jyrkkiö, S; Laitinen, T; Mahmoudian, M; Rautakorpi, L; Seyednasrollah, F | 1 |
| Andersen, R; Borch, TH; Ellebaek, E; Hansen, M; Iversen, TZ; Kongsted, P; Lindberg, H; Met, Ö; Sengeløv, L; Svane, IM | 1 |
| Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW | 1 |
| Feinman, HE; Figg, WD; Price, DK | 1 |
| Bastick, P; Briscoe, K; Gurney, H; Horvath, LG; Lin, HM; Mahon, KL; Mallesara, G; Marx, G; Spielman, C; Stockler, MR; Swarbrick, A | 1 |
| Bergman, AM; Blumenstein, B; Chi, KN; de Bono, JS; Ferrero, JM; Feyerabend, S; Gleave, M; Gravis, G; Higano, CS; Jacobs, C; Merseburger, AS; Mukherjee, SD; Reeves, J; Saad, F; Stenzl, A; Zalewski, P | 1 |
| Fujisawa, M; Harada, K; Miyake, H; Sakai, I; Terakawa, T | 1 |
| Etienne-Grimaldi, MC; Fischel, JL; Lo Nigro, C; Merlano, M; Milano, G; Monteverde, M; Tonissi, F | 1 |
| Byun, SS; Hong, SK; Jeong, CW; Jeong, SJ; Kwak, C; Lee, SE; Yoon, CY | 1 |
| Armstrong, AJ; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA | 1 |
| Hatano, K; Kawashima, A; Meguro, N; Mukai, M; Nagahara, A; Nakai, Y; Nakayama, M; Nishimura, K; Nonomura, N; Oka, D; Sato, M; Shimizu, K; Takayama, H; Tanigawa, T; Tsujimura, A; Uemura, M; Yamaguchi, S; Yoshida, T | 1 |
| Inoue, T; Kamba, T; Kita, Y; Ogawa, O; Shimizu, Y; Yoshimura, K | 1 |
| Fujii, R; Hara, I; Inagaki, T; Kohjimoto, Y; Kuramoto, T; Matusmura, N; Nanpo, Y; Nishizawa, S; Sasaki, Y | 1 |
| Bian, XJ; Dai, B; Shen, YJ; Xie, HY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y | 1 |
| Arévalo, E; Carranza, OE; Castañón, E; Castillo, A; Collado-Gómez, V; Fusco, JP; Gil-Aldea, I; Gil-Bazo, I; López, I; Zudaire, ME | 1 |
| Akakura, K; Ichikawa, T; Kamiya, N; Masai, M; Mikami, K; Nakatsu, H; Naya, Y; Nomura, K; Okano, T; Ooki, T; Ota, S; Sato, N; Suzuki, H; Ueda, T | 1 |
107 review(s) available for docetaxel anhydrous and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review.
Topics: Adrenal Cortex Hormones; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Hydrocortisone; Ketoconazole; Male; Prednisolone; Prednisone; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies | 2021 |
The role of chemotherapy in metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2022 |
The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context.
Topics: Androgen Antagonists; Canada; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms, Castration-Resistant | 2022 |
Recent advances in the treatment of advanced prostate cancer: maximizing existing therapies while searching for novel solutions.
Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2022 |
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2022 |
Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis.
Topics: Docetaxel; Hemoglobins; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance.
Topics: Androgen Antagonists; Castration; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant | 2022 |
Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis.
Topics: BRCA1 Protein; BRCA2 Protein; Docetaxel; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan.
Topics: Alkaline Phosphatase; Docetaxel; Humans; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Taiwan; Treatment Outcome | 2023 |
Prostate cancer and novel pharmacological treatment options-what's new for 2022?
Topics: Androgen Antagonists; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant | 2023 |
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium | 2023 |
Treatments and challenges in advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2023 |
Emerging treatment options for prostate cancer.
Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Lutetium; Male; Prostatic Neoplasms, Castration-Resistant | 2023 |
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Network Meta-Analysis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2023 |
Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Progression-Free Survival; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2023 |
Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Bayes Theorem; Cost-Effectiveness Analysis; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Advances in the treatment of metastatic prostate cancer.
Topics: Androgen Antagonists; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant | 2023 |
[Metastatic castration-resistant prostate cancer-what are rational sequential treatment options?]
Topics: Androgen Antagonists; Docetaxel; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant | 2023 |
[Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?]
Topics: Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2023 |
Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Humans; Male; Pharmacogenomic Variants; Prostatic Neoplasms, Castration-Resistant | 2019 |
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
Topics: Androstenes; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Tumor Microenvironment | 2020 |
[Treatment of metastatic, castration-resistant prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Germany; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
[Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?]
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Therapy, Combination; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Thiohydantoins; Treatment Outcome | 2020 |
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Ethnicity; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2020 |
Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2020 |
Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts | 2020 |
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Castration; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings.
Topics: Androgen Antagonists; Castration; Docetaxel; Humans; Male; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2021 |
Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions.
Topics: Androstenes; Animals; Benzamides; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, LHRH; Signal Transduction | 2020 |
[Advanced prostate cancer: sequence of androgen receptor-targeted substances and chemotherapy determines long-term survival].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Receptors, Androgen; Treatment Outcome | 2021 |
Contemporary management of advanced prostate cancer: an evolving landscape.
Topics: Adenocarcinoma; Androstenes; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Docetaxel; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Radium; Taxoids; Therapies, Investigational | 2021 |
Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?
Topics: Aged; Antineoplastic Agents; Docetaxel; Geriatric Assessment; Humans; Male; Neoplasm Metastasis; Patient Selection; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Topics: Bone Neoplasms; Disease Management; Docetaxel; Humans; Italy; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Treatment Outcome | 2017 |
Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature.
Topics: Androstenes; Benzamides; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2017 |
[Review on quality of life in CRPC patients].
Topics: Abiraterone Acetate; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Survival Rate; Treatment Outcome | 2017 |
[Monitoring of treatment for metastatic castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Outcome and Process Assessment, Health Care; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids | 2017 |
Dose considerations for anti-cancer drugs in metastatic prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cognition Disorders; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Humans; Male; Precision Medicine; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
[Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Early Medical Intervention; Evidence-Based Medicine; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2017 |
Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2017 |
Current approaches to incorporation of radium-223 in clinical practice.
Topics: Androstenes; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen; Taxoids; Treatment Outcome | 2018 |
Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies.
Topics: Aged; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Prednisone; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2018 |
Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Treatment of Castration-naive Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2017 |
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
Acute myositis: an unusual and severe side effect of docetaxel: a case report and literature review.
Topics: Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Male; Middle Aged; Myositis; Prostatic Neoplasms, Castration-Resistant | 2018 |
Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2017 |
The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Network Meta-Analysis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2018 |
Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison.
Topics: Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids; Treatment Outcome | 2017 |
Treatment of hormone-naïve metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
[DNA damage repair: An emerging strategy in metastatic prostate cancer].
Topics: Androstenes; Antineoplastic Agents; Benzamides; DNA Damage; DNA Repair; Docetaxel; Genomic Instability; Humans; Male; Nitriles; Phenylthiohydantoin; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis.
Topics: Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms, Castration-Resistant | 2018 |
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; White People | 2019 |
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2019 |
Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.
Topics: Area Under Curve; Clinical Trials as Topic; Docetaxel; Humans; Incidence; Logistic Models; Male; Neoplasm Metastasis; Neoplasms; Neutropenia; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future.
Topics: Androstenes; Docetaxel; Humans; Male; Medical Oncology; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Randomized Controlled Trials as Topic | 2019 |
Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or….
Topics: Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant | 2019 |
[Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2019 |
Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tissue Extracts | 2013 |
Perspectives on treatment of metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2013 |
Current, new and novel therapy for castration-resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids | 2014 |
Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstadienes; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Multicenter Studies as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2013 |
PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Design; Drug Resistance, Neoplasm; Humans; Male; Molecular Targeted Therapy; Mutation; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Signal Transduction; Taxoids; Up-Regulation | 2014 |
Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality Improvement; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom | 2013 |
[Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Docetaxel; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Male; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2013 |
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlorides; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Tissue Extracts | 2013 |
Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Docetaxel; Humans; Male; Neutropenia; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids | 2014 |
[Recent advances in treatment of patients with castration-resistant prostate cancer after docetaxel failure].
Topics: Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Reconsideration of progression to CRPC during androgen deprivation therapy.
Topics: Androgen Antagonists; Androgens; Dehydroepiandrosterone; Disease Progression; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Steroids; Taxoids | 2015 |
Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2014 |
Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Drug Therapy; Drug Therapy, Combination; Humans; Male; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome | 2014 |
[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring].
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review).
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Clusterin; Docetaxel; Drug Resistance, Neoplasm; Growth Differentiation Factor 15; Heat-Shock Proteins; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tumor Microenvironment | 2014 |
Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer.
Topics: Decision Making; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2014 |
PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Trials as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids | 2014 |
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
Topics: Abiraterone Acetate; Androstadienes; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2014 |
[Current treatment concepts for castration resistant prostate cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brachytherapy; Combined Modality Therapy; Docetaxel; Evidence-Based Medicine; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
Topics: Algorithms; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2014 |
Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2015 |
[Case of portal venous gas and pneumatosis cystoides intestinalis occurring during chemotherapy for a castration-resistant prostate cancer].
Topics: Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Decompression; Docetaxel; Embolism, Air; Fatal Outcome; Humans; Male; Pneumatosis Cystoides Intestinalis; Portal Vein; Prostatic Neoplasms, Castration-Resistant; Radiography; Taxoids | 2014 |
Prostate cancer in 2014: The year chemotherapy finally gets some respect!
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC).
Topics: Alkaline Phosphatase; Biomarkers, Tumor; Docetaxel; Genetic Markers; Humans; Inflammation; Kallikreins; L-Lactate Dehydrogenase; Male; MicroRNAs; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Managing advanced prostate cancer: the rapidly changing treatment landscape.
Topics: Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Cancer Vaccines; Diagnostic Imaging; Docetaxel; Humans; Male; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Corticosteroids in the management of prostate cancer: a critical review.
Topics: Adrenal Cortex Hormones; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
[How to manage patients with CRPC?].
Topics: Abiraterone Acetate; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Tissue Extracts | 2015 |
Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Australia; Disease Progression; Docetaxel; General Practice; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2015 |
Sequencing of agents in castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts; Treatment Outcome | 2015 |
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
Topics: Abiraterone Acetate; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Young Adult | 2015 |
Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Topics: Androgen Antagonists; Animals; Cell Cycle Checkpoints; Docetaxel; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Taxoids | 2015 |
A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease-Free Survival; Docetaxel; Endothelin A Receptor Antagonists; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2015 |
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts | 2015 |
Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Secondary Prevention; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2015 |
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.
Topics: Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.
Topics: Androgen Receptor Antagonists; Benzamides; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Platinum Compounds; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Treatment Outcome | 2016 |
Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature.
Topics: Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.
Topics: Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids | 2016 |
Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Understanding the role of new systemic agents in the treatment of prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2016 |
Early use of chemotherapy in metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; History, 20th Century; History, 21st Century; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Time Factors | 2017 |
Advances in the management of castration resistant prostate cancer.
Topics: Aged; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Management; Docetaxel; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
178 trial(s) available for docetaxel anhydrous and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Metformin; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retrospective Studies; Treatment Outcome | 2021 |
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Disease Progression; Docetaxel; Humans; Kallikreins; Lycopene; Male; Middle Aged; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Time Factors | 2021 |
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Humans; Male; Middle Aged; Nivolumab; Prostatic Neoplasms, Castration-Resistant | 2022 |
A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anemia; Antineoplastic Agents; Diarrhea; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fatigue; Follow-Up Studies; Humans; Male; Middle Aged; Nail Diseases; Neutropenia; Pneumonia; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Stomatitis | 2021 |
Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Docetaxel; Double-Blind Method; Female; Humans; Immunotherapy; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2022 |
Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multice
Topics: Adolescent; Adult; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; China; Docetaxel; Humans; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2022 |
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase 4; Docetaxel; Febrile Neutropenia; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Purines; Treatment Outcome | 2022 |
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyrazoles | 2022 |
ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Immunotherapy; Male; Prostatic Neoplasms, Castration-Resistant | 2022 |
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
Topics: Abiraterone Acetate; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Topics: Androgen Antagonists; Benzamides; Docetaxel; Hormones; Humans; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2022 |
Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Treatment Outcome | 2022 |
Is docetaxel-free interval a predictive factor for castration-resistant prostate cancer?
Topics: Disease-Free Survival; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Topics: Aged; Docetaxel; Humans; Male; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Response Evaluation Criteria in Solid Tumors | 2023 |
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Humans; Male; Pain; Patient Reported Outcome Measures; Phthalazines; Piperazines; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone | 2022 |
Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; T-Lymphocytes | 2023 |
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Humans; Male; Neutropenia; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2023 |
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2023 |
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Genes, BRCA1; Genes, BRCA2; Humans; Indoles; Male; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2023 |
Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Receptors, Androgen; Treatment Outcome | 2023 |
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
Topics: Androgen Antagonists; Docetaxel; Hormones; Humans; Immunotherapy; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Vaccines | 2023 |
Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer.
Topics: Docetaxel; Humans; Male; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2023 |
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Prednisolone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2023 |
Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2023 |
Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2023 |
[
Topics: Dipeptides; Docetaxel; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Outcome | 2023 |
Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.
Topics: Anilides; Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Pyridines; Retrospective Studies; Risk Factors; Survival Rate | 2020 |
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome | 2019 |
Topics: Aged; Anoctamins; Antineoplastic Agents; Biomarkers, Tumor; Cohort Studies; Docetaxel; Genetic Variation; Humans; Male; Middle Aged; Prognosis; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2019 |
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel.
Topics: Aged; Androgen Receptor Antagonists; Docetaxel; Humans; Male; Molecular Targeted Therapy; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2020 |
Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Dexamethasone; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kallikreins; Male; Middle Aged; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Response Evaluation Criteria in Solid Tumors; T-Lymphocytes, Cytotoxic; Vaccines, Subunit | 2020 |
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Topics: Aged; Alleles; Androgen Antagonists; Disease Progression; Disease-Free Survival; Docetaxel; Genotype; Humans; Male; Middle Aged; Multienzyme Complexes; Neoplasm Metastasis; Progesterone Reductase; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Steroid Isomerases; Treatment Outcome | 2020 |
Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2020 |
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Ipilimumab; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Time Factors | 2020 |
[CARD study: relevance for the treatment of advanced prostate cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Nitriles; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyridines; Treatment Outcome | 2021 |
A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel.
Topics: Aged; Aged, 80 and over; Cancer Vaccines; Docetaxel; Double-Blind Method; HLA-A24 Antigen; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Vaccination; Vaccines, Subunit | 2021 |
CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Body Composition; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prospective Studies; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Psoas Muscles; Subcutaneous Fat; Tomography, X-Ray Computed | 2021 |
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retreatment; Taxoids; Treatment Outcome | 2020 |
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Time Factors; United Kingdom | 2021 |
Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Treatment Failure; Treatment Outcome | 2021 |
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Curcumin; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Humans; Male; Medical Futility; Medication Adherence; Middle Aged; Placebos; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2021 |
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Kallikreins; Male; Middle Aged; Neoplasm Grading; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Ritonavir; Treatment Outcome | 2021 |
Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Treatment Outcome | 2021 |
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prednisolone; Prednisone; Progression-Free Survival; Prostate; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2021 |
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2021 |
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial.
Topics: Aged; Antineoplastic Agents; Cancer Vaccines; CD8-Positive T-Lymphocytes; Disease-Free Survival; Docetaxel; Humans; Immunity; Immunization; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; T-Lymphocytes, Regulatory; Telomerase | 2021 |
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Female; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2021 |
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Survival Analysis | 2021 |
The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Regression Analysis; Taxoids; Treatment Outcome | 2017 |
A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organometallic Compounds; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
Topics: Aged; Biomarkers, Tumor; Cell Nucleus; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Male; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids | 2017 |
No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2017 |
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Docetaxel; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Netherlands; Pragmatic Clinical Trials as Topic; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Registries; Retrospective Studies; Treatment Outcome; Tubulin Modulators | 2018 |
Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2017 |
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
Topics: Adult; Aged; Androstenes; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Internationality; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prednisone; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Thionucleotides; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; International Agencies; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Quinolones; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Belgium; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; France; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
Topics: Aged; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Blood Platelets; Disease-Free Survival; Docetaxel; Glutamate Carboxypeptidase II; Humans; Kallikreins; Male; Middle Aged; Neuropeptide Y; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2018 |
Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Canada; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Emergency Service, Hospital; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Multivariate Analysis; Nitriles; Ontario; Phenylthiohydantoin; Population Surveillance; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2018 |
No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2018 |
Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).
Topics: Aged; Aged, 80 and over; Benzimidazoles; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Somatostatin; Treatment Outcome | 2018 |
[Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer].
Topics: Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Goserelin; Humans; Male; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tosyl Compounds; Treatment Outcome | 2017 |
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Diarrhea; Disease-Free Survival; Docetaxel; Fatigue; Humans; Male; Middle Aged; Nanoparticles; Nausea; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Italy; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2018 |
Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Mellitus; Docetaxel; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2019 |
Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; DNA; DNA Methylation; Docetaxel; Glutathione Transferase; Humans; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radiotherapy; Steroid Synthesis Inhibitors; Tubulin Modulators | 2019 |
Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Survival Rate | 2019 |
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pantoprazole; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2019 |
Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Japan; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2019 |
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radium | 2019 |
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Multivariate Analysis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2018 |
Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Placebos; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2013 |
Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Algorithms; Comorbidity; Disease-Free Survival; Docetaxel; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Pain; Pain Measurement; Palliative Care; Peripheral Nervous System Diseases; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Survival; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Docetaxel; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Position-Specific Scoring Matrices; Prednisone; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Survival; Taxoids | 2013 |
Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Vaccines, DNA | 2013 |
Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy; Bone Neoplasms; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Staging; Predictive Value of Tests; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2014 |
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Comorbidity; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2015 |
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Taxoids; Treatment Outcome; Viscera | 2014 |
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Fatigue; Humans; Hypertension; Hypokalemia; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Survival Rate; Taxoids | 2014 |
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Models, Statistical; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Pain; Predictive Value of Tests; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2013 |
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Approval; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Sorafenib; Survival Analysis; Taxoids; Treatment Failure | 2014 |
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Etoposide; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Vinblastine; Vinorelbine | 2015 |
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dasatinib; Disease Progression; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Taxoids; Thiazoles; Treatment Failure | 2013 |
A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Humans; Male; Oligonucleotides; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Discovery; Gossypol; Humans; Indoles; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Radiography; Retrospective Studies; Sunitinib; Survival Rate; Taxoids; Time Factors | 2014 |
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Receptor, IGF Type 1; Taxoids | 2014 |
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Collagen Type I; Disease-Free Survival; Docetaxel; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Peptide Fragments; Peptides; Predictive Value of Tests; Procollagen; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; ROC Curve; Taxoids; Treatment Failure | 2014 |
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; ROC Curve; Survival Rate; Taxoids; Time Factors | 2014 |
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2014 |
Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study.
Topics: Aged; Biomarkers, Tumor; Bone and Bones; Cell Movement; Disease-Free Survival; Docetaxel; Endothelial Progenitor Cells; Humans; Kinetics; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Taxoids | 2014 |
Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Outcome | 2014 |
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Collagen Type I; Dasatinib; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mutation; Peptides; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; src-Family Kinases; Taxoids; Thiazoles; Treatment Outcome | 2014 |
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Hemoglobins; Humans; Indoles; Inflammation; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Placebos; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Retrospective Studies; Sunitinib; Taxoids | 2014 |
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Docetaxel; Double-Blind Method; Humans; Ipilimumab; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Indoles; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tubulin Modulators | 2014 |
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Spain; Taxoids | 2014 |
Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Cholecalciferol; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Calcitriol; Taxoids; Treatment Outcome | 2014 |
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids | 2015 |
Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Topics: Aged; Androgens; Androstenes; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Incidence; Male; Orchiectomy; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Republic of Korea; Survival Rate; Taiwan; Taxoids; Treatment Failure | 2014 |
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Topics: Adenocarcinoma; Administration, Metronomic; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2014 |
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle Proteins; DNA Methylation; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Neoplasm Metastasis; Nuclear Proteins; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Biological Availability; Cross-Over Studies; Dietary Fats; Docetaxel; Double-Blind Method; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Young Adult | 2014 |
Docetaxel with or without zoledronic acid for castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome; Zoledronic Acid | 2014 |
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Male; Nitriles; Phenylthiohydantoin; Placebos; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Self Report; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2015 |
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arteries; Bevacizumab; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Thromboembolism; Venous Thromboembolism | 2015 |
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPC
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2014 |
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Everolimus; Fluorodeoxyglucose F18; Humans; Male; Maximum Tolerated Dose; Middle Aged; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Follow-Up Studies; Humans; International Agencies; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neutrophils; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids | 2015 |
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dehydroepiandrosterone Sulfate; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Middle Aged; Naphthalenes; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone | 2015 |
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy:
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Europe; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Naphthalenes; Neoplasm Grading; North America; Odds Ratio; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids; Treatment Outcome | 2015 |
Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Nitriles; North America; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Disease-Free Survival; Docetaxel; Humans; Kallikreins; Lymph Nodes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Cell Count; Docetaxel; Humans; Longitudinal Studies; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids | 2015 |
A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2014 |
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Placebos; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide | 2015 |
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids; Treatment Outcome | 2015 |
Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Humans; Japan; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; Blood Proteins; Cell Death; Cell Line, Tumor; Cohort Studies; Computational Biology; Docetaxel; Drug Resistance, Neoplasm; Exosomes; Extracellular Matrix; Humans; Intracellular Signaling Peptides and Proteins; Male; Nanoparticles; Poly(A)-Binding Proteins; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proteome; Taxoids | 2015 |
Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids | 2015 |
Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Neoplasms; Bone Remodeling; Collagen Type I; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Staging; Peptides; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Precision Medicine; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Topics: Adenocarcinoma; Administration, Metronomic; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dendritic Cells; Docetaxel; Humans; Immunotherapy; Kaplan-Meier Estimate; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Nomograms; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Risk Factors; T-Lymphocyte Subsets; Taxoids; Time Factors; Treatment Outcome | 2015 |
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Ramucirumab; Taxoids; Time Factors; Treatment Outcome; United States; Young Adult | 2015 |
Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).
Topics: Aged; Antibodies, Neoplasm; Antineoplastic Agents; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Docetaxel; Humans; Immunoglobulin G; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2015 |
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Everolimus; Humans; Male; Neoplastic Cells, Circulating; Phosphorylation; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 1 Protein; Tumor Suppressor Proteins | 2015 |
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Topics: Abiraterone Acetate; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Survival Rate; Taxoids | 2016 |
Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Sirolimus; Taxoids; Treatment Outcome | 2015 |
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; HSP90 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; Triazoles | 2016 |
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromogranin A; Curcumin; Docetaxel; Geriatric Assessment; Humans; Male; Medication Adherence; Middle Aged; Phosphopyruvate Hydratase; Pilot Projects; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Kallikreins; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Neutrophils; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Severity of Illness Index; Taxoids; Time Factors; Treatment Outcome | 2016 |
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retreatment; Taxoids; Treatment Outcome | 2016 |
Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Standard of Care; Taxoids; Treatment Outcome | 2016 |
TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oncogene Proteins, Fusion; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Placebos; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Double-Blind Method; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Polyneuropathies; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diphosphonates; Docetaxel; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; Zoledronic Acid | 2016 |
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Quality-Adjusted Life Years; Strontium Radioisotopes; Taxoids; Zoledronic Acid | 2016 |
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Imidazoles; Maintenance Chemotherapy; Male; Middle Aged; Naphthalenes; Pain Measurement; Placebos; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids; Treatment Outcome | 2016 |
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Lenalidomide; Male; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Thalidomide | 2017 |
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide | 2017 |
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Management; Docetaxel; Follow-Up Studies; Humans; Indoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Sunitinib; Survival Rate; Taxoids | 2016 |
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Crowdsourcing; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Nomograms; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Young Adult | 2017 |
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Taxoids | 2017 |
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Topics: Antineoplastic Agents; Benzamides; Carcinoma; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Disease-Free Survival; Docetaxel; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Transplantation, Autologous; Treatment Outcome | 2017 |
A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; Cohort Studies; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Survival Rate; Taxoids | 2017 |
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Thionucleotides | 2017 |
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Prednisone; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2013 |
Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Docetaxel; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
[Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2012 |
545 other study(ies) available for docetaxel anhydrous and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs.
Topics: Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Nitriles; Norway; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Topics: Anilides; Aniline Compounds; Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Cellular Senescence; Docetaxel; Humans; Male; Mice; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sulfonamides; Tosyl Compounds; Xenograft Model Antitumor Assays | 2021 |
Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Docetaxel; Humans; Male; Mice; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors | 2021 |
Baseline neutrophil-lymphocyte ratio is associated with outcomes in patients with castration-resistant prostate cancer treated with Docetaxel in South China.
Topics: Age Factors; Aged; Antineoplastic Agents; China; Disease-Free Survival; Docetaxel; Electron Transport Complex IV; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Neoplasm Grading; Neutrophils; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2021 |
Zhoushi Qi Ling decoction represses docetaxel resistance and glycolysis of castration-resistant prostate cancer via regulation of SNHG10/miR-1271-5p/TRIM66 axis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Humans; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Prostatic Neoplasms, Castration-Resistant; RNA, Long Noncoding; Warburg Effect, Oncologic | 2021 |
Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant | 2022 |
Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
Topics: Antineoplastic Agents; Carbon Radioisotopes; Docetaxel; Drug Monitoring; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies | 2022 |
Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.
Topics: Animals; Black People; Docetaxel; Heterografts; Humans; Male; Mice; Orchiectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2022 |
Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction | 2022 |
Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; United States; Veterans Health | 2021 |
Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
Topics: Androstenes; Antineoplastic Agents; Benzamides; Black People; Docetaxel; Guadeloupe; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Immunotherapeutic role of cabazitaxel treatment in the activation of TLR3 signalling in metastatic castration-resistant prostate cancer in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Humans; Immunotherapy; Interferon Regulatory Factor-3; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Taxoids; Toll-Like Receptor 3; Tumor Microenvironment | 2022 |
Costs of managing castrate-resistant metastatic prostate cancer patients at Inkosi Albert Luthuli Central Hospital.
Topics: Aged; Docetaxel; Hospitals; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Treatment Outcome | 2021 |
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Biomarkers; Chromatography, Liquid; Docetaxel; Drug Resistance, Neoplasm; Humans; Hyaluronan Receptors; Male; Prostatic Neoplasms, Castration-Resistant; Proteome; Tandem Mass Spectrometry | 2022 |
Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines.
Topics: Cell Line; Cisplatin; Docetaxel; Humans; Male; Platinum; Prostatic Neoplasms, Castration-Resistant | 2022 |
Differential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer - An exploratory analysis.
Topics: Body Mass Index; Disease-Free Survival; Docetaxel; Humans; Male; Obesity; Overweight; Prostatic Neoplasms, Castration-Resistant | 2022 |
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Docetaxel; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Rural Health; Treatment Outcome | 2022 |
Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?
Topics: Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Standard of Care | 2022 |
Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.
Topics: Aged; Cohort Studies; Docetaxel; Humans; Male; Ontario; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Propensity Score; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2022 |
Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice.
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Bone Neoplasms; Databases, Factual; Docetaxel; Humans; Japan; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Recurrence; Taxoids; Time Factors; Treatment Outcome | 2022 |
Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer.
Topics: Biomarkers, Tumor; Cell-Free Nucleic Acids; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2022 |
Translation of Prognostic and Pharmacodynamic Biomarkers from Trial to Non-trial Patients with Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel.
Topics: Docetaxel; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Treatment Outcome | 2022 |
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
Topics: Biomarkers, Tumor; Docetaxel; Female; Humans; Lipidomics; Lipids; Male; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Sphingolipids | 2022 |
Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2022 |
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Registries; Retrospective Studies; Treatment Outcome | 2023 |
CRPC Membrane-Camouflaged, Biomimetic Nanosystem for Overcoming Castration-Resistant Prostate Cancer by Cellular Vehicle-Aided Tumor Targeting.
Topics: Animals; Antineoplastic Agents; Biomimetics; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Humans; Male; Mice; Nanoparticles; Prostatic Neoplasms, Castration-Resistant | 2022 |
[A CASE OF CASTRATION-RESISTANT PROSTATE CANCER THAT COMPLETELY AMELIORATED AFTER TRANSITION TO BEST SUPPORTIVE CARE].
Topics: Aged; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
[COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
Topics: Aged; Androgen Antagonists; Androgens; Costs and Cost Analysis; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant | 2021 |
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer.
Topics: Basophils; Docetaxel; Hormones; Humans; Lymphocytes; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2022 |
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
Topics: Castration; Chromatography, Liquid; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tandem Mass Spectrometry; Treatment Outcome | 2022 |
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer.
Topics: DNA Copy Number Variations; Docetaxel; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Treatment Outcome | 2022 |
Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.
Topics: Androgen Antagonists; Breast Neoplasms; Docetaxel; Humans; Male; Phenotype; Prostatic Neoplasms, Castration-Resistant | 2022 |
Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Androstenes; Benzamides; Brain Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Nonsteroidal Anti-Androgens; Propensity Score; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
Topics: Androstenes; Benzamides; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2022 |
Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.
Topics: Bone Neoplasms; Docetaxel; Hormones; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2022 |
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Topics: Activated-Leukocyte Cell Adhesion Molecule; Antigens, CD; Benzamides; Cell Adhesion Molecules, Neuronal; Cell Line; Chromatography, Liquid; Docetaxel; Drug Resistance, Neoplasm; Fetal Proteins; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proteome; RNA, Small Interfering; Tandem Mass Spectrometry; Treatment Outcome | 2022 |
Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tumor Burden | 2022 |
Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Treatment Outcome | 2022 |
Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Retrospective Studies; Taxoids; Treatment Outcome | 2022 |
Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neutropenia; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Treatment Outcome | 2022 |
The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Denosumab; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Sweden; Zoledronic Acid | 2022 |
An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome; United States | 2022 |
Fever as a first presentation of castration-resistant prostate cancer: A case report.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Leuprolide; Male; Naproxen; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2022 |
Cases in the management of prostate cancer: the addition of darolutamide to androgen deprivation therapy and docetaxel in a 55-year-old man with metastatic hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyrazoles | 2022 |
Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort.
Topics: Biomarkers; Castration; Docetaxel; Humans; Inflammation; Lymphocytes; Male; Neutrophils; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2023 |
Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2022 |
Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Role of baseline
Topics: Docetaxel; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Effect of different molecular weight and terminal group PLGA on docetaxel nanoparticles: characterization and cytotoxic activity of castration-resistant prostate cancer cells.
Topics: Antineoplastic Agents; Docetaxel; Drug Carriers; Emulsions; Humans; Male; Molecular Weight; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Prostatic Neoplasms, Castration-Resistant; Solvents | 2022 |
Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Androgens; Cell Cycle Proteins; Docetaxel; Histone Demethylases; Humans; Lysine; Male; Minor Histocompatibility Antigens; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Trans-Activators | 2022 |
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Topics: Androgen Antagonists; Biomarkers; Castration; Disease-Free Survival; Docetaxel; Humans; Male; Mutation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome | 2022 |
Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
Topics: Androgen Antagonists; Choline; Disease Progression; Docetaxel; Humans; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2022 |
Active Targeting of P-Selectin by Fucoidan Modulates the Molecular Profiling of Metastasis in Docetaxel-Resistant Prostate Cancer.
Topics: Androgen Antagonists; Androgens; Cyclooxygenase 2; Docetaxel; Humans; Male; Neoplasm Metastasis; NF-kappa B; P-Selectin; Polysaccharides; Prostatic Neoplasms, Castration-Resistant | 2022 |
Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2022 |
Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
Topics: Aged; Androgen Antagonists; Androgens; Benzamides; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
[Apalutamide, Erleada®].
Topics: Androgen Antagonists; Androgens; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ligands; Male; Nonsteroidal Anti-Androgens; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Receptors, Androgen; Testosterone; Thiohydantoins | 2022 |
Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer.
Topics: Androgens; Bridged-Ring Compounds; Cell Cycle Proteins; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Androgen; Taxoids | 2022 |
Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Continuing enzalutamide with docetaxel in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Ontario; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer.
Topics: Androgens; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Tomography, X-Ray Computed | 2022 |
Docetaxel Resistance in Castration-Resistant Prostate Cancer: Transcriptomic Determinants and the Effect of Inhibiting Wnt/β-Catenin Signaling by XAV939.
Topics: Antineoplastic Agents; beta Catenin; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; RNA Isoforms; Transcriptome | 2022 |
The efficacy of sequential therapy with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan.
Topics: Docetaxel; Humans; Japan; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
A population-based study of factors associated with systemic treatment in advanced prostate cancer decedents.
Topics: Androgen Antagonists; Docetaxel; Humans; Male; Ontario; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Proteomics; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2022 |
Small ankyrin 1 (sANK1) promotes docetaxel resistance in castration-resistant prostate cancer cells by enhancing oxidative phosphorylation.
Topics: Ankyrins; Cell Line, Tumor; Cytoskeletal Proteins; Docetaxel; Drug Resistance, Neoplasm; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Male; Oxidative Phosphorylation; Polypyrimidine Tract-Binding Protein; Prostatic Neoplasms, Castration-Resistant | 2023 |
Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein.
Topics: Docetaxel; Humans; Idarubicin; Male; Nitriles; Prostate; Prostatic Neoplasms, Castration-Resistant; Taxoids; Xeroderma Pigmentosum Group A Protein | 2022 |
The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Humans; Male; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2023 |
Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androgen Receptor Antagonists; Androgens; Docetaxel; Genetic Variation; Humans; Male; Membrane Proteins; Nitriles; Organic Anion Transporters; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2023 |
Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Topics: Androstenes; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Relationships of body composition and adipocytokines with outcomes in metastatic castration-resistant prostate cancer patients receiving docetaxel chemotherapy.
Topics: Adipokines; China; Docetaxel; Humans; Leptin; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Strong instrumental variables biased propensity scores in comparative effectiveness research: A case study in oncology.
Topics: Comparative Effectiveness Research; Docetaxel; Humans; Male; Propensity Score; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2023 |
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer.
Topics: Activities of Daily Living; Aged; Docetaxel; Fatigue; Frailty; Humans; Male; Pain; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2023 |
[LONG TERM ADMINISTRATION OF RELATIVE DOSE INTENSITY-ADJUSTED CABAZITAXEL FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A CASE REPORT].
Topics: Aged; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2022 |
Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Topics: Docetaxel; Health Care Costs; Humans; Insurance Carriers; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2023 |
US lawmakers call on Biden Administration to lower the price of enzalutamide.
Topics: Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Politics; Prostatic Neoplasms, Castration-Resistant | 2023 |
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Republic of Korea; Retrospective Studies; Treatment Outcome | 2023 |
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer.
Topics: Adult; Androgen Antagonists; Androgens; Castration; Docetaxel; Humans; Male; Physicians; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies | 2023 |
Differential adoption of castration-resistant prostate cancer treatment across facilities in a national healthcare system.
Topics: Delivery of Health Care; Docetaxel; Humans; Ketoconazole; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2023 |
KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation.
Topics: Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Kinesins; Male; Oncogene Proteins; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt | 2023 |
Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.
Topics: Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Pain; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Treatment Outcome | 2023 |
Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2023 |
Upfront Androgen Receptor-Axis-Targeted Therapies in Men with De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies | 2023 |
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Female; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2023 |
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel.
Topics: Adult; Docetaxel; Febrile Neutropenia; Humans; Incidence; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2023 |
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Jumonji Domain-Containing Histone Demethylases; Male; MicroRNAs; Prostatic Neoplasms, Castration-Resistant; Tubulin | 2023 |
The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
Topics: Cell Line, Tumor; Chemokine CCL2; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Receptors, CCR2; RNA, Small Interfering | 2023 |
The utility of the [-2]pro-prostate-specific antigen level as a prognostic marker in patients with castration-resistant prostate cancer treated with enzalutamide.
Topics: Docetaxel; Humans; Male; Nitriles; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2023 |
Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; CRISPR-Cas Systems; Docetaxel; Early Detection of Cancer; GTPase-Activating Proteins; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer.
Topics: Docetaxel; Humans; Male; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms, Castration-Resistant | 2023 |
A FOXC2 inhibitor, MC-1-F2, as a therapeutic candidate for targeting EMT in castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androgens; Cell Line, Tumor; Docetaxel; Epithelial-Mesenchymal Transition; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Transcription Factors | 2023 |
Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan.
Topics: Docetaxel; Humans; Japan; Male; Product Surveillance, Postmarketing; Prostatic Neoplasms, Castration-Resistant | 2023 |
Real-world analysis of metastatic prostate cancer demonstrates increased frequency of PSA-imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy.
Topics: Androgen Antagonists; Disease Progression; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Treatment Outcome | 2023 |
Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Docetaxel; Heterografts; Humans; Male; Mice; Nitriles; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Salts | 2023 |
Predictors of outcomes of docetaxel treatment in de novo metastatic hormone-sensitive prostate cancer: A single-center cohort study.
Topics: Androgen Antagonists; Cohort Studies; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2023 |
Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel.
Topics: Docetaxel; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Testosterone; Treatment Outcome | 2024 |
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort.
Topics: Aged; Australia; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study.
Topics: Androgen Antagonists; Cohort Studies; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
[The Relationship Between Prognosis and Duration of Drug Holidays after Docetaxel Therapy for Castration-Resistant Prostate Cancer].
Topics: Docetaxel; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2023 |
Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Fibrinogen; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Platelet Count; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Serum Albumin; Survival Analysis | 2019 |
Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Drugs, Chinese Herbal; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Male; Mice, Nude; MicroRNAs; Prostatic Neoplasms, Castration-Resistant | 2019 |
Drivers of AR indifferent anti-androgen resistance in prostate cancer cells.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Prostate; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction | 2019 |
Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Japan; Male; Middle Aged; Neoplasms, Second Primary; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Taxoids; Treatment Outcome | 2019 |
Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxel-A pooled analysis of 3 randomized studies.
Topics: Aged; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Gene Knockdown Techniques; Humans; Liposomes; Male; Mice; Molecular Targeted Therapy; Nanoparticles; Oncogene Proteins, Fusion; Prostatic Neoplasms, Castration-Resistant; Random Allocation; RNA, Messenger; RNA, Small Interfering; Transcriptional Regulator ERG; Xenograft Model Antitumor Assays | 2020 |
Association of Hyponatremia With Survival in Patients With Castration-resistant Prostate Cancer: A Clinical Commentary.
Topics: Aged; Antineoplastic Agents; Docetaxel; Follow-Up Studies; Humans; Hyponatremia; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Sodium; Treatment Outcome | 2019 |
Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer.
Topics: Aged; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Tubulin | 2019 |
Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Synergism; Fatty Acid-Binding Proteins; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Taxoids; Xenograft Model Antitumor Assays | 2020 |
PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Topics: Adult; Aged; Aged, 80 and over; China; Docetaxel; Humans; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2020 |
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy.
Topics: AMP-Activated Protein Kinase Kinases; Apoptosis; Autophagy; Autophagy-Related Protein 7; Beclin-1; Cell Line, Tumor; Cell Proliferation; Chloroquine; Docetaxel; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Protein Kinases; TOR Serine-Threonine Kinases | 2020 |
[Efficacy of Primary Prophylaxis with Pegfilgrastim after Docetaxel for Castration-Resistant Prostate Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Polyethylene Glycols; Prostatic Neoplasms, Castration-Resistant; Recombinant Proteins | 2019 |
Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression.
Topics: Antineoplastic Agents; Apoptosis; Bexarotene; Biomarkers, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Steroid; Receptors, Thyroid Hormone; Tumor Cells, Cultured | 2020 |
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer.
Topics: Aged; Albumins; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; C-Reactive Protein; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Predictive Value of Tests; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2019 |
Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Age Factors; Aged; Androgen Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Neoplasm Grading; Nitriles; Observational Studies as Topic; Phenylthiohydantoin; Progression-Free Survival; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2020 |
A castrate-resistant metastatic prostate cancer patient with severe pancytopenia, successfully treated with docetaxel chemotherapy.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Pancytopenia; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Severity of Illness Index; Treatment Outcome | 2020 |
The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer.
Topics: Aged; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Humans; Lymphocyte Count; Lymphocytes; Male; Neutrophils; Predictive Value of Tests; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2019 |
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.
Topics: Abiraterone Acetate; Aged; Androgen Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Follow-Up Studies; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2020 |
Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Testosterone | 2020 |
Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate.
Topics: Administration, Oral; Aged; Androstenes; Antineoplastic Agents; Benzamides; Biopsy; Docetaxel; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Propensity Score; Prostate; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Treatment Outcome | 2020 |
Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prostatic Neoplasms, Castration-Resistant; Ubiquitin Thiolesterase | 2020 |
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Registries; Taxoids | 2020 |
Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; E-Selectin; Glycolipids; Humans; Male; Mice; PC-3 Cells; Peptides; Prostatic Neoplasms, Castration-Resistant; Receptors, CXCR4; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2019 |
[Docetaxel for octogerian metastatic castration-resistant prostate cancer patient: A multicentric ten years' experience].
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors | 2020 |
[A Case of Pneumatosis Cystoides Intestinalis during Castration-Resistant Prostate Cancer Treatment].
Topics: Aged; Docetaxel; Humans; Male; Pneumatosis Cystoides Intestinalis; Prostatic Neoplasms, Castration-Resistant; Tomography, X-Ray Computed | 2019 |
Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Circulating MicroRNA; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2020 |
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2020 |
p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer.
Topics: Cell Line, Tumor; Cell Movement; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; p300-CBP Transcription Factors; Prostatic Neoplasms, Castration-Resistant; Up-Regulation | 2020 |
Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Models, Statistical; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Time Factors | 2020 |
AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2020 |
Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress.
Topics: Androgens; Animals; Apoptosis; Cell Movement; Disease Progression; Docetaxel; Endoplasmic Reticulum Stress; Humans; Male; Mice; Neoplasm Metastasis; Proscillaridin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2020 |
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Tissue Extracts | 2020 |
Combined targeting of EGFR and HER2 against prostate cancer stem cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Docetaxel; ErbB Receptors; Humans; Male; Mice; Mice, SCID; Neoplastic Stem Cells; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2020 |
Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; RNA, Small Interfering; Transcriptome; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
[A Case of Primary Central Nervous System Lymphoma that Developed during the Treatment of Castration-Resistant Prostate Cancer].
Topics: Androgens; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Nervous System; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Is there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?
Topics: Aged; Antineoplastic Agents; Cold Climate; Docetaxel; Humans; Male; Middle Aged; Norway; Prognosis; Prostatic Neoplasms, Castration-Resistant; Rural Population; Seasons; Survival Rate; Treatment Outcome | 2020 |
CD133 antibody targeted delivery of gold nanostars loading IR820 and docetaxel for multimodal imaging and near-infrared photodynamic/photothermal/chemotherapy against castration resistant prostate cancer.
Topics: AC133 Antigen; Animals; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Docetaxel; Drug Delivery Systems; Gold; Heterografts; Humans; Indocyanine Green; Male; Mice; Molecular Targeted Therapy; Multimodal Imaging; Nanoparticles; Photochemotherapy; Photothermal Therapy; Prostatic Neoplasms, Castration-Resistant | 2020 |
NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Mice; Mice, Nude; Microtubule-Associated Proteins; Prostate; Prostatic Neoplasms, Castration-Resistant; RNA, Small Interfering; Sequestosome-1 Protein; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2020 |
Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2020 |
69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent.
Topics: Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2020 |
Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; United States | 2020 |
Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Androstenes; Antineoplastic Agents; Benzamides; Chromogranin A; Docetaxel; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Phosphopyruvate Hydratase; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Proton Pump Inhibitors; Survival Rate | 2021 |
Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Topics: Androgen Antagonists; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tumor Burden | 2020 |
Aptamer-Conjugated Multifunctional Polymeric Nanoparticles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems for Treatment of Castration-Resistant Prostate Cancer.
Topics: Aptamers, Nucleotide; Contrast Media; Delayed-Action Preparations; Docetaxel; Drug Carriers; Humans; Magnetic Resonance Imaging; Male; Nanoparticles; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant | 2020 |
Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
Topics: Androgen Receptor Antagonists; Antibodies, Monoclonal; Antineoplastic Agents; Cell Line, Tumor; Coculture Techniques; Combined Modality Therapy; Curcumin; Docetaxel; HEK293 Cells; Humans; Immunotherapy, Adoptive; Killer Cells, Natural; Lectins, C-Type; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Receptors, Cell Surface; Up-Regulation | 2020 |
Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer: A protocol of systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carboplatin; Docetaxel; Drug Therapy, Combination; Humans; Male; Meta-Analysis as Topic; Prostatic Neoplasms, Castration-Resistant; Systematic Review as Topic; Treatment Outcome | 2020 |
Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer.
Topics: Aged; Androstenes; Benzamides; Biomarkers, Tumor; Docetaxel; Erythrocytes; Humans; Male; Mean Platelet Volume; Nitriles; Phenylthiohydantoin; Platelet Count; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Treatment Outcome | 2020 |
Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
A Multimodal Theranostic Nanoformulation That Dramatically Enhances Docetaxel Efficacy Against Castration Resistant Prostate Cancer.
Topics: Cell Survival; Docetaxel; Humans; Male; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Precision Medicine; Prostatic Neoplasms, Castration-Resistant | 2020 |
[Sequential therapy for asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2020 |
Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel-A Real-world Data Assessment.
Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Male; Neoplasms, Second Primary; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retrospective Studies | 2021 |
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2020 |
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid | 2020 |
Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling.
Topics: Androgens; Animals; Apoptosis; Cell Line, Tumor; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Docetaxel; Drug Synergism; Epithelial Cells; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Male; Mice; Mice, Knockout; Nitric Oxide; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Sildenafil Citrate | 2020 |
DNA polymerase theta repression enhances the docetaxel responsiveness in metastatic castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; DNA Polymerase theta; DNA-Directed DNA Polymerase; Docetaxel; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Experimental; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; RNA, Messenger; Tumor Cells, Cultured | 2020 |
Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel.
Topics: Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; Turkey | 2020 |
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2021 |
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2020 |
Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
Topics: Acetylation; Androgen Antagonists; Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Survival; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Solute Carrier Organic Anion Transporter Family Member 1B3; Testosterone; Tubulin | 2020 |
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Matrix Metalloproteinase 7; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2021 |
Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Docetaxel; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Risk Factors; Signal Transduction; Taxoids | 2021 |
Efficacy and safety of docetaxel and prednisolone chemotherapy in very elderly men with metastatic castration-resistant prostate cancer (mCRPC) in real world: a single institute experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Docetaxel; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2021 |
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Docetaxel; Humans; Male; Mice; Platinum; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-bcl-2; Taxoids | 2021 |
Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2021 |
Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Cell Proliferation; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Models, Theoretical; Neoplasm Metastasis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Tumor Burden | 2020 |
Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2021 |
Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control.
Topics: Aged; Aged, 80 and over; Dexamethasone; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2020 |
Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.
Topics: Apoptosis; Autophagy; Benzamides; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Immunophenotyping; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2021 |
Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Withholding Treatment | 2021 |
PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel.
Topics: Androgen Antagonists; Androgens; Castration; Docetaxel; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2021 |
Prognostic impact of prior local therapy in castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis | 2021 |
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Docetaxel; Genes, BRCA1; Genes, BRCA2; Genetic Testing; Humans; Male; Medical Oncology; Nitriles; Orchiectomy; Phenylthiohydantoin; Phthalazines; Piperazines; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Randomized Controlled Trials as Topic; Societies, Medical; Spain; Thiohydantoins | 2021 |
Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2021 |
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers.
Topics: Aged; Aged, 80 and over; Cell Count; Docetaxel; Epithelial-Mesenchymal Transition; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-myc; Transcriptome; Zinc Finger E-box-Binding Homeobox 1 | 2021 |
Patient reported outcomes interfering with daily activities in prostate cancer patients receiving antineoplastic treatment.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Patient Reported Outcome Measures; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration‑resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Docetaxel; Down-Regulation; Drug Synergism; Ferroptosis; Gene Expression Regulation, Neoplastic; Humans; Lipid Peroxidation; Male; Mice; Piperazines; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Reactive Oxygen Species; Receptors, Androgen; Xenograft Model Antitumor Assays | 2021 |
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
Topics: Ataxia Telangiectasia Mutated Proteins; BRCA1 Protein; Carboplatin; Cyclin-Dependent Kinases; Docetaxel; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2021 |
Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Neoplasms; Carcinogenesis; Cell Line, Tumor; Cyclams; Docetaxel; Epithelial-Mesenchymal Transition; Humans; Interleukin-11; Kruppel-Like Transcription Factors; Male; Mice; Mutation; Osteogenesis; Prostatic Neoplasms, Castration-Resistant; Receptors, CXCR4; Signal Transduction; Transforming Growth Factor beta | 2021 |
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemoradiotherapy; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Factors influencing treatment of veterans with advanced prostate cancer.
Topics: Androgen Antagonists; Docetaxel; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; Veterans | 2021 |
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Retrospective Studies; Survival Rate; Taxoids | 2021 |
Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP.
Topics: Androstenes; Benzamides; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Patient Selection; Pharmaceutical Preparations; Phenylthiohydantoin; Poly(ADP-ribose) Polymerase Inhibitors; Prostate; Prostatic Neoplasms, Castration-Resistant | 2021 |
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Canada; Docetaxel; Geroscience; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cystitis; Docetaxel; Dose Fractionation, Radiation; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Grading; Orchiectomy; Proctitis; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Injuries; Radiosurgery; Random Allocation; Survival Rate; Tumor Burden | 2021 |
Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
Topics: Androgen Antagonists; Developing Countries; Docetaxel; Follow-Up Studies; Humans; Male; Prostatic Neoplasms, Castration-Resistant | 2021 |
Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).
Topics: Androgen Antagonists; Developing Countries; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms, Castration-Resistant | 2021 |
Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.
Topics: Adult; Aged; Aged, 80 and over; China; Cohort Studies; Docetaxel; Febrile Neutropenia; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2021 |
Inflammatory factor-based prognostic risk stratification for patients with metastatic castration-resistant prostate cancer treated with docetaxel.
Topics: Androgen Antagonists; Blood Platelets; Docetaxel; Humans; Lymphocytes; Male; Neutrophils; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment | 2021 |
Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
Topics: Asian People; Biomarkers, Tumor; Circulating Tumor DNA; DNA Damage; DNA Repair; Docetaxel; Genomics; Humans; Male; Prostatic Neoplasms, Castration-Resistant | 2021 |
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kinetics; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Treatment Outcome | 2021 |
Tumor-Associated Macrophage Promotes the Survival of Cancer Cells upon Docetaxel Chemotherapy via the CSF1/CSF1R-CXCL12/CXCR4 Axis in Castration-Resistant Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Survival; Chemokine CXCL12; Docetaxel; Humans; Macrophage Colony-Stimulating Factor; Male; Mice; PC-3 Cells; Prostate; Prostatic Neoplasms, Castration-Resistant; RAW 264.7 Cells; Receptors, CXCR4; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Signal Transduction; Tumor-Associated Macrophages; Xenograft Model Antitumor Assays | 2021 |
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prednisone; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2021 |
[Management of metastatic hormone-naive prostate cancer at diagnosis].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Belgium; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Real world treatment utilization patterns in patients with castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Docetaxel; Humans; Male; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant | 2021 |
Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2021 |
Developmentally regulated GTP-binding protein 2 levels in prostate cancer cell lines impact docetaxel-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Docetaxel; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gene Expression; Gene Knockdown Techniques; GTP-Binding Proteins; Humans; M Phase Cell Cycle Checkpoints; Male; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; RNA, Small Interfering; Transfection | 2021 |
Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2021 |
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2022 |
Multi-gene mutation metastatic castrate-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Docetaxel; Humans; Male; Mutation; Prostatic Neoplasms, Castration-Resistant | 2021 |
[Second/Third-Line Therapie nach Versagen von Docetaxel bei metastasiertem Prostatakarzinom (mCRPC)].
Topics: Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant | 2021 |
Activation of the
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tumor Cells, Cultured | 2021 |
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Australia; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Docetaxel; Humans; Incidence; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2021 |
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2021 |
Particle Swarm Optimized Gaussian Process Classifier for Treatment Discontinuation Prediction in Multicohort Metastatic Castration-Resistant Prostate Cancer Patients.
Topics: Area Under Curve; Docetaxel; Humans; Male; Normal Distribution; Prostatic Neoplasms, Castration-Resistant; ROC Curve | 2022 |
Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients.
Topics: Aged; Androgen Receptor Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Blood Cell Count; Docetaxel; Hemoglobins; Humans; Japan; Male; Middle Aged; Neoplasm Grading; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis | 2022 |
[Clinical efficacy of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer].
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Progression-Free Survival; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
Topics: Aged; Androstenes; Benzamides; Docetaxel; Drug Costs; Health Care Costs; Humans; Male; Medicare; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; United States | 2017 |
Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Hyaluronan Receptors; Male; Mice; Neoplasm Recurrence, Local; Polyploidy; Prostatic Neoplasms, Castration-Resistant; Taxoids; Xenograft Model Antitumor Assays | 2017 |
Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Agents, Phytogenic; Budgets; Computer Simulation; Cost Savings; Docetaxel; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Male; Managed Care Programs; Models, Economic; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Prostate cancer: Custirsen fails to improve outcomes.
Topics: Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thionucleotides | 2017 |
First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
Topics: Age Factors; Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Bone and Bones; Docetaxel; Humans; Male; Medical Audit; Medical Oncology; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Practice Patterns, Physicians'; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Oncology; Radionuclide Imaging; Regression Analysis; Surveys and Questionnaires; Taxoids; Tumor Burden; Urology | 2017 |
Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate.
Topics: Abiraterone Acetate; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Pharmacogenetics; Prostate; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
Topics: Androgens; Calpain; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Quinazolines; Receptors, Androgen; Signal Transduction; Taxoids | 2017 |
The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Neoplasm Metastasis; Neoplasm Proteins; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists.
Topics: Androgen Antagonists; Docetaxel; Europe; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; United Kingdom; United States | 2017 |
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Response Evaluation Criteria in Solid Tumors; Survival Analysis; Taxoids | 2017 |
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
Topics: Androstenes; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Practice Patterns, Physicians'; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires; Taxoids; Treatment Outcome; Tubulin Modulators | 2018 |
The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Biological Transport; Cell Line; Disease Progression; Docetaxel; Drug Synergism; Electronic Health Records; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitriles; Organic Anion Transporters; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Time Factors; United States | 2017 |
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Longitudinal Studies; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids; Treatment Outcome | 2017 |
The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.
Topics: Biomarkers; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Management of Castration-Resistant, Taxane-Resistant Prostate Cancer.
Topics: Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2017 |
Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2017 |
Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chromogranin A; Docetaxel; Humans; Male; Middle Aged; Peptide Fragments; Phosphopyruvate Hydratase; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Recombinant Proteins; Survival Analysis; Taxoids | 2017 |
Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Phenylurea Compounds; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyridines; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome | 2017 |
Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carboxymethylcellulose Sodium; Cell Line, Tumor; Delayed-Action Preparations; Docetaxel; Drug Carriers; Drug Compounding; Drug Liberation; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Neutropenia; Particle Size; Prostatic Neoplasms, Castration-Resistant; Solubility; Taxoids; Tissue Distribution; Xenograft Model Antitumor Assays | 2017 |
[Clinical Study on the Efficacy and Continuous Docetaxel Based Chemotherapy Treatment for Castration-Resistant Prostate Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
Mifepristone Has Limited Activity to Enhance the
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Neoplasms; Cell Proliferation; Docetaxel; Hormone Antagonists; Humans; Male; Mice; Mifepristone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].
Topics: Docetaxel; Humans; Male; Neoplasms, Second Primary; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Naphthalenes; Piperazines; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Random Allocation; Taxoids; Xenograft Model Antitumor Assays | 2018 |
Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Docetaxel; Down-Regulation; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Male; Naphthalenes; Prostatic Neoplasms, Castration-Resistant; Protein Stability; Receptors, Androgen; Signal Transduction; Tubulin; Vorinostat | 2018 |
Self-assembled albumin nanoparticles for combination therapy in prostate cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Infrared Rays; Male; Mice, Nude; Nanoparticles; Photochemotherapy; Phototherapy; Prostatic Neoplasms, Castration-Resistant; Taxoids; Xenograft Model Antitumor Assays | 2017 |
Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Chlorine; Choline; Docetaxel; Gene Dosage; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction | 2017 |
Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Signal Transduction; Taxoids | 2017 |
Evaluating Metformin as a Potential Chemosensitizing Agent when Combined with Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Cells.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Male; Metformin; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
Topics: Aged; Animals; Antineoplastic Agents; Disease Models, Animal; Docetaxel; Gene Silencing; Humans; Male; Mice; MicroRNAs; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Italy; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Retrospective Studies; Taxoids | 2018 |
Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3.
Topics: Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; STAT3 Transcription Factor; Taxoids | 2018 |
[Experience with cabazitaxel therapy for patients with metastatic castrate resistant prostate cancer in Hungary].
Topics: Age Factors; Aged; Biopsy, Needle; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Hungary; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Patient Safety; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Japan; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome | 2018 |
Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Severity of Illness Index; Survival Analysis; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2018 |
Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Humans; Immunoblotting; Immunohistochemistry; Male; Mice; Prostate; Prostatic Neoplasms, Castration-Resistant; Pyrazines; Sulfonamides; Xenograft Model Antitumor Assays | 2018 |
Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Propensity Score; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |
Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ductal; Docetaxel; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2018 |
Re: The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer: M. J. Mayer, L. H. Klotz and V. Venkateswaran J Urol 2017;197:1068-1075.
Topics: Diabetes Mellitus; Docetaxel; Humans; Male; Metformin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Reply by Authors.
Topics: Diabetes Mellitus; Docetaxel; Humans; Male; Metformin; Prostatic Neoplasms, Castration-Resistant | 2018 |
Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Beclin-1; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Phosphorylation; Polyphenols; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tea; TOR Serine-Threonine Kinases | 2018 |
Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Japan; Male; Middle Aged; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2018 |
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Anti-Inflammatory Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2018 |
Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Topics: Antineoplastic Agents; Bcl-2-Like Protein 11; Cdc20 Proteins; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; PC-3 Cells; Prognosis; Prostatic Neoplasms, Castration-Resistant | 2018 |
Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Survival Rate; Taxoids | 2018 |
Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Topics: Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in
Topics: Adult; Aged; Amyloid Precursor Protein Secretases; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Proteins; Receptors, Notch; Signal Transduction; Taxoids; Tetrahydronaphthalenes; Valine; Xenograft Model Antitumor Assays | 2018 |
Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naïve prostate cancer: The first real-life experience in Asia.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Granulocyte Colony-Stimulating Factor; Hong Kong; Humans; Kallikreins; Male; Middle Aged; Neutropenia; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2018 |
Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Docetaxel; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Mutation; Neoplasm Metastasis; Predictive Value of Tests; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Registries; Retrospective Studies; Survival Rate; Time Factors | 2018 |
Long-term abiraterone withdrawal syndrome.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Substance Withdrawal Syndrome; Treatment Outcome | 2018 |
Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Eye Proteins; Humans; Macrophages; Male; Mice; Mice, SCID; Neoplasm Metastasis; Nerve Growth Factors; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Recombinant Proteins; Serpins; Taxoids; Xenograft Model Antitumor Assays | 2018 |
MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
Topics: Biomimetic Materials; Cell Line, Tumor; Cell Survival; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; MicroRNAs; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Denosumab; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radionuclide Imaging; Radium; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Drug Resistance, Neoplasm; Fas Ligand Protein; Humans; Male; Matrix Metalloproteinase 7; Middle Aged; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome | 2018 |
[Metronomic chemotherapy with oral cyclophosphamide : An individual option for the metastatic castration-resistant prostate cancer patient?]
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2019 |
Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blood Cell Count; Docetaxel; Humans; Male; Middle Aged; Neutropenia; Patient Outcome Assessment; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Patient Selection; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2018 |
Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2019 |
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chitinase-3-Like Protein 1; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2018 |
Oncological Outcome of Docetaxel-Based Chemotherapy for Men with Metastatic Castration-Resistant Prostate Cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Humans; Male; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2016 |
Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Models, Biological; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2018 |
Efficacy of a PSMA-targeted nanoparticle.
Topics: Antigens, Surface; Docetaxel; Glutamate Carboxypeptidase II; Humans; Male; Nanoparticles; Prostatic Neoplasms, Castration-Resistant | 2018 |
Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Molecular Structure; Prostatic Neoplasms, Castration-Resistant; Protein Binding; Quinolines; Reactive Oxygen Species; Tubulin | 2018 |
An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Neutrophils; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Survival Rate; Taxoids | 2019 |
Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2018 |
[Chinese experts consensus on the treatment of metastatic prostate cancer 2018 edition].
Topics: Antineoplastic Agents; China; Consensus; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2018 |
Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cytochromes c; Docetaxel; Humans; Male; Microtubule-Associated Proteins; Mitochondria; Mitophagy; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; RNA-Binding Proteins; Sirolimus; TOR Serine-Threonine Kinases; Trehalose | 2018 |
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncolo
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2018 |
Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Registries; Treatment Outcome | 2018 |
No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2018 |
[Chemotherapy in metastatic castration resistant prostate cancer.]
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Dietary Supplements; Docetaxel; Drug Synergism; Equol; Food-Drug Interactions; Genistein; Glycine max; Isoflavones; Male; Mice; Mice, Nude; Prostatic Neoplasms, Castration-Resistant; Random Allocation; Taxoids; Xenograft Model Antitumor Assays | 2019 |
Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2019 |
Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line; Cytokines; Docetaxel; Humans; Macrophages; Male; Mice; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor | 2019 |
Macro-CK type 2 in metastatic prostate cancer.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Creatine Kinase; Diagnosis, Differential; Docetaxel; Electrophoresis, Agar Gel; Humans; Isoenzymes; Male; Prostatic Neoplasms, Castration-Resistant | 2019 |
Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Testosterone | 2019 |
Codelivery of miR-4638-5p and Docetaxel Based on Redox-Sensitive Polypeptide Micelles as an Improved Strategy for the Treatment of Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Delivery Systems; Drug Liberation; Humans; Male; Membrane Proteins; Micelles; MicroRNAs; Nerve Tissue Proteins; Oxidation-Reduction; Peptides; Prostatic Neoplasms, Castration-Resistant | 2019 |
A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Follow-Up Studies; Geography; Humans; Male; Middle Aged; Prednisolone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2019 |
Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Deamino Arginine Vasopressin; Docetaxel; Humans; Male; Mice; Pilot Projects; Prostatic Neoplasms, Castration-Resistant; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Bridged-Ring Compounds; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Terminal Care; Treatment Outcome | 2019 |
Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Antigens, Differentiation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2019 |
The Effect of Time to Castration Resistance on Overall Survival and Success of Docetaxel Treatment in Castration Resistant Prostate Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2019 |
GSTP1 as a Potential Marker of Early Chemotherapy Response for Noninvasive Detection.
Topics: DNA; Docetaxel; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Male; Prostatic Neoplasms, Castration-Resistant | 2019 |
A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Middle Aged; Models, Theoretical; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Time Factors; Treatment Outcome; Young Adult | 2017 |
ERG expression can predict the outcome of docetaxel combinedwith androgen deprivation therapy in metastatic hormone-sensitiveprostate cancer.
Topics: Adult; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Transcriptional Regulator ERG; Treatment Outcome | 2019 |
Glyceryl trinitrate‑induced cytotoxicity of docetaxel‑resistant prostatic cancer cells is associated with differential regulation of clusterin.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clusterin; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Growth Differentiation Factor 15; Humans; Male; Nitroglycerin; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays; Zebrafish | 2019 |
Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio.
Topics: Aged; Androgen Receptor Antagonists; Antineoplastic Agents; Docetaxel; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2019 |
Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Netherlands; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2019 |
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Kallikreins; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Spain; Time Factors | 2019 |
Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphocytes; Male; Neutrophils; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2019 |
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Topics: Benzamides; Biomarkers, Tumor; Bridged-Ring Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockout Techniques; Humans; Male; Nitriles; Oncogene Proteins, Fusion; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Transcriptional Regulator ERG | 2019 |
A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2019 |
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
Topics: Adult; Aged; Androgen Antagonists; Androstenes; Dehydroepiandrosterone Sulfate; Disease Progression; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Grading; Organic Anion Transporters; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Solute Carrier Organic Anion Transporter Family Member 1B3; Testosterone; Treatment Outcome | 2019 |
Raddeanin A down-regulates androgen receptor and its splice variants in prostate cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; PC-3 Cells; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA Splicing; Saponins | 2019 |
Prognostic value of neutrophil-to-lymphocyte ratio in castration resistant prostate cancer: Single-centre study of Nigerian men.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2019 |
Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Models, Theoretical; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Simulation Training; Survival Rate; Treatment Outcome | 2019 |
Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Clinical Decision-Making; Cohort Studies; Docetaxel; Humans; Male; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2020 |
Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Chemokine CCL5; Docetaxel; Drug Resistance, Neoplasm; Humans; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; STAT3 Transcription Factor; Tumor Microenvironment | 2019 |
A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Feasibility Studies; Humans; Male; Middle Aged; Neoplasm Grading; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors | 2019 |
Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
Topics: Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms, Castration-Resistant; Sensitivity and Specificity; Treatment Outcome | 2020 |
Editorial Comment to Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
Topics: Administration, Oral; Dexamethasone; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2019 |
Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA).
Topics: Circulating Tumor DNA; Docetaxel; Exons; Humans; Male; Polymorphism, Single Nucleotide; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2019 |
Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Docetaxel; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Time Factors | 2019 |
Exosome-derived miR-27a produced by PSC-27 cells contributes to prostate cancer chemoresistance through p53.
Topics: Cell Line, Tumor; Cells, Cultured; Cisplatin; Coculture Techniques; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Exosomes; Fibroblasts; Gene Expression; Genes, p53; Humans; Male; MicroRNAs; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Tumor Microenvironment | 2019 |
Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells.
Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; L-Lactate Dehydrogenase; Male; Oxamic Acid; Prostatic Neoplasms, Castration-Resistant | 2019 |
Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Topics: Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Early Detection of Cancer; Humans; Liquid Biopsy; Lung Neoplasms; Male; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2019 |
Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antihypertensive Agents; Antineoplastic Agents; Comorbidity; Docetaxel; Humans; Hypertension; Japan; Male; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Survival Rate | 2019 |
Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Flutamide; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome | 2019 |
Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.
Topics: Abiraterone Acetate; Cost-Benefit Analysis; Disease Management; Docetaxel; Drug Costs; Health Care Surveys; Hong Kong; Humans; Male; Markov Chains; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Treatment Outcome | 2020 |
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Topics: Aged; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Image-Guided Biopsy; Immunohistochemistry; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2019 |
Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Biopsy, Large-Core Needle; Bone Neoplasms; Docetaxel; Endosonography; Health Resources; Health Services Accessibility; Humans; Iraq; Kallikreins; Kuwait; Lebanon; Lymph Node Excision; Magnetic Resonance Imaging; Male; Margins of Excision; Middle East; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Risk; Salvage Therapy; Saudi Arabia; Syria | 2020 |
Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report.
Topics: Administration, Intravenous; Aged; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Dyspnea; Follow-Up Studies; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Methylprednisolone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Kallikreins; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Safety; Taxoids; Treatment Outcome | 2019 |
No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Treatment Outcome | 2019 |
Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Topics: Aged; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Kallikreins; Male; Middle Aged; Neoplasm Staging; Prognosis; Progression-Free Survival; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Severity of Illness Index | 2019 |
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Topics: Abiraterone Acetate; Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Docetaxel; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Multivariate Analysis; Pain; Prednisone; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Spain; Taxoids; Treatment Outcome | 2019 |
Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2014 |
Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2014 |
Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Disease-Free Survival; Docetaxel; Hong Kong; Humans; Male; Middle Aged; Pain; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Tertiary Care Centers; Treatment Outcome | 2013 |
Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids | 2013 |
Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cellular Reprogramming; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Nude; Octamer Transcription Factor-3; Prostatic Neoplasms, Castration-Resistant; Ribavirin; SOXB1 Transcription Factors; Taxoids; Xenograft Model Antitumor Assays | 2013 |
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure | 2014 |
Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Multicenter Studies as Topic; Netherlands; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Risedronic Acid; Survival Analysis; Taxoids | 2013 |
Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; ATP Binding Cassette Transporter, Subfamily D, Member 1; ATP-Binding Cassette Transporters; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2013 |
Metastatic castration-resistant prostate cancer: integrating new learnings to optimise treatment outcomes.
Topics: Antineoplastic Agents; Biomarkers; Decision Trees; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Docetaxel; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Orchiectomy; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Quinolines; Taxoids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for
Topics: Adult; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Approval; European Union; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2013 |
Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cyclophosphamide; Docetaxel; Flow Cytometry; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androstadienes; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Severity of Illness Index; Survival Analysis; Taxoids; Tumor Burden | 2013 |
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Benzamides; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Towards random sequencing or precision medicine in castration-resistant prostate cancer?
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Docetaxel; Drug Approval; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Survival; Taxoids; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms, Castration-Resistant; Safety; Taxoids | 2014 |
Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
Topics: Antigens, Neoplasm; Antigens, Surface; Antineoplastic Agents; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Count; Cell Line, Tumor; DNA Methylation; Docetaxel; Epithelial Cell Adhesion Molecule; Flow Cytometry; Glutamate Carboxypeptidase II; Humans; Hyaluronan Receptors; Immunohistochemistry; Leukocyte Common Antigens; Male; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Vimentin | 2014 |
Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Humans; Male; Phosphoproteins; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Signal Transduction; Sulfonamides; Taxoids | 2014 |
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
Topics: Active Transport, Cell Nucleus; Androstenes; Androstenols; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Green Fluorescent Proteins; Humans; Male; Microscopy, Confocal; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Time-Lapse Imaging | 2013 |
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
Topics: Abiraterone Acetate; Aged; Androstadienes; Antineoplastic Agents; Benzamides; Cohort Studies; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Kallikreins; Linear Models; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure; Treatment Outcome | 2014 |
Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Pharmacological; C-Reactive Protein; Docetaxel; Hemoglobins; Humans; Male; Middle Aged; Neoplasm Grading; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Castrate-resistant prostate cancer with peritoneal metastases treated with docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Neoplasm Grading; Peritoneal Neoplasms; Prostate; Prostatic Neoplasms, Castration-Resistant; Registries; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Topics: Aged; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2014 |
Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure | 2014 |
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Geriatrics; Humans; Male; Mitoxantrone; Neoplasm Staging; Orchiectomy; Patient Selection; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Male; Molecular Targeted Therapy; Polo-Like Kinase 1; Prostatic Neoplasms, Castration-Resistant; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA, Small Interfering; Taxoids; Tissue Array Analysis; Transcriptome; Transfection; Tumor Suppressor Proteins | 2014 |
Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Predictive Value of Tests; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2014 |
Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Leukocyte Count; Lymphatic Metastasis; Lymphocytes; Male; Middle Aged; Neutrophils; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2014 |
Androgen receptor splice variants determine taxane sensitivity in prostate cancer.
Topics: Animals; Cell Line, Tumor; Cell Nucleus; Disease Models, Animal; Docetaxel; Dynactin Complex; HEK293 Cells; Humans; Male; Mice; Mice, SCID; Microtubule-Associated Proteins; Microtubules; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Protein Structure, Tertiary; Receptors, Androgen; RNA Splicing; Signal Transduction; Taxoids; Transfection; Xenograft Model Antitumor Assays | 2014 |
[Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Streptonigrin; Taxoids; Tegafur; Uracil | 2013 |
Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Humans; Male; Octreotide; Prostatic Neoplasms, Castration-Resistant; RNA, Messenger; Taxoids; Up-Regulation; Vascular Endothelial Growth Factor A | 2014 |
Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2014 |
Efficacy and Toxicity of Every 2 Weeks Docetaxel Regimen in Comparison With Weekly or Every 3 Weeks in Metastatic Prostate Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2014 |
One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Lung Neoplasms; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Eye Proteins; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Nerve Growth Factors; Prostatic Neoplasms, Castration-Resistant; Serpins; Taxoids; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
A near miss for prostate cancer immunotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Docetaxel; Humans; Ipilimumab; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Signal Transduction; Taxoids; Time Factors; Treatment Outcome | 2015 |
Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Neoplasms; Carboxymethylcellulose Sodium; Cell Line, Tumor; Docetaxel; Drug Carriers; Gene Expression; Humans; Male; Mice, Inbred BALB C; Nanoparticles; Particle Size; Prostatic Neoplasms, Castration-Resistant; Surface Properties; Survival Analysis; Taxoids; Xenograft Model Antitumor Assays | 2014 |
Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Calcium; Disease Progression; Disease-Free Survival; Docetaxel; Follow-Up Studies; Hemoglobins; Humans; Logistic Models; Male; Middle Aged; Neoplasm Grading; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2014 |
Predictive factors for neutropenia after docetaxel-based systemic chemotherapy in Korean patients with castration- resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Creatinine; Docetaxel; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Neutropenia; Neutrophils; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Serum Albumin; Taxoids | 2014 |
EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Male; Mice, Inbred BALB C; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2015 |
Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids | 2015 |
Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms, Castration-Resistant; Remission Induction; Retreatment; Retrospective Studies; Taxoids | 2015 |
The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Risk Factors; Taxoids; Treatment Outcome | 2014 |
Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indoles; Male; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; Sunitinib; Taxoids; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Compassionate Use Trials; Docetaxel; Drug Therapy, Combination; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.
Topics: Adult; Aged; Aged, 80 and over; Docetaxel; Humans; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Drug Monitoring; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Japan; Male; Middle Aged; Patient Selection; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Severity of Illness Index; Taxoids; Treatment Outcome | 2014 |
The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Docetaxel; Drug Synergism; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome; Venous Thromboembolism; Warfarin | 2015 |
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids | 2015 |
KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment.
Topics: Adult; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Leukocytes, Mononuclear; Longitudinal Studies; Male; Middle Aged; Nucleic Acid Hybridization; Oncogene Proteins, Fusion; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; RNA, Messenger; Taxoids; Treatment Outcome; Young Adult | 2014 |
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Topics: Adenocarcinoma; Aged; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2014 |
Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; HSP90 Heat-Shock Proteins; Isoxazoles; Male; Mice; Mice, SCID; Prostatic Neoplasms, Castration-Resistant; Proteasome Endopeptidase Complex; Receptors, Androgen; Resorcinols; Taxoids; Transcription, Genetic; Transplantation, Heterologous | 2014 |
Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
The role of testicular nuclear receptor 4 in chemo-resistance of docetaxel in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression; Genetic Vectors; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lentivirus; Male; Nuclear Receptor Subfamily 2, Group C, Member 2; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Transduction, Genetic | 2014 |
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Compassionate Use Trials; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Europe; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2015 |
Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Curcumin; Docetaxel; Endoplasmic Reticulum Stress; Epithelial Cells; Humans; Male; Mice; Mice, Nude; Nelfinavir; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Taxoids; Thapsigargin | 2014 |
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Gene Expression Regulation; Homeodomain Proteins; Humans; Immunoprecipitation; Male; Nanog Homeobox Protein; Nitriles; Phenylthiohydantoin; Polymorphism, Restriction Fragment Length; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Taxoids; Up-Regulation | 2014 |
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Canada; Cytochrome P-450 Enzyme Inhibitors; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer.
Topics: Age Factors; Aged; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Humans; Male; Middle Aged; Neutropenia; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Risk Factors; Taxoids | 2015 |
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2015 |
Docetaxel in castration-resistant prostate cancer: a single-centre experience.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Fatigue; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients.
Topics: Adrenal Cortex Hormones; Aged; Algorithms; Antineoplastic Agents; Bone Neoplasms; Cross-Sectional Studies; Diphosphonates; Docetaxel; Europe; Health Status; Humans; Male; Models, Theoretical; Pain; Pain Management; Palliative Care; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Surveys and Questionnaires; Taxoids | 2015 |
Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Sensitivity and Specificity; Survival Rate; Taxoids | 2014 |
ERG induces taxane resistance in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cohort Studies; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Trans-Activators; Transcriptional Regulator ERG; Tubulin | 2014 |
Effect of docetaxel on safety and efficacy of radium-223.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2014 |
2-weekly docetaxel: issues for clinical practice.
Topics: Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Italy; Male; Multivariate Analysis; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Failure; Treatment Outcome | 2015 |
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
Topics: Aged; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Ki-67 Antigen; Male; Mice; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2015 |
Parotid gland metastasis from prostate cancer: is docetaxel still the best treatment option?
Topics: Abiraterone Acetate; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Parotid Neoplasms; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
Topics: Administration, Metronomic; Aged; Aged, 80 and over; Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Salvage Therapy; Taxoids | 2015 |
The diffusion of docetaxel in patients with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Comorbidity; Docetaxel; Drug Approval; Humans; Male; Medicare; Middle Aged; Practice Patterns, Physicians'; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; SEER Program; Taxoids; United States | 2015 |
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
[Fatal neutropenic enterocolitis in a patient with castration-resistant prostate cancer treated with first-line chemotherapy].
Topics: Antineoplastic Agents; Docetaxel; Enterocolitis, Neutropenic; Fatal Outcome; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
[Treatment of metastatic castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Time Factors; Treatment Outcome | 2015 |
Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Docetaxel; Drug Synergism; Hedgehog Proteins; Humans; Male; Mice; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Random Allocation; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2015 |
Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Follow-Up Studies; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Grading; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Flow Cytometry; Humans; Immunoblotting; Male; Mice; Microscopy, Fluorescence; Models, Molecular; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Transcriptome; Xenograft Model Antitumor Assays | 2015 |
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Biomarkers, Tumor; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation, Missense; Neoplasm Metastasis; Neoplastic Cells, Circulating; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids | 2015 |
Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T.
Topics: Aged; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tissue Extracts; Treatment Outcome | 2015 |
Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
[Clinical study of long-term docetaxel based chemotherapy treatment for patients with castration-resistant prostate cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2014 |
[Prostate cancer of unknown primary origin with multiple lymph nodes metastasis; a case report].
Topics: Adenocarcinoma; Biomarkers, Tumor; Diagnosis, Differential; Docetaxel; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tomography, X-Ray Computed | 2014 |
Long-Term Administration of Docetaxel Over 70 Cycles for Castration-Resistant Prostate Cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Fatal Outcome; Humans; Maintenance Chemotherapy; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiography; Taxoids | 2015 |
Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Body Composition; Body Mass Index; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Simultaneous chylothorax and chylous ascites in a patient with castration-resistant prostate cancer after docetaxel chemotherapy: An unusual manifestation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chylothorax; Chylous Ascites; Docetaxel; Humans; Lumbar Vertebrae; Male; Prostatic Neoplasms, Castration-Resistant; Spinal Neoplasms; Taxoids; Thoracic Vertebrae | 2015 |
Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Humans; Japan; Male; Medical Records; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Coculture Techniques; Cytokines; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Macrophages; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
Topics: Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Ductal; Disease Progression; Docetaxel; Humans; Incidence; Kallikreins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents, Hormonal; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Grading; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Japan; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
[Risk factors for predicting severe leukopenia induced by docetaxel plus prednisolone in patients with Castration-Resistant Prostate cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Leukopenia; Male; Middle Aged; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Taxoids | 2015 |
Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Androgen Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Rhodamines; Taxoids; Tosyl Compounds; Xenograft Model Antitumor Assays | 2015 |
New treatment options in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Receptors, Androgen; Taxoids | 2015 |
Evaluation of Docetaxel-Sensitive and Docetaxel-Resistant Proteomes in PC-3 Cells.
Topics: Antineoplastic Agents; Calreticulin; Cathepsin D; Cell Line, Tumor; Cofilin 1; Docetaxel; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Male; Mass Spectrometry; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Proteome; Proteomics; Taxoids; Up-Regulation | 2015 |
Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Exosomes; Humans; Male; Prostatic Neoplasms, Castration-Resistant; RNA, Small Interfering; Taxoids; Transfection | 2015 |
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Docetaxel; Humans; Male; Orchiectomy; Practice Guidelines as Topic; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Taxoids | 2015 |
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Endpoint Determination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Failure | 2015 |
High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2015 |
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2015 |
Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.
Topics: Active Transport, Cell Nucleus; Alternative Splicing; Animals; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Cytoplasm; Docetaxel; Drug Resistance, Neoplasm; Fluorescence Recovery After Photobleaching; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; Microtubules; Prostatic Neoplasms, Castration-Resistant; Protein Structure, Tertiary; Receptors, Androgen; Signal Transduction; Taxoids; Transcription, Genetic; Up-Regulation | 2015 |
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Academic Medical Centers; Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Baltimore; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Patient Selection; Phenotype; Phenylthiohydantoin; Predictive Value of Tests; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Risk Factors; RNA, Messenger; Taxoids; Time Factors; Treatment Outcome | 2015 |
[Docetaxel and prostate cancer: Early but not too early].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Congresses as Topic; Docetaxel; Humans; Life Expectancy; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Time Factors | 2015 |
Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prednisolone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2015 |
Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
[Predictor analysis of PSA response of docetaxel combined with prednisone in the treatment of metastatic castration resistant prostate cancer].
Topics: Disease Progression; Docetaxel; Humans; Lymphatic Metastasis; Male; Neoplasm Grading; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2015 |
Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.
Topics: Aged; Aged, 80 and over; Carbon Radioisotopes; Choline; Docetaxel; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Brachytherapy; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Pain; Pain Measurement; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium; Taxoids | 2015 |
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Brachytherapy; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Treatment Outcome | 2015 |
Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.
Topics: Antigens, Surface; Clinical Trials as Topic; Docetaxel; Europe; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Oligopeptides; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Taxoids | 2015 |
Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.
Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Drug Monitoring; Drug Resistance, Neoplasm; Drug Substitution; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Netherlands; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Viscera | 2015 |
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Integrin beta1; Male; Membrane Proteins; MicroRNAs; Neoplasm Metastasis; Neoplasm Proteins; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Taxoids; Treatment Outcome | 2016 |
Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers; CD24 Antigen; Cell Line, Transformed; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Hyaluronan Receptors; Male; Mice; Neoplastic Stem Cells; Prostatic Neoplasms, Castration-Resistant; Protein Binding; ras GTPase-Activating Proteins; Taxoids; Tumor Stem Cell Assay; Wnt Signaling Pathway | 2016 |
Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Count; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Predictive Value of Tests; Prednisone; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Risk Factors; Serum Albumin; Serum Albumin, Human; Taxoids; Time Factors; Treatment Outcome | 2015 |
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
Topics: Antineoplastic Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Ureteral Metastasis: Uncommon Manifestation in Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Ureteral Neoplasms | 2015 |
Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2016 |
New developments in metastatic prostate cancer therapy.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Staging; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiotherapy; Radium; Risk Assessment; Taxoids; Therapies, Investigational; United Kingdom | 2015 |
Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
Topics: Androstenes; Androstenols; Benzamides; Bridged-Ring Compounds; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Taxoids | 2015 |
Metastatic prostate cancer in 2015: The new and the old that is new again.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
Topics: Adenocarcinoma; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Genes, BRCA2; Humans; Male; Middle Aged; Mutation; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cancer Vaccines; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Singapore; Taxoids; Tissue Extracts | 2015 |
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromogranin A; Disease Progression; Docetaxel; Gastrin-Releasing Peptide; Humans; Lymphatic Metastasis; Male; Middle Aged; Phosphopyruvate Hydratase; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
[Role of chemotherapy in the treatment of castration resistant prostate cancer].
Topics: Antinematodal Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Recurrence; Taxoids | 2016 |
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.
Topics: Abiraterone Acetate; Aged; Belgium; Compassionate Use Trials; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Diagnosis, Computer-Assisted; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Predictive Value of Tests; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2016 |
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Outcome Assessment, Health Care; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Registries; Statistics as Topic; Survival Analysis; Taxoids; United Kingdom | 2016 |
Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
Topics: Aged; Antineoplastic Agents; Dexamethasone; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2016 |
Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Male; Mice, Nude; Nuclear Proteins; Nucleophosmin; Nucleoproteins; Peptides; Phosphorylation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Binding; Receptors, Androgen; Taxoids; Threonine; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
Topics: Animals; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Prostate cancer: Validating early PSA response to enable improved treatment decisions.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Outcome Assessment, Health Care; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Registries; Statistics as Topic; Survival Analysis; Taxoids; United Kingdom | 2016 |
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; C-Reactive Protein; Diphosphonates; Docetaxel; Humans; Kallikreins; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Serum Albumin; Survival Rate; Taxoids | 2016 |
Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Budgets; Docetaxel; Drug Costs; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States | 2016 |
Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest® System for Detection of Circulating Tumor Cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2016 |
Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Humans; Kallikreins; L-Lactate Dehydrogenase; Logistic Models; Male; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids | 2016 |
Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Chromatin Immunoprecipitation; Docetaxel; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Histone Demethylases; Humans; Immunoprecipitation; Male; Minor Histocompatibility Antigens; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Taxoids; Tumor Cells, Cultured | 2016 |
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Benzamides; Biomarkers, Tumor; Disease-Free Survival; DNA; Docetaxel; Drug Resistance, Neoplasm; Gene Dosage; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2016 |
High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
Topics: Androgen Antagonists; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Cell Survival; Docetaxel; Flutamide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Kaplan-Meier Estimate; Male; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2016 |
Development of a Nomogram for Predicting Severe Neutropenia Associated With Docetaxel-Based Chemotherapy in Patients With Castration-Resistant Prostate Cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Incidence; Kallikreins; Logistic Models; Male; Middle Aged; Neutropenia; Nomograms; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Taxoids | 2017 |
Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Multimodal Imaging; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
[Docetaxel chemotherapy against CRPC].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Humans; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Female; G1 Phase; Histone Demethylases; Histones; Humans; Ligands; Male; Mice; Mice, Nude; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-myc; Receptors, Androgen; Resting Phase, Cell Cycle; Signal Transduction; Taxoids | 2016 |
High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Monocytes; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Hemoglobins; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Practice Patterns, Physicians'; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids | 2017 |
Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.
Topics: Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.
Topics: Aged; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Topics: Abdominal Neoplasms; Abiraterone Acetate; Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Geriatric Assessment; Humans; Male; Predictive Value of Tests; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids | 2017 |
[ASCO 2016: Confirmation of respective roles of docetaxel and cabazitaxel in prostate cancer patients].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer.
Topics: Animals; Apoptosis; Caspases; Cell Line, Tumor; Docetaxel; Fatty Alcohols; Humans; Insulin-Like Growth Factor I; Male; Mice; Potassium Channel Blockers; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
The Utility of Serum CA9 for Prognostication in Prostate Cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carbonic Anhydrase IX; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phenotype; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cdc20 Proteins; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer.
Topics: Aged; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer.
Topics: Aged; Antineoplastic Agents; Blood Vessels; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Hyaluronan Receptors; Kinesins; Male; Neoplasm Grading; Neoplasm Invasiveness; Neoplastic Stem Cells; Prostate; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; RNA, Messenger; RNA, Small Interfering; Spheroids, Cellular; Taxoids | 2017 |
Statin derivatives as therapeutic agents for castration-resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholesterol; Docetaxel; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplasm Invasiveness; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Receptors, Androgen; S Phase Cell Cycle Checkpoints; Signal Transduction; Simvastatin; Taxoids | 2016 |
Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.
Topics: Abiraterone Acetate; Aged, 80 and over; Androstenes; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Safety-Based Drug Withdrawals; Taxoids; Time Factors; Treatment Outcome | 2017 |
A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Decision Support Techniques; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Judgment; Male; Neoplasm Metastasis; Oncologists; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Taxoids | 2017 |
Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Topics: Aged; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Japan; Male; Patient Preference; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2016 |
Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Computational Biology; Databases, Genetic; Disease Progression; Disease-Free Survival; Docetaxel; Gene Amplification; Gene Dosage; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mucin-1; Neoplastic Stem Cells; Neuroendocrine Tumors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger; Signal Transduction; Survival Analysis; Taxoids; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Immunohistochemistry; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; SOX9 Transcription Factor; Taxoids; Time Factors; Tissue Array Analysis; Transcriptional Regulator ERG; Treatment Outcome | 2016 |
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study.
Topics: Aged; Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Clinical Trials, Phase III as Topic; Docetaxel; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Mitoxantrone; Neoplasm Staging; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Taxoids | 2017 |
The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Docetaxel; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2017 |
Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Movement; Chitosan; Docetaxel; Drug Carriers; Drug Liberation; High-Energy Shock Waves; Humans; Male; Nanostructures; Paclitaxel; Particle Size; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Female; Humans; Inflammation; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2017 |
Editorial Comment.
Topics: Diabetes Mellitus; Docetaxel; Humans; Male; Metformin; Prostatic Neoplasms, Castration-Resistant | 2017 |
Editorial Comment.
Topics: Diabetes Mellitus; Docetaxel; Humans; Male; Metformin; Prostatic Neoplasms, Castration-Resistant | 2017 |
Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclooxygenase 2 Inhibitors; Disease Progression; Docetaxel; Heparin, Low-Molecular-Weight; Humans; Male; Metformin; Models, Theoretical; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; ROC Curve; Taxoids; Treatment Outcome; Warfarin | 2017 |
Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Docetaxel; Humans; Lymphocyte Count; Male; Middle Aged; Neoplasm Staging; Neutrophils; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Serum Albumin; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Time Factors; Treatment Outcome | 2017 |
How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?
Topics: Antineoplastic Agents; Bayes Theorem; Clinical Decision-Making; Decision Support Techniques; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Principal Component Analysis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2017 |
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?
Topics: Abiraterone Acetate; Aged; Docetaxel; Humans; Male; Prednisone; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; ROC Curve; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk; Taxoids; Treatment Outcome | 2013 |
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Male; Piperidines; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Taxoids; Tetrazolium Salts; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Insulin-Like Growth Factor I; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-met; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Sunitinib; Taxoids; Zinc Sulfate | 2013 |
Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Estramustine; Humans; Lymphatic Metastasis; Male; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.
Topics: 14-alpha Demethylase Inhibitors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Outcome | 2013 |
Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study.
Topics: Aged; Aged, 80 and over; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |